Compounds and methods for treating coronaviruses

Compounds targeting PLpro in coronaviruses like SARS-CoV2 inhibit viral replication and immune dysregulation, offering a new treatment approach to combat coronavirus infections.

JP2024540877AInactive Publication Date: 2024-11-06CLEAR CREEK BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024522531
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-15
Filing Date
2022-10-13
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for new treatments to combat coronaviruses, particularly SARS-CoV2, which has caused significant global health crises, as existing treatments are inadequate.

Method used

Development of compounds that allosterically inhibit papain-like cysteine protease (PLpro), a key enzyme in coronavirus replication, to reduce viral replication and modulate immune pathways, potentially used alone or in combination with other antiviral agents.

Benefits of technology

The compounds effectively inhibit PLpro activity, reducing viral replication and associated symptoms by protecting uninfected cells, thereby mitigating the impact of coronavirus infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540877000001_ABST
    Figure 2024540877000001_ABST
Patent Text Reader

Abstract

The present invention relates to a compound of formula (I″) Compounds for inhibiting papain-like protease (PLpro) to inhibit viruses, including TIFF2024540877001079.tif3957 and pharma- ceutically acceptable salts thereof, are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 255,186, filed October 13, 2021; U.S. Provisional Patent Application No. 63 / 277,531, filed November 9, 2021; U.S. Provisional Patent Application No. 63 / 314,357, filed February 25, 2022; and U.S. Provisional Patent Application No. 63 / 352,580, filed June 15, 2022, the entire contents of each of which are incorporated herein by reference.

[0002] The present invention provides compounds and methods of their use and manufacture for treating hosts infected with coronaviruses, such as SARS CoV-2. These compounds inhibit papain-like cysteine ​​protease (PLpro) and can therefore be used to treat any virus that expresses papain-like cysteine ​​protease (PLpro). [Background technology]

[0003] Coronaviruses (CoVs) (order Nidovirales, family Coronaviridae, subfamily Coronavirinae) are enveloped viruses with single-stranded, positive-sense RNA genomes. CoVs have genomes that range in size from 26 to 32 kilobases (kb) in length, which is large for an RNA virus. The CoV genome encodes four major structural proteins: spike (S), nucleocapsid (N), membrane (M), and envelope (E) proteins, all of which are required to produce structurally complete virus particles. See, e.g., P.S. Masters, The molecular biology of coronavirus. Adv. Virus Res. 2014:101:105-12.

[0004] A novel coronavirus, SARS-CoV2, is the cause of the current respiratory illness COVID-19, which emerged in Wuhan, China in late 2019. To date, over 400 million people have been infected globally and over 8 million have died. The SARS-CoV2 pandemic has put pressure on healthcare systems and governments worldwide.

[0005] Given the severe impact of coronaviruses, particularly SARS-CoV2, on people and healthcare systems worldwide, it is important to provide new treatments for infected individuals. Summary of the Invention [Problem to be solved by the invention]

[0006] It is therefore an object of the present invention to provide new drugs for treating coronaviruses, including SARS-CoV2, for treating infected or at risk of infection in humans. [Means for solving the problem]

[0007] The present invention provides new compounds and their pharmaceutically acceptable salts for the allosteric inhibition of papain-like protease (PL), a key enzyme used by coronaviruses, such as SARS-CoV2, involved in generating a functional replicase complex that enables the virus to replicate, along with their uses and manufacture. PL also cleaves ubiquitin and ISG15, known regulators of host innate immune pathways; therefore, these allosteric inhibitors can be used to modulate certain immune pathways. Thus, in certain embodiments, the present invention includes the new compounds and the administration of an effective amount of such compounds or their pharmaceutically acceptable salts to a host, e.g., a human, alone or in combination with another active antiviral or adjuvant, to treat coronaviruses, including SARS-CoV2.

[0008] Due to the unique mechanism of action of PLpro, the compounds of the present invention can directly reduce viral replication and simultaneously reduce the symptoms caused by the virus by inhibiting the protease activity of PLpro in host cells. For example, in certain embodiments, the compounds of the present invention or pharmaceutically acceptable salts thereof can inhibit the dysregulation of the signal transduction cascade triggered by PL, which leads to the cell death of adjacent non-infected cells. By inhibiting the protease activity of PL, the compounds of the present invention or pharmaceutically acceptable salts thereof can rescue adjacent non-infected cells, thereby reducing the symptoms of the virus in the host.

[0009] In one embodiment, a compound of formula (I')

[0010] [ka]

[0011] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In another embodiment, a compound of formula (I″)

[0012] [ka]

[0013] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some embodiments, the compound of formula (I') or (I'') is a compound of formula (Ia'):

[0014] [ka]

[0015] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some embodiments, the compound of formula (I') or (I'') is a compound of formula (Ib'):

[0016] [ka]

[0017] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some embodiments, the compound of formula (I') or (I'') is a compound of formula (Ic'):

[0018] [ka]

[0019] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some embodiments, the compound of formula (I') or (I'') is a compound of formula (Id'):

[0020] [ka]

[0021] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some embodiments, the compound of formula (I'') is a compound of formula (Ie'):

[0022] [ka]

[0023] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In another embodiment, a compound of formula (I-1″)

[0024] [ka]

[0025] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In another embodiment, a compound of formula (II')

[0026] [ka]

[0027] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In another embodiment, a compound of formula (II″)

[0028] [ka]

[0029] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some embodiments, the compound of formula (II') or (II'') is a compound of formula (IIa'):

[0030] [ka]

[0031] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some embodiments, the compound of formula (II') or (II'') is a compound of formula (IIb'):

[0032] [ka]

[0033] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some embodiments, the compound of formula (II') or (II'') is a compound of formula (IIc'):

[0034] [ka]

[0035] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In another embodiment, a compound of formula (III″)

[0036] [ka]

[0037] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In another embodiment, a compound of formula (IV″)

[0038] [ka]

[0039] or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, is provided herein. In another embodiment, a compound of formula (VI″):

[0040] [ka]

[0041] or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, is provided herein. In another embodiment, a compound of formula (VII″):

[0042] [ka]

[0043] or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, is provided herein. In another embodiment, a compound of formula (VIII″)

[0044] [ka]

[0045] or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, is provided herein. In another embodiment, a compound of formula (IX″):

[0046] [ka]

[0047] or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, is provided herein. In another embodiment, a compound of formula (X″)

[0048] [ka]

[0049] or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, is provided herein. In another aspect, provided herein is a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0050] In another aspect, provided herein is a method of treating a viral infection in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition disclosed herein.

[0051] In another aspect, provided herein is a method of preventing a viral infection in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition disclosed herein.

[0052] In some embodiments, the viral infection is a coronavirus infection. In some embodiments, the viral infection is caused by a coronavirus. In some embodiments, the coronavirus is SARS-CoV-2.

[0053] In another aspect, provided herein is a method of inhibiting PLPro in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition disclosed herein.

[0054] In another aspect, provided herein is a method of preventing viral replication in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition disclosed herein.

[0055] In some embodiments, the virus is a coronavirus. In some embodiments, the coronavirus is SARS-Cov-2. DETAILED DESCRIPTION OF THE INVENTION

[0056] The present invention provides compounds for inhibiting papain-like protease (PLpro), which is essential for viral replication. In certain embodiments, inhibition of PLpro directly inhibits viral replication. In certain embodiments, inhibition of PLpro inhibits the dysregulation of signal transduction cascades in infected cells, the absence of which leads to cell death of surrounding uninfected cells.

[0057] definition As used herein, the term "alkyl" refers to a saturated monovalent chain of carbon atoms, which may be branched; the term "alkenyl" refers to an unsaturated monovalent chain of carbon atoms, which may be branched, containing at least one double bond; the term "alkylene" refers to a saturated divalent chain of carbon atoms, which may be branched; and the term "cycloalkylene" refers to a saturated divalent chain of carbon atoms, which may be branched, portions of which form a ring.

[0058] As used herein, the term "alkynyl" refers to a monovalent chain of carbon atoms having one or more (e.g., 1, 2, 3, or 4) carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds).

[0059] As used herein, the term "alkylene" generally refers to a divalent saturated hydrocarbon group, which hydrocarbon group can be a straight-chain or branched-chain hydrocarbon group. Non-limiting illustrative examples include methylene, 1,2-ethylene, 1-methyl-1,2-ethylene, 1,4-butylene, 2,3-dimethyl-1,4-butylene, 2-methyl-2-ethyl-1,5-pentylene, and the like.

[0060] As used herein, the term "cycloalkyl" generally refers to a monovalent saturated hydrocarbon ring. As used herein, the term "cycloalkenyl" refers to a monovalent hydrocarbon ring containing one or more (e.g., 1, 2, 3, or 4) unsaturated bonds.

[0061] As used herein, the term "carbocyclyl" or "carbocyclic" refers to a radical of a non-aromatic cyclic hydrocarbon group having 3 to 12 ring carbon atoms (a "3- to 12-membered carbocyclyl") and 0 heteroatoms in a non-aromatic ring system.

[0062] As used herein, the term "isotopic derivative" refers to a compound in which one or more (e.g., one, two, three, or four) atoms are isotopically enriched with an isotope, for example, greater than about 50%, 60%, 70%, 80%, 90%, 95%, or 99%. Isotopes are atoms that have the same number of protons but different numbers of neutrons (e.g., hydrogen has one proton, and an isotope of hydrogen called deuterium has one proton and one neutron). Non-limiting examples of isotopes include isotopes of hydrogen (e.g., deuterium), isotopes of carbon, isotopes of nitrogen, isotopes of oxygen, isotopes of fluorine, and isotopes of chlorine.

[0063] "Aryl" refers to the radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic arrangement) having 6 to 14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ("C6-14 aryl"). Aryl groups include, but are not limited to, phenyl and naphthyl. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted aryl") or substituted with one or more (e.g., 1, 2, 3, or 4) substituents ("substituted aryl").

[0064] As used herein, the terms "bicycle" and "bicyclic" include molecular fragments or radicals containing two fused rings, where the rings are independently selected from aryl, heteroaryl, cycloalkyl, heterocycle, and cycloalkenyl.

[0065] As used herein, the terms "tricycle" and "tricyclic" include molecular fragments or radicals containing three fused rings, wherein the rings are independently selected from aryl, heteroaryl, cycloalkyl, heterocycle, and cycloalkenyl.

[0066] As used herein, the terms "heteroalkyl" and "heteroalkylene" include molecular fragments or radicals containing monovalent and divalent groups, respectively, formed from straight or branched chains of carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur, such as alkoxyalkyl, alkyleneoxyalkyl, aminoalkyl, alkylaminoalkyl, alkyleneaminoalkyl, alkylthioalkyl, alkylenethioalkyl, alkoxyalkylaminoalkyl, alkylaminoalkoxyalkyl, alkyleneoxyalkylaminoalkyl, and the like. It should be understood that neither heteroalkyl nor heteroalkylene includes oxygen-oxygen fragments. It should also be understood that neither heteroalkyl nor heteroalkylene includes oxygen-sulfur fragments, unless sulfur is oxidized as S(O) or S(O)2.

[0067] As used herein, the terms “heterocycle” and “heterocyclyl” refer to a non-aromatic ring containing one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., N, O, and / or S) selected from nitrogen, oxygen, and sulfur, or a monovalent radical thereof, such as, but not limited to, tetrahydrofuran, aziridine, pyrrolidine, oxazolidine, 3-methoxypyrrolidine, 3-methylpiperazine, etc. The heterocycle or heterocyclyl may be optionally fused to an aromatic or non-aromatic ring. As used herein, the term "heterocyclylene" refers to a divalent radical of a heterocycle.

[0068] As used herein, the term "cycloheteroalkyl" generally refers to an optionally branched chain of atoms containing both carbon and at least one heteroatom, where the chain optionally contains one or more unsaturated bonds, and at least a portion of the chain forms one or more rings. As used herein, the term "cycloheteroalkyl" is also understood to include "heterocycloalkyl," "heterocycle," and "heterocyclyl." As used herein, the term "heterocycloalkenyl" refers to a monovalent chain of carbon atoms and heteroatoms, a portion of which forms a ring and contains one or more unsaturated bonds, the heteroatoms being selected from nitrogen, oxygen, or sulfur. Exemplary cycloheteroalkyls include, but are not limited to, tetrahydrofuryl, bis(tetrahydrofuranyl), pyrrolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, homopiperazinyl, quinuclidinyl, dihydrofuryl, pyrrolinyl, dihydropyranyl, and the like. It should also be understood that cycloheteroalkyl includes polycyclic radicals, including fused bicyclic rings, spiro bicyclic rings, and the like.

[0069] As used herein, the term "acyl" refers to hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl bonded as a substituent through a carbonyl group, such as, but not limited to, formyl, acetyl, pivalolyl, benzoyl, phenacetyl, and the like.

[0070] "Heteroaryl" refers to a radical of a 5-14 membered monocyclic, bicyclic, or tricyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having ring carbon atoms and 1-4 ring heteroatoms (e.g., O, N, and / or S) provided in the aromatic ring system, each heteroatom independently selected from nitrogen, oxygen, and sulfur ("5-12 membered heteroaryl"). In heteroaryl groups containing one or more (e.g., 1, 2, 3, or 4) nitrogen atoms, the point of attachment can be at a carbon atom or a nitrogen atom, if valence permits. Heteroaryl bicyclic ring systems can contain one or more (e.g., 1, 2, 3, or 4) heteroatoms in one or both rings. "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused to one or more (e.g., 1, 2, 3, or 4) aryl groups, and the point of attachment is on the aryl ring or the heteroaryl ring; in such cases, the number of ring members represents the number of ring members in the fused (aryl / heteroaryl) ring system. In bicyclic heteroaryl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, etc.), the point of attachment can be on either ring, i.e., on the ring containing a heteroatom (e.g., 2-indolyl) or on the ring without a heteroatom (e.g., 5-indolyl). As used herein, the term "heteroarylene" refers to a divalent radical of heteroaryl.

[0071] As used herein, "haloalkyl" is generally understood to mean an alkyl group in which one or more (e.g., one, two, three, or four) hydrogen atoms are replaced by halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine, and iodine. Non-limiting illustrative examples include difluoromethyl, 2,2,2-trifluoroethyl, 2-chlorobutyl, 2-chloro-2-propyl, trifluoromethyl, bromodifluoromethyl, and the like.

[0072] "Alkoxyl" or "alkoxy" refers to an alkyl group having the formula RO that is single-bonded to an oxygen atom. Alkoxyl includes, for example, methoxy (CHO-) and ethoxy (CHCHO-). "Cycloalkoxyl" refers to a cycloalkyl group that is single-bonded to an oxygen atom, including "aryloxy" groups in which the aryl group is single-bonded to the oxygen, e.g., a phenoxy group (CHO). Similarly, the term "heteroalkoxyl" refers to a cycloalkyl group that is single-bonded to an oxygen atom, including "aryloxy" groups in which the aryl group is single-bonded to the oxygen atom, e.g., a phenoxy group (CHO). Similarly, the term "heteroalkoxyl" refers to a cycloalkyl group that is single-bonded to an oxygen atom, e.g., a heteroalkoxy group in which the aryl group is single-bonded to the oxygen atom. refers to a single-bonded heteroalkyl group, and the term "cycloheteroalkoxyl" refers to a cycloheteroalkyl group that is single-bonded to an oxygen atom.

[0073] As used herein, the term "haloalkoxy" refers to a haloalkyl group that is attached to another moiety through an oxygen atom, for example, -OCHCF2 or -OCF3. "Halo" or "halogen," alone or as part of another substituent, generally refers to a fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) atom. The term "halide," alone or as part of another substituent, refers to a fluoride, chloride, bromide, or iodide atom.

[0074] As used herein, the term "optionally substituted" includes a wide variety of groups replacing one or more (e.g., one, two, three, or four) hydrogens on a carbon, nitrogen, oxygen, or sulfur atom, including monovalent and divalent groups. For example, optional substitutions on carbons include, but are not limited to, halo, hydroxy, alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, arylalkyl, acyl, acyloxy, and the like. In one aspect, optional substitutions on aryl carbons include, but are not limited to, halo, amino, hydroxy, alkyl, alkenyl, alkoxy, arylalkyl, arylalkyloxy, hydroxyalkyl, hydroxyalkenyl, alkylenedioxy, aminoalkyl, arylalkyl, and / or acyl groups, in which the amino group may also be substituted with one or two alkyl groups, nitro, acyl, and derivatives thereof, such as oxime, hydrazone, cyano, alkylsulfonyl, alkylsulfonylamino, and the like. Illustratively, optional substitutions for nitrogen, oxygen, and sulfur include, but are not limited to, alkyl, haloalkyl, aryl, arylalkyl, acyl, etc., as well as protecting groups, such as alkyl, ether, ester, and acyl protecting groups, and prodrug groups. It is further understood that each of said optional substituents may itself be further optionally substituted, for example, with halo, hydroxy, alkyl, alkoxy, haloalkyl, haloalkoxy, etc.

[0075] It is understood that the substitutions and any functional groups may independently be ortho-, para-, or meta- It is understood that cyclic groups may be aromatic or non-aromatic. "Stereoisomers": It should also be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space are referred to as "isomers." Isomers that differ in the arrangement of their atoms in space are referred to as "stereoisomers." Stereoisomers that are not mirror images of each other are referred to as "diastereomers," and stereoisomers that are non-superimposable mirror images of each other are referred to as "enantiomers." When a compound has an asymmetric center, e.g., it is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and are described by the R- and S-sequencing rules of Cahn and Prelog or by the way the molecule rotates the plane of polarized light, designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers, respectively). Chiral compounds can exist as either individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0076] "Tautomers" refer to interchangeable forms of a particular compound structure, altered by the displacement of hydrogen atoms and electrons. Thus, two structures can be in equilibrium through the shifting of π electrons and atoms (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci and nitro forms of phenylnitromethane, which are also formed by treatment with acid or base. Tautomeric forms can be relevant to achieving optimal chemical reactivity and biological activity of a desired compound.

[0077] compound In one embodiment, a compound of formula (I')

[0078] [ka]

[0079] or a pharmaceutically acceptable salt thereof (In the formula, Ring A is selected from the group consisting of naphthyl, anthracenyl, 8- to 12-membered bicyclic or tricyclic heteroaryl, 8- to 12-membered bicyclic or tricyclic heterocyclyl, and 8- to 12-membered partially unsaturated bicyclic carbocyclyl, wherein naphthyl, 8- to 12-membered bicyclic or tricyclic heteroaryl, and 8- to 12-membered partially unsaturated bicyclic carbocyclyl are selected from the group consisting of one or more (e.g., one, two, three, or four) R 1 may be replaced by; Each X is CH2, CH, or NR h and O, independently selected from the group consisting of (NH, CH, NR h (R h =H), any hydrogen atom in R x may be substituted with); R x When R is substituted on a carbon atom, each R x independently, C 1~6 alkyl or halo, or R x When R is substituted on the nitrogen atom, each R x independently, C 1~6 is alkyl; m is 0, 1, or 2;

[0080] [ka]

[0081] is a single or double bond; n is 1 or 2; Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, 3- to 7-membered heterocyclyl, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 C optionally substituted with alkynyl, phenyl 1~6 Alkoxy, -OC 1~6 Alkylene-C 1~6 Alkoxy, -C(O)OR i, -S(O) t C 1~6 Alkyl, -SC 1~6 Haloalkyl, -NR e R f , -C(O)NR g R h , -O-phenyl, and hydroxy; phenyl and 5-6 membered heteroaryl are independently selected from the group consisting of halo, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each selected from the group consisting of alkoxy; t is 0, 1, or 2; R 2 Ha, Halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~6 Alkoxy, hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 alkylene -OH), and -NR e R f a 3- to 8-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of: c R d May be substituted with -OC 3~7 Cycloalkyl, -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)OC 1~6 alkyl, 3- to 8-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of: -NR c R d may be substituted with C 1~6 Alkyl, -O-(5-6 membered heteroaryl), C 0~6 Alkylene-CN, C 0~6Alkylene-C(O)O(C1 ~6 alkyl), C 0~6 Alkylene-C(O)NR e R f , and -NR A R B C 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; R 4 is H, C 1~6 Alkyl, halo, hydroxy, and -NR e R f or R 3 and R 4 together with the atoms to which they are attached to form a phenyl-fused aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring, the 5- to 10-membered ring containing at least one heteroatom, and the 5- to 10-membered ring is -NR c R d may be substituted with C 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5-6 membered heteroaryl, -(C 0~6 (alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -C(O)-NCH3OCH3, -(C 0~6 (Alkylene)-NR c R d , -(C 0~6 Alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 Alkylene)-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; Each R 3a is C 1~6 Alkyl, -NR A R B , C 1~6 Alkoxy, hydroxy, -C(O)NR c R d , 3- to 8-membered heterocyclyl, phenyl, 5- to 6-membered heteroaryl, and -(C 0~6 alkylene)-(NR c R d may be substituted with C 3~6 cycloalkyl), wherein the 3-8 membered heterocyclyl and the 5-6 membered heteroaryl are independently selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, phenyl, benzyl, C 1~6 Alkylene-OH, and C 0~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O)2C 1~6 Alkyl, -C(O)-C 1~6 Alkyl, C 1~6 Alkylene-NR c R d , 3- to 6-membered heterocyclyl optionally substituted with oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy, -(C 0~6 alkylene)-phenyl, and -(C 0~6Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Cycloalkyl is hydroxy or C 1~6 each optionally substituted with alkoxy; Each R c and R d independently, for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and R d may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; Each R e and R f independently, for each occurrence, H, C 1~6 Alkyl, -C(O)C 1~6 Alkyl, and -C(O)OC 1~6 alkyl; and Each R g , R h , and R i independently, for each occurrence, H or C 1~6 alkyl) is provided herein.

[0082] In another embodiment, a compound of formula (I″)

[0083] [ka]

[0084] or a pharmaceutically acceptable salt thereof (In the formula, Ring A is selected from the group consisting of naphthyl, anthracenyl, phenanthrenyl, 8-14 membered bicyclic or tricyclic heteroaryl, 8-12 membered bicyclic or tricyclic heterocyclyl, and 8-12 membered partially unsaturated bicyclic carbocyclyl, wherein naphthyl, 8-14 membered bicyclic or tricyclic heteroaryl, and 8-12 membered partially unsaturated bicyclic carbocyclyl are selected from the group consisting of one or more (e.g., one, two, three, or four) R 1 may be replaced by When ring A is an 8- to 12-membered bicyclic heterocyclyl or an 8- to 12-membered partially unsaturated bicyclic carbocyclyl, R 3 is one or more (e.g., one, two, three, or four) R 3a may be substituted with C 1~6 is alkoxy; Each X is CH2, CH, or NR h and O, independently selected from the group consisting of (NH, CH, NR h (R h =H), any hydrogen atom in R x may be substituted with); R x When R is substituted on a carbon atom, each R x are independent, D, C 1~6 alkyl or halo, or R x When R is substituted on the nitrogen atom, each R x independently, C 1~6 is alkyl; m is 0, 1, 2, 3, or 4;

[0085] [ka]

[0086] is a single or double bond; n is 1 or 2; Each R 1 is phenyl, 5- to 9-membered heteroaryl, C 3~7 carbocyclyl, one or more (e.g., one, two, three, or four) R 1a3- to 7-membered heterocyclyl optionally substituted with C 1~6 Haloalkyl, C 1~6 C optionally substituted with haloalkoxy, halo, -CN, hydroxy 1~6 Alkyl, C 3~6 Cycloalkyl or C 0~6 C optionally substituted with alkyl-substituted phenyl 2~6 alkenyl, optionally substituted with one or more (e.g., one, two, three, or four) halo; 2~6 C optionally substituted with alkynyl, phenyl 1~6 Alkoxy, -OC 1~6 Alkylene-C 1~6 Alkoxy, -C(O)-C 1~6 Alkyl, -C(O)OR i , -S(O) t C 1~6 Alkyl, -SC 1~6 Haloalkyl, -OS(O) t C 1~6 Haloalkyl, -NR j R k , -C(O)NR g R h , -O-phenyl, -B(OR m )2, and hydroxy; phenyl and 5-9 membered heteroaryl are independently selected from the group consisting of halo, cyano, phenyl, 3-7 membered heterocyclyl, C 1~6 Alkyl, C 1~6 alkylene-(3- to 7-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) halo), C substituted with hydroxy 1~6 Alkylene, C 1~6 Alkylene-NR A R B , -C(O)-3 to 6-membered heterocyclyl, hydroxy, C 1~6 Haloalkyl, C 1~6 Alkoxy, and -C(O)-C 1~6 From the group consisting of alkyl each optionally substituted with one or more (e.g., 1, 2, 3, or 4) independently selected substituents; t is 0, 1, or 2; R1a is oxo, halo, C 1~6 Haloalkyl, and C 1~6 selected from the group consisting of alkoxy; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; R 7 is H and C 1~6 alkyl; R 2 Ha, Halo, C 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~20 Alkoxy, hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 Alkylene -OH), -C(O)OC 1~6 Alkyl, and -NR e R f -3- to 10-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of: c R d May be substituted with -OC 3~7 Cycloalkyl, -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)OC 1~6 alkyl, 3- to 9-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of -NR c R d may be substituted with C 1~6 Alkyl, -O-(5-6 membered heteroaryl), C 0~6 Alkylene-CN, C 0~6Alkylene-C(O)O(C 1~6 alkyl), C 0~6 Alkylene-C(O)NR e R f , and -NR AA R BB C 1~20 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; R 4 is H, C 1~6 C optionally substituted with alkyl, phenyl or 5- to 6-membered heteroaryl 2~6 Alkynyl, halo, hydroxy, and -NR e R f or R 3 and R 4 together with the atoms to which they are attached to form a phenyl-fused aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring, the 5- to 10-membered ring containing at least one heteroatom, and the 5- to 10-membered ring is -NR c R d may be substituted with C 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5-6 membered heteroaryl, -(C 0~6 (alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -C(O)-NCH3OCH3, -(C 0~6 (Alkylene)-NR c R d , -(C 0~6 Alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 Alkylene)-C 1~6an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to a phenyl, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl, and wherein the aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to a phenyl is not imidazole; R AA and R BB is H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O)2C 1~6 Alkyl, -C(O)-C 1~6 Alkyl, C 1~20 Alkylene-NR c R d , 3- to 6-membered heterocyclyl optionally substituted with oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy, -(C 0~6 alkylene)-phenyl, -(C 0~20 alkylene)-(3- to 10-membered heterocyclyl), and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene, 3- to 10-membered heterocyclyl, and C 3~6 Cycloalkyl is C 1~6 Alkyl, hydroxy and C 1~6 each optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O)2C 1~6 Alkyl, -C(O)-C 1~6 Alkyl, C 1~6 Alkylene-NR c R d , 3- to 6-membered heterocyclyl optionally substituted with oxo, C 1~6Alkyl or C 1~6 5-6 membered heterocyclic group optionally substituted with alkoxy Aryl, -(C 0~6 alkylene)-phenyl, and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Cycloalkyl is hydroxy or C 1~6 each optionally substituted with alkoxy; Each R c and R d independently, for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and R d may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; Each R e and R f independently, for each occurrence, H, C 1~6 Alkyl, -C(O)C 1~6 Alkyl, -C(O)OC 1~6 Alkyl, and -S(O)C 1~6 selected from the group consisting of alkyl; Each R g , R h , and R i independently, for each occurrence, H or C 1~6 is alkyl; and Each R j and R k is independently, for each occurrence, H, C which may be substituted with phenyl 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)C 1~6 Alkyl, -S(O)C 1~6 Alkyl, and -C(O)OC 1~6 selected from the group consisting of alkyl; Each R 3a D, C 1~6 Alkyl, -NRA R B , C 1~6 Alkoxy, hydroxy, -C(O)NR c R d , 3- to 10-membered heterocyclyl, phenyl, 5- to 6-membered heteroaryl, and -(C 0~6 alkylene)-(NR c R d may be substituted with C 3~6 cycloalkyl), wherein the 3- to 10-membered heterocyclyl and the 5- to 6-membered heteroaryl are optionally substituted with halo, hydroxy, one or more (e.g., 1, 2, 3, or 4) D. 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, phenyl, benzyl, C 1~6 Alkylene-OH, and C 0~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; and Each R m is hydrogen and C 1~6 alkyl, or two (OR m ) groups together with the boron atom to which they are attached form a pinacol ester,

[0087] [ka]

[0088] may form; However, when ring A is naphthyl, R 4 is hydrogen, -F, -Cl, C 1~6 Alkyl, and -NR e R f R 5 is hydrogen; R 6is hydrogen or halo; X is CH2; n is 1; R 2 Ha, Halo, C 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~6 Alkoxy, hydroxy, C 1~6 alkylene-(one or more (e.g., one, two, three, or four) R XX 3-10 membered heterocyclyl optionally substituted with one or more (e.g., one, two, three, or four) R XX 3-membered heterocyclyl optionally substituted with one or more (e.g., one, two, three, or four) R XX a 4-membered heterocyclyl substituted with, a 5-membered partially unsaturated heterocyclyl, a 5-membered saturated heterocyclyl having the point of attachment (to the phenyl) on a carbon atom of the heterocyclyl, at least two (e.g., two, three, or four) R XX 5-membered saturated heterocyclyl substituted with at least two (e.g., two, three, or four) R substituted on a carbon atom of the heterocyclyl XX 6-membered heterocyclyl having -NR c R d May be substituted with -OC 3~7 Cycloalkyl, -(C 0~6 alkylene)-O-(C 1~6 Alkyl , benzyl and -C(O)OC 1~6 alkyl, 3- to 9-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of -NR c R d may be substituted with C 1~6 Alkyl, -O-5-6 membered heteroaryl, C 0~6 Alkylene-CN, C 0~6 Alkylene-C(O)O(C 1~6 alkyl), C 0~6 Alkylene-C(O)NRe R f , and -NR AA R BB C 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; Each R XX is C 1~6 Alkyl, (C 1~6 alkylene)-OH, -C(O)OC 1~6 Alkyl, and -NR e R f are independently selected from the group consisting of: R AA and R BB is H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, -C(O)-C 1~6 Alkyl, -(C 0~6 alkylene)-phenyl, and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Cycloalkyl is hydroxy or C 1~6 each optionally substituted with alkoxy, R AA and R BB at least one of is not hydrogen; or R AA is hydrogen and R BB is C 1~6 Alkylene-NR c R d is) is provided herein.

[0089] In another embodiment, a compound of formula (I''-A)

[0090] [ka]

[0091] or a pharmaceutically acceptable salt thereof (In the formula, Ring A is selected from the group consisting of naphthyl, anthracenyl, phenanthrenyl, 8-14 membered bicyclic or tricyclic heteroaryl, 8-12 membered bicyclic or tricyclic heterocyclyl, and 8-12 membered partially unsaturated bicyclic carbocyclyl, wherein naphthyl, 8-14 membered bicyclic or tricyclic heteroaryl, and 8-12 membered partially unsaturated bicyclic carbocyclyl are selected from the group consisting of one or more (e.g., one, two, three, or four) R 1 may be replaced by When ring A is an 8- to 12-membered bicyclic heterocyclyl or an 8- to 12-membered partially unsaturated bicyclic carbocyclyl, R 3 is one or more (e.g., one, two, three, or four) R 3a may be substituted with C 1~6 is alkoxy; Each X is CH2, CH, or NR h and O, independently selected from the group consisting of (NH, CH, NR h (R h =H), any hydrogen atom in R x may be substituted with); R x When R is substituted on a carbon atom, each R x are independent, D, C 1~6 alkyl or halo, or R x When R is substituted on the nitrogen atom, each R x independently, C 1~6 is alkyl; m is 0, 1, 2, 3, or 4;

[0092] [ka]

[0093] is a single or double bond; n is 1 or 2; Each R 1 is phenyl, 5- to 9-membered heteroaryl, C 3~7carbocyclyl, one or more (e.g., one, two, three, or four) R 1a 3- to 7-membered heterocyclyl optionally substituted with C 1~6 Haloalkyl, C 1~6 C optionally substituted with haloalkoxy, halo, -CN, hydroxy 1~6 Alkyl, C 3~6 Cycloalkyl or C 0~6 C optionally substituted with alkyl-substituted phenyl 2~6 alkenyl, optionally substituted with one or more (e.g., one, two, three, or four) halo; 2~6 C optionally substituted with alkynyl, phenyl 1~6 Alkoxy, -OC 1~6 Alkylene-C 1~6 Alkoxy, -C(O)-C 1~6 Alkyl, -C(O)OR i , -S(O) t C 1~6 Alkyl, -SC 1~6 Haloalkyl, -OS(O) t C 1~6 Haloalkyl, -NR j R k , -C(O)NR g R h , -O-phenyl, -B(OR m )2, and hydroxy; phenyl and 5-9 membered heteroaryl are independently selected from the group consisting of halo, cyano, phenyl, 3-7 membered heterocyclyl, C 1~6 Alkyl, C 1~6 alkylene-(3- to 7-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) halo), C substituted with hydroxy 1~6 Alkylene, C 1~6 Alkylene-NR A R B , -C(O)-3 to 6-membered heterocyclyl, hydroxy, C 1~6 Haloalkyl, C 1~6 Alkoxy, and -C(O)-C 1~6optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkyl; t is 0, 1, or 2; R 1a is oxo, halo, C 1~6 Haloalkyl, and C 1~6 selected from the group consisting of alkoxy; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; R 7 is H and C 1~6 alkyl; R 2 Ha, Halo, C 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~20 Alkoxy, hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 Alkylene -OH), -C(O)OC 1~6 Alkyl, and -NR e R f -3- to 10-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of: c R d May be substituted with -OC 3~7 Cycloalkyl, -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)OC 1~6 alkyl, 3- to 9-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of -NR c Rd may be substituted with C 1~6 Alkyl, -O-(5-6 membered heteroaryl), C 0~6 Alkylene-CN, C 0~6 Alkylene-C(O)O(C 1~6 alkyl), C 0~6 Alkylene-C(O)NR e R f , and -NR AA R BB C 1~20 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; R 4 is H, C 1~6 C optionally substituted with alkyl, phenyl or 5- to 6-membered heteroaryl 2~6 Alkynyl, halo, hydroxy, and -NR e R f or R 3 and R 4 together with the atoms to which they are attached to form a phenyl-fused aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring, the 5- to 10-membered ring containing at least one heteroatom, and the 5- to 10-membered ring is -NR c R d may be substituted with C 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5-6 membered heteroaryl, -(C 0~6 (alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -C(O)-NCH3OCH3, -(C 0~6 (Alkylene)-NR c R d , -(C 0~6 Alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C( O)OH, and -(C 0~6 Alkylene)-C 1~6an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to a phenyl, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl, and wherein the aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to a phenyl is not imidazole; R AA and R BB is H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O)2C 1~6 Alkyl, -C(O)-C 1~6 Alkyl, C 1~20 Alkylene-NR c R d , 3- to 6-membered heterocyclyl optionally substituted with oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy, -(C 0~6 alkylene)-phenyl, -(C 0~20 alkylene)-(3- to 10-membered heterocyclyl), and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene, 3- to 10-membered heterocyclyl, and C 3~6 Cycloalkyl is C 1~6 Alkyl, hydroxy and C 1~6 each optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O)2C 1~6 Alkyl, -C(O)-C 1~6 Alkyl, C 1~6 Alkylene-NR c R d , 3- to 6-membered heterocyclyl optionally substituted with oxo, C 1~6Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy, -(C 0~6 alkylene)-phenyl, and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Cycloalkyl is hydroxy or C 1~6 each optionally substituted with alkoxy; Each R c and R d independently, for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and R d may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; Each R e and R f independently, for each occurrence, H, C 1~6 Alkyl, -C(O)C 1~6 Alkyl, -C(O)OC 1~6 Alkyl, and -S(O)C 1~6 selected from the group consisting of alkyl; Each R g , R h , and R i independently, for each occurrence, H or C 1~6 is alkyl; and Each R j and R k is independently, for each occurrence, H, C which may be substituted with phenyl 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)C 1~6 Alkyl, -S(O)C 1~6 Alkyl, and -C(O)OC 1~6 selected from the group consisting of alkyl; Each R 3a D, C 1~6 Alkyl, -NR A RB , C 1~6 Alkoxy, hydroxy, -C(O)NR c R d , 3- to 10-membered heterocyclyl, phenyl, 5- to 6-membered heteroaryl, and -(C 0~6 alkylene)-(NR c R d may be substituted with C 3~6 cycloalkyl), wherein the 3- to 10-membered heterocyclyl and the 5- to 6-membered heteroaryl are optionally substituted with halo, hydroxy, one or more (e.g., 1, 2, 3, or 4) D. 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, phenyl, benzyl, C 1~6 Alkylene-OH, and C 0~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; and Each R m is hydrogen and C 1~6 alkyl, or two (OR m ) groups together with the boron atom to which they are attached form a pinacol ester,

[0094] [ka]

[0095] may form; R AA and R BB is H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, -C(O)-C 1~6 Alkyl, -(C 0~6 alkylene)-phenyl, and -(C 0~6Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Cycloalkyl is hydroxy or C 1~6 each optionally substituted with alkoxy, R AA and R BB at least one of is not hydrogen; or R AA is hydrogen and R BB is C 1~6 Alkylene-NR c R d is) is provided herein.

[0096] In some embodiments, the compound of formula (I′), (I″), or (I″-A) is a compound of formula (Ia′):

[0097] [ka]

[0098] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined above. In some embodiments, the compound of Formula (I′), (I″), or (I″-A) is a compound of Formula (Ib′):

[0099] [ka]

[0100] or a pharmaceutically acceptable salt thereof (In the formula, G 1 , G 2 , G 3 , G 4 , G 5 , G 6 , and G 7 each is independently selected from CH and N; s is 0, 1, 2, or 3; X, n, R1 , R 2 , R 3 , R 4 , R 5 , and R 6 is as defined above) is.

[0101] In some embodiments, the compound of Formula (I'), (I''), or (I''-A) is a compound of Formula (Ic'):

[0102] [ka]

[0103] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined above. In some embodiments, the compound of formula (I'), (I''), or (I''-A) is a compound of formula (Id'):

[0104] [ka]

[0105] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined above. In some embodiments, the compounds of the present disclosure are 1 , G 2 , G 3 , G 4 , G 5 , G 6 , and G 7 is CH. In some embodiments, the compounds of the present disclosure have a structure of formula (I'), (I''), or (I''-A), wherein G 1 is N and G 2 , G 3 , G 4 , G 5 , G 6 , and G 7 is CH; or G 2 is N and G 1 , G 3 , G 4, G 5 , G 6 , and G 7 is CH. In some embodiments, the compounds of the present disclosure have a structure of formula (I'), (I''), or (I''-A), wherein G 3 is N and G 1 , G 2 , G 4 , G 5 , G 6 , and G 7 is CH; or G 4 is N and G 1 , G 2 , G 3 , G 5 , G 6 , and G 7 is CH. In some embodiments, the compounds of the present disclosure have a structure of formula (I'), (I''), or (I''-A), wherein G 5 is N and G 1 , G 2 , G 3 , G 4 , G 6 , and G 7 is CH; or G 6 is N and G 1 , G 2 , G 3 , G 4 , G 5 , and G 7 is CH. In some embodiments, the compounds of the present disclosure have a structure of formula (I'), (I''), or (I''-A), wherein G 7 is N and G 1 , G 2 , G 3 , G 4 , G 5 , and G 6 is CH.

[0106] In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where s is 0. In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where s is 1. In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where s is 2.

[0107] In some embodiments, compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A), where Ring A is naphthyl. In some embodiments, compounds of the present disclosure are those in which ring A is

[0108] [ka]

[0109] and having a structure of formula (I'), (I''), or (I''-A), selected from: In some embodiments, compounds of the present disclosure have the structure of Formula (I") or (I"-A), where Ring A is anthracenyl. In some embodiments, compounds of the present disclosure have the structure of Formula (I") or (I"-A), where Ring A is phenanthrenyl.

[0110] In some embodiments, compounds of the present disclosure have the structure of Formula (I") or (I"-A), where Ring A is an 8-14 membered bicyclic or tricyclic heteroaryl. In some embodiments, Ring A is a 10 membered bicyclic heteroaryl. In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where Ring A is quinolinyl.

[0111] In some embodiments, compounds of the present disclosure are those in which ring A is

[0112] [ka]

[0113] and having a structure of formula (I'), (I''), or (I''-A), selected from the group consisting of: In some embodiments, compounds of the present disclosure are those in which ring A is

[0114] [ka]

[0115] and having a structure of formula (I'), (I''), or (I''-A): In some embodiments, compounds of the present disclosure include those wherein Ring A is isoquinolinyl,

[0116] [ka]

[0117] and having a structure of formula (I'), (I''), or (I''-A): In some embodiments, compounds of the present disclosure are those in which ring A is

[0118] [ka]

[0119] and having a structure of formula (I'), (I''), or (I''-A), selected from the group consisting of: In some embodiments, the compound of formula (I'') or (I''-A) is of formula (Ie'): Compound:

[0120] [ka]

[0121] or a pharmaceutically acceptable salt thereof (In the formula,

[0122] [ka]

[0123] is cyclopropylene or oxetan-3-ylene (i.e.,

[0124] [ka]

[0125] ) represents; R 1aa Ha, Halo, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2-, 5-, or 6-membered monocyclic heteroaryl, 4-, or 5-membered heterocyclyl; R 1bb H, halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 haloalkyl; R 2 Ha, Halo, C 1~6 Alkyl, and C 1~6 haloalkyl; R 4 is H, hydroxy, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 Alkyl)2, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 haloalkyl; E is -O-, -N(H)-, and -N(C 1~6 alkyl)-; R CC is H or C 1~2 is alkyl; R DD is H or C 1~2 is alkyl; R c is H or C1~6 is alkyl; or R CC is H and R DD and R c may form a 4- to 5-membered heterocyclic ring together with the carbon atom and nitrogen atom to which they are attached; R d is H or C 1~6 alkyl) is.

[0126] In some embodiments, the compounds of the present disclosure are

[0127] [ka]

[0128] is cyclopropylene (i.e.,

[0129] [ka]

[0130] ) and has a structure of formula (Ie'). In some embodiments, the compounds of the present disclosure are

[0131] [ka]

[0132] is oxetan-3-ylene (i.e.,

[0133] [ka]

[0134] ) and has a structure of formula (Ie'). In some embodiments, the compounds of the present disclosure are 1aa C 1~6In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie'), wherein R 1aa C 2~6 It has the structure of formula (Ie'), which is alkenyl.

[0135] In some embodiments, the compounds of the present disclosure are 1bb is H. In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie'), wherein R 1bb C 1~6 It has the structure of formula (Ie'), which is alkyl.

[0136] In some embodiments, the compounds of the present disclosure are 2 C 1~6 It has the structure of formula (Ie'), which is alkyl. In some embodiments, compounds of the present disclosure have the structure of formula (Ie'), where E is -O-. In some embodiments, compounds of the present disclosure have the structure of formula (Ie'), where E is -N(H)-. In some embodiments, compounds of the present disclosure have the structure of formula (Ie'), where E is -N(C 1~6 alkyl)-, having the structure of formula (Ie').

[0137] In some embodiments, the compounds of the present disclosure are CC is H and R DD and R c which together with the carbon atom and nitrogen atom to which they are attached form a 4- to 5-membered heterocycle, have the structure of formula (Ie').

[0138] In some embodiments, the compounds of the present disclosure are d is H. In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie'), wherein R d C 1~6 It has the structure of formula (Ie'), which is alkyl.

[0139] In some embodiments, the compound of formula (I'), (I''), or (I''-A) is a compound of formula (Ie''):

[0140] [ka]

[0141] or a pharmaceutically acceptable salt thereof (In the formula,

[0142] [ka]

[0143] is cyclopropylene or oxetan-3-ylene (i.e.,

[0144] [ka]

[0145] ) represents; R 1aa Ha, Halo, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -NH(C 1~6 alkyl), -N(C 1~6 alkyl) 2-, 5-, or 6-membered monocyclic heteroaryl, 4-, or 5-membered heterocyclyl; R 1bb H, halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 haloalkyl; R 2 Ha, Halo, C 1~6 Alkyl, and C 1~6 haloalkyl; R 4 is H, hydroxy, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 alkyl)2, and C 1~6 selected from the group consisting of alkyl; R 3 is C 1~6Alkoxy or -NR A R B Selected from C 1~6 The alkoxy may be substituted with one or more (e.g., one, two, three, or four) 3- to 8-membered heterocyclyls, and the 3- to 8-membered heterocyclyls are C 1~6 optionally substituted with alkyl; and R A and R B is H, C 1~6 Alkyl, and -C 1~6 Alkylene-NR c R d and R is independently selected from the group consisting of c and R d H and C 1~6 alkyl) is.

[0146] In some embodiments, the compounds of the present disclosure are

[0147] [ka]

[0148] is cyclopropylene (i.e.,

[0149] [ka]

[0150] ) and has a structure of formula (Ie″). In some embodiments, the compounds of the present disclosure are

[0151] [ka]

[0152] is oxetan-3-ylene (i.e.,

[0153] [ka]

[0154] ) and has a structure of formula (Ie″). In some embodiments, the compounds of the present disclosure are 1aa C 1~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie″), wherein R 1aa C 2~6 It has a structure of formula (Ie″), which is alkenyl.

[0155] In some embodiments, the compounds of the present disclosure are 1bb is H. In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie″), wherein R 1bb C 1~6 It has the structure of formula (Ie″), which is alkyl.

[0156] In some embodiments, the compounds of the present disclosure are 2 C 1~6 It has the structure of formula (Ie″), which is alkyl. In some embodiments, the compounds of the present disclosure are 3 C 1~6 In some embodiments, C has a structure of formula (Ie″), wherein C is alkoxy. 1~6 In some embodiments, the alkoxy is substituted with a 3- to 8-membered heterocyclyl. 1~6 The alkoxy is substituted with a 3- to 8-membered heterocyclyl substituted with methyl.

[0157] In some embodiments, the compounds of the present disclosure are 3 NR A R B It has a structure of formula (Ie″), In some embodiments, the compounds of the present disclosure are A Ga-C 1~6 Alkylene-NR c R d and R B is H or C 1~6 It has the structure of formula (Ie″), which is alkyl.

[0158] In some embodiments, the compounds of the present disclosure are c and R d C 1~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie″), wherein R c and R d is H. In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie″), wherein R c C 1~6 alkyl, and R d is H.

[0159] In some embodiments, the compounds of the present disclosure are A and R B C 1~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie″), wherein R A and R B is H. In some embodiments, the compounds of the present disclosure have a structure of Formula (Ie″), wherein R A C 1~6 alkyl, and R B is H.

[0160] In some embodiments, compounds of the present disclosure have the structure of formula (I'), (I''), or (I''-A), where X is CH. In some embodiments, compounds of the present disclosure have the structure of formula (I'), (I''), or (I''-A), where X is CH. In some embodiments, compounds of the present disclosure have the structure of formula (I'), (I''), or (I''-A), where X is NH. In some embodiments, compounds of the present disclosure have the structure of formula (I'), (I''), or (I''-A), where X is O. It has the structure (I'), (I''), or (I''-A).

[0161] In some embodiments, compounds of the present disclosure have a structure of formula (I'), (I''), or (I''-A), where n is 2, one X is O, and the other X is CH2. In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where m is 0. In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where m is 1. In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where m is 2. In some embodiments, compounds of the present disclosure have the structure of Formula (I") or (I"-A), where m is 3. In some embodiments, compounds of the present disclosure have the structure of Formula (I") or (I"-A), where m is 4.

[0162] In some embodiments, the compounds of the present disclosure are

[0163] [ka]

[0164] is a single bond. In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A),

[0165] [ka]

[0166] is a double bond. In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where n is 1. In some embodiments, compounds of the present disclosure have the structure of Formula (I'), (I"), or (I"-A), where n is 2.

[0167] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, halo, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C1~6 Alkoxy, -S(O) t -C 1~6 Alkyl, -NR e R f and hydroxy.

[0168] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 is phenyl, 5-9 membered heteroaryl, C 3~7 carbocyclyl, one or more (e.g., one, two, three, or four) R 1a 3- to 7-membered heterocyclyl optionally substituted with C 1~6 C optionally substituted with haloalkyl, halo, -CN, hydroxy 1~6 Alkyl, C 3~6 Cycloalkyl or C 0~6 C optionally substituted with alkyl-substituted phenyl 2~6 alkenyl, optionally substituted with one or more (e.g., one, two, three, or four) halo; 2~6 C optionally substituted with alkynyl, phenyl 1~6 Alkoxy, -S(O) t -C 1~6 Alkyl, -C(O)-C 1~6 Alkyl, OS(O) t C 1~6 Haloalkyl, -NR j R k and hydroxy, having the structure of formula (I'') or (I''-A):

[0169] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, halo, and C 1~6 alkyl, phenyl, and 5-6 membered heteroaryl, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6and having a structure of formula (I'), (I"), or (I"-A), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

[0170] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 is phenyl, 5-9 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, halo, and C 1~6 alkyl, phenyl, and 5-9 membered heteroaryl; halo, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy; and optionally substituted with:

[0171] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 is a 5- to 9-membered heteroaryl, one or more (e.g., one, two, three, or four) R 1a 3- to 7-membered heterocyclyl optionally substituted with C 1~6 C optionally substituted with haloalkyl, halo, or hydroxy 1~6 Alkyl, C 3~6 Cycloalkyl or C 0~6 C optionally substituted with alkyl-substituted phenyl 2~6 alkenyl, optionally substituted with one or more (e.g., one, two, three, or four) halo; 2~6 C optionally substituted with alkynyl, phenyl 1~6 Alkoxy, -NR j R k and wherein the 5-9 membered heteroaryl is selected from the group consisting of halo, cyano, phenyl, 3-7 membered heterocyclyl, C 1~6 Alkyl, C 1~6alkylene-(3- to 7-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) halo), C substituted with hydroxy 1~6 Alkylene, C 1~6 Alkylene-NR A R B , -C(O)-3 to 6-membered heterocyclyl, hydroxy, C 1~6 Haloalkyl, C 1~6 Alkoxy, and -C(O)-C 1~6 and (I''-A) optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each selected from the group consisting of alkyl.

[0172] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 is 5-9 membered heteroaryl, 3-7 membered heterocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, and -NR j R k and (I''-A) independently selected from the group consisting of:

[0173] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 Halo, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -NH(C 1~6 alkyl), -N(C 1~6 alkyl), 2, 5- or 6-membered monocyclic heteroaryl, and 4- or 5-membered heterocyclyl, having the structure of Formula (I'') or (I''-A):

[0174] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 H, halo, C 1~6 Alkyl, C 1~6Alkoxy, and C 1~6 haloalkyl, having a structure of formula (I'') or (I''-A):

[0175] In some embodiments, the compounds of the present disclosure are 2 Halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 3~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I"), or (I"-A), wherein R is selected from the group consisting of cycloalkyl. 2 Halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 2~6 Alkynyl, and C 3~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I"), or (I"-A), wherein R is selected from the group consisting of cycloalkyl. 2 Halo, C 1~6 Alkyl, and C 1~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I"), or (I"-A), wherein R is selected from the group consisting of haloalkyl. 2 is halo. In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A), wherein R 2 C 1~6 and having the structure of formula (I'), (I''), or (I''-A), wherein:

[0176] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy, hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 alkylene -OH), and -NR e R f a 3- to 8-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of: c R dMay be substituted with -OC 3~7 Cycloalkyl, -(C 0~6 alkylene)-(C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 -O-3 to 8-membered heterocyclyl, each optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents independently selected from the group consisting of alkyl, and -NR A R B C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a and optionally substituted with:

[0177] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy, hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 Alkylene -OH), -C(O)OC 1~6 Alkyl, and -NR e R f -3- to 10-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of: c R d May be substituted with -OC 3~7 Cycloalkyl, -(C 0~6 alkylene)-(C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 O-3 to 9-membered heterocyclyl, each optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents independently selected from the group consisting of alkyl, and NR AA R BB C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a and optionally substituted with:

[0178] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy and -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)OC 1~6 alkyl, 3- to 8-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of: -NR c R d May be substituted with -OC 3~7 cycloalkyl, C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a and optionally substituted with:

[0179] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy and -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)OC 1~6 alkyl, 3- to 9-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of -NR c R d May be substituted with -OC 3~7 cycloalkyl, C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a and optionally substituted with:

[0180] In some embodiments, the compounds of the present disclosure are 3 Ga-NR AA R BB or one or more (e.g., one, two, three, or four) R 3a may be substituted with C1~20 and (I''-A) having the structure of formula (I'') or (I''-A), wherein:

[0181] In some embodiments, the compounds of the present disclosure are 3 One or more (e.g., one, two, three, or four) R 3a may be substituted with C 1~20 and (I''-A) having the structure of formula (I'') or (I''-A), wherein:

[0182] In some embodiments, the compounds of the present disclosure are A and R B are each independently H or C 1~6 It has the structure of formula (I'') or (I''-A), which is alkyl. In some embodiments, the compounds of the present disclosure are 3 Ga-NR AA R BB and has a structure of formula (I'') or (I''-A):

[0183] In some embodiments, the compounds of the present disclosure are AA and R BB H, C 1~6 Alkyl, C 1~20 Alkylene-NR c R d , and -(C 0~20 alkylene)-(3- to 10-membered heterocyclyl), wherein the 3- to 10-membered heterocyclyl is selected from the group consisting of C 1~6 Alkyl, hydroxy, and C 1~6 and having a structure of formula (I'') or (I''-A), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

[0184] In some embodiments, the compounds of the present disclosure are AA and R BB H, C 1~6 Alkyl, C 1~20 Alkylene-NR c R d, and -(C 1~20 alkylene)-(3- to 5-membered heterocyclyl), wherein the 3- to 5-membered heterocyclyl is C 1~6 It has the structure of formula (I'') or (I''-A), optionally substituted with alkyl.

[0185] In some embodiments, the compounds of the present disclosure include a compound in which each R c and R d are independently H or C 1~6 It has the structure of formula (I'') or (I''-A), which is alkyl. In some embodiments, the compounds of the present disclosure are 3 There can be one or more (e.g., one, two) , three, or four) R 3a may be substituted with C 1~6 and having the structure of formula (I'), (I''), or (I''-A), wherein the aryl group is alkoxy.

[0186] In some embodiments, the compounds of the present disclosure are 3 But-(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)OC 1~6 and 3-8 membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkyl, aryl, arylsulfonyl ...

[0187] In some embodiments, the compounds of the present disclosure are 3 But-(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)OC 1~6 and 3-9 membered heterocyclyl, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of alkyl, aryl, arylsulfonyl ...

[0188] In some embodiments, the compounds of the present disclosure are4 H, C 1~6 and halo, and has a structure of formula (I'), (I''), or (I''-A):

[0189] In some embodiments, the compounds of the present disclosure are 4 H, C 1~6 C optionally substituted with alkyl, phenyl or 5- to 6-membered heteroaryl 2~6 and halo, having the structure of formula (I'') or (I''-A):

[0190] In some embodiments, the compounds of the present disclosure are 4 H, hydroxy, -NR e R f , C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (I'') or (I''-A), wherein R 4 H, hydroxy, -NH2, -NH(C 1~6 alkyl), -N(C 1~6 Alkyl)2, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 haloalkyl, having a structure of formula (I'') or (I''-A):

[0191] In some embodiments, the compounds of the present disclosure are 4 is H. In some embodiments, the compounds of the present disclosure are 3 and R 4 together with the atoms to which they are attached form an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to phenyl, the 5- to 10-membered ring containing at least one heteroatom, and the 5- to 10-membered ring is 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5-6 membered heteroaryl, -(C0~6 (alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -(C 0~6 (Alkylene)-NR c R d , -(C 0~6 Alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 Alkylene)-C 1~6 and having a structure of formula (I'), (I"), or (I"-A), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

[0192] In some embodiments, the compounds of the present disclosure are 5 is H or C 1~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A), wherein R 5 is H. In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A), wherein R 5 C 1~6 and having the structure of formula (I'), (I''), or (I''-A), wherein:

[0193] In some embodiments, the compounds of the present disclosure are 6 is H or C 1~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A), wherein R 6 is H. In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A), wherein R 6 C 1~6 and having the structure of formula (I'), (I''), or (I''-A), wherein:

[0194] In some embodiments, the compounds of the present disclosure include a compound in which each R3a Ga-NR A R B , C 1~6 Alkoxy, hydroxy, 3- to 8-membered heterocyclyl, and -(C 0~6 alkylene)-(NR c R d may be substituted with C 3~6 cycloalkyl), 3 ~8-membered heterocyclyl is halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 and having a structure of formula (I'), (I"), or (I"-A), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

[0195] In some embodiments, the compounds of the present disclosure include a compound in which each R 3a D, -NR A R B , C 1~6 Alkoxy, hydroxy, 3- to 10-membered heterocyclyl, and -(C 0~6 alkylene)-(NR c R d may be substituted with C 3~6 cycloalkyl), wherein the 3- to 10-membered heterocyclyl is optionally substituted with halo, hydroxy, one or more (e.g., 1, 2, 3, or 4) D. 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C1~6 Alkylene-C 1~6 and having a structure of formula (I'') or (I''-A), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

[0196] In some embodiments, the compounds of the present disclosure include a compound in which each R 3a Ga-NR A R B In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A), wherein each R 3a is a 3- to 8-membered heterocyclyl, and the 3- to 8-membered heterocyclyl is selected from halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 and having a structure of formula (I'), (I"), or (I"-A), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

[0197] In some embodiments, the compounds of the present disclosure include a compound in which each R 3a is a 3- to 10-membered heterocyclyl, and the 3- to 10-membered heterocyclyl is selected from halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene -OH, -C(O)OC 1~6 Alkyl, and C 1~6 Alkylene-C 1~6and having a structure of formula (I'') or (I''-A), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

[0198] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylene-NR c R d , 3- to 6-membered heterocyclyl optionally substituted with oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy, -(C 0~6 alkylene)-phenyl, and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 The cycloalkyl has the structure of formula (I'), (I''), or (I''-A), each optionally substituted with hydroxy.

[0199] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 Alkylene-NR c R d having a structure of formula (I'), (I'') or (I''-A), selected from the group consisting of:

[0200] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H or C 1~6 and having the structure of formula (I'), (I'') or (I''-A), wherein:

[0201] In some embodiments, the compounds of the present disclosure include a compound in which each R c and R d independently, for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl and having a structure of formula (I'), (I'') or (I''-A), selected from:

[0202] In some embodiments, the compounds of the present disclosure include a compound in which each R c and R d independently, for each occurrence, H or C 1~6 In some embodiments, the compounds of the present disclosure have a structure of Formula (I'), (I''), or (I''-A), wherein each R c and R d is H.

[0203] In some embodiments, the compounds of the present disclosure include a compound in which each R e and R f is H. In some embodiments, the compounds of the present disclosure are g and R h is H.

[0204] In some embodiments, the compounds of the present disclosure are i is H. In some embodiments, the compounds of the present disclosure are x C 1~6 In some embodiments, the compounds of the present disclosure have the structure of Formula (I'') or (I''-A), wherein R x is halo. In some embodiments, the compounds of the present disclosure have the structure of Formula (I'') or (I''-A), wherein R x is D.

[0205] In another embodiment, a compound of formula (I-1″)

[0206] [ka]

[0207] or a pharmaceutically acceptable salt thereof (In the formula, Each R 1 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 independently selected from the group consisting of haloalkoxy, halo, and -CN; n is 0, 1, or 2; R 2 , R 3 , R 4 , and R 6 Each of 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 independently selected from the group consisting of haloalkoxy, halo, and -CN; R 5 is C 1~6 alkylene-C(O)NH2, where each hydrogen of NH2 is optionally substituted is provided herein.

[0208] In some embodiments, compounds of the present disclosure have the structure of formula (I-1′), where n is 0. In some embodiments, the compounds of the present disclosure are 2 , R 3 , R 4 , and R 6 is hydrogen.

[0209] In some embodiments, the compounds of the present disclosure are 5 C 1~6 Alkylene-C(O)NH-NH-C(O)-C 2~6 Alkenylene-C(O)OC 1~6 It has the structure of formula (I-1'), which is alkyl.

[0210] In some embodiments, the compounds of the present disclosure are 5 is C2 alkylene-C(O)NH—NH—C(O)—C2 alkenylene-C(O)OCH3,

[0211] In another embodiment, a compound of formula (II')

[0212] [ka]

[0213] or a pharmaceutically acceptable salt thereof (In the formula, Ring A may contain one or more (e.g., one, two, three, or four) R 1 is phenyl optionally substituted with; Each X is independently selected from the group consisting of CH, CH, NH, and O (NH, CH, NR h (R h =H), any hydrogen atom in R x may be substituted with); R x When R is substituted on a carbon atom, each R x independently, C 1~6 alkyl or halo, or R x When R is substituted on the nitrogen atom, each R x independently, C 1~6 is alkyl; m is 0, 1, or 2;

[0214] [ka]

[0215] is a single or double bond; n is 1 or 2; Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7Carbocyclyl, 3- to 7-membered heterocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 Alkyl, C 1~6 Alkoxy, -O-(C 0~6 (alkylene)-phenyl, -SC 1~6 Alkyl, -SC 1~6 Haloalkyl, -NR e R f and hydroxy, wherein phenyl and 5- to 6-membered heteroaryl are optionally substituted with halo, 3- to 7-membered heterocyclyl. 1~6 Alkyl, C 1~6 Alkylene-NR A R B , C 1~6 Haloalkyl, and C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each selected from the group consisting of alkoxy; R 2 Ha, Halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~6 Alkoxy, hydroxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d May be substituted with -OC 3~7 Cycloalkyl, -C(O)OC 1~6 -O-3 to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d may be substituted with C 1~6 Alkyl, -O-5-6 membered heteroaryl, C 0~6 Alkylene-CN, C 0~6 Alkylene-C(O)NR e R f , and -NR A R B C 1~6Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; R 4 is H, C 1~6 Alkyl, halo, hydroxy, and -NR e R f or R3 and R4, together with the atoms to which they are attached, together form an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to phenyl, the 5- to 10-membered ring containing at least one heteroatom, and the 5- to 10-membered ring is 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5-6 membered heteroaryl, -(C 0~6 alkylene)-C(O )NR e R f , -C(O)-C 1~6 Heteroalkyl, -(C 0~6 (Alkylene)-NR c R d , -(C 0~6 Alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 Alkylene)-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; Each R 3a is C 1~6 Alkyl, -NR A R B , C 1~6 Alkoxy, hydroxy, -C(O)NR c R d , 3- to 8-membered heterocyclyl, phenyl, and -(C0~6 alkylene)-(NR c R d may be substituted with C 3~6 cycloalkyl), wherein the 3- to 8-membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, S(O)2C 1~6 Alkyl, -C(O)-C 1~6 Alkyl, C 1~6 Alkylene-NR c R d , 3- to 6-membered heterocyclyl optionally substituted with oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy, -(C 0~6 alkylene)-phenyl, and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Each cycloalkyl may be optionally substituted with hydroxy; Each R c and R d independently, for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and Rd may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; and Each R e and R f independently, for each occurrence, H or C 1~6 alkyl) is provided herein.

[0216] In another embodiment, a compound of formula (II″)

[0217] [ka]

[0218] or a pharmaceutically acceptable salt thereof (In the formula, Ring A may contain one or more (e.g., one, two, three, or four) R 1 is phenyl optionally substituted with; Each X is independently selected from the group consisting of CH, CH, NH, and O (NH, CH, NR h (R h =H), any hydrogen atom in R x may be substituted with); R x When R is substituted on a carbon atom, each R x independently, C 1~6 alkyl or halo, or R x When R is substituted on the nitrogen atom, each R x independently, C 1~ 6 alkyl; m is 0, 1, or 2;

[0219] [ka]

[0220] is a single or double bond; n is 1 or 2; Each R1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, 3- to 7-membered heterocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 Alkyl, C 1~6 Alkoxy, -O-(C 0~6 (alkylene)-phenyl, -SC 1~6 Alkyl, -SC 1~6 Haloalkyl, -NR e R f and hydroxy, wherein phenyl and 5- to 6-membered heteroaryl are optionally substituted with halo, 3- to 7-membered heterocyclyl. 1~6 Alkyl, C 1~6 Alkylene-NR A R B , C 1~6 Haloalkyl, and C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each selected from the group consisting of alkoxy; R 2 Ha, Halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~6 Alkoxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d May be substituted with -OC 3~7 Cycloalkyl, -C(O)OC 1~6 -O-3 to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d may be substituted with C 2~6 Alkyl, -O-5-6 membered heteroaryl, C 0~6 Alkylene-C(O)NR e R f , and -NR A R B C 1~6Alkoxy is one or more (e.g., one, two, three, or four) R 3a is substituted with R 3 is neither -N(H)C(O)CH3 nor -NH2; R 4 is H, C 1~6 Alkyl, halo, hydroxy, and -NR e R f or R 3 and R 4 together with the atoms to which they are attached form a phenyl-fused aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring, the 5- to 10-membered ring containing at least one heteroatom, and the 5- to 10-membered ring is 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5-6 membered heteroaryl, -(C 0~6 (alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -(C 0~6 (Alkylene)-NR c R d , -(C 0~6 Alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 Alkylene)-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; Each R 3a is C 1~6 Alkyl, -NR A R B , C 1~6 Alkoxy, hydroxy, -C(O)NRc R d , 3- to 8-membered heterocyclyl, phenyl, and -(C 0~6 alkylene)-(NR c R d may be substituted with C 3~6 cycloalkyl), wherein the 3- to 8-membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, S(O)2C 1~6 Alkyl, -C(O)-C 1~6 Alkyl, C 1~6 Alkylene-NR c R d , oxo or -C(O)OC 1~6 3- to 6-membered heterocyclyl optionally substituted with alkyl, C 1~6 Alkyl or C 1~6 may be substituted with alkoxy 5-6 membered heteroaryl, -(C 0~6 alkylene)-phenyl, and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Each cycloalkyl may be optionally substituted with hydroxy; Each R c and R d independently, for each occurrence, H, C 1~6Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and R d may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; and Each R e and R f independently, for each occurrence, H or C 1~6 alkyl) is provided herein.

[0221] In some embodiments, the compound of formula (II') or (II'') is a compound of formula (IIa'):

[0222] [ka]

[0223] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined above. In some embodiments, the compound of formula (II') or (II'') is a compound of formula (IIb'):

[0224] [ka]

[0225] or a pharmaceutically acceptable salt thereof (In the formula, s is 0, 1, 2, or 3; and R 1 ~R 6 is as defined above) is.

[0226] In some embodiments, the compound of formula (II') or (II'') is a compound of formula (IIc'):

[0227] [ka]

[0228] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined above. In some embodiments, compounds of the present disclosure have formula (II') or (II') where X is CH2. In some embodiments, the compounds of the present disclosure have the structure of formula (II') or (II"), where X is NH. In some embodiments, the compounds of the present disclosure have the structure of formula (II') or (II"), where X is O.

[0229] In some embodiments, compounds of the present disclosure have the structure of Formula (II') or (II"), where m is 0. In some embodiments, compounds of the present disclosure have the structure of Formula (II') or (II"), where m is 1. In some embodiments, compounds of the present disclosure have the structure of Formula (II') or (II"), where m is 2.

[0230] In some embodiments, the compounds of the present disclosure are

[0231] [ka]

[0232] is a single bond. In some embodiments, the compounds of the present disclosure have a structure of formula (II') or (II''):

[0233] [ka]

[0234] is a double bond. In some embodiments, compounds of the present disclosure have the structure of formula (II') or (II"), where n is 1. In some embodiments, compounds of the present disclosure have the structure of formula (II') or (II"), where n is 2.

[0235] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 Alkyl, C 1~6 Alkoxy, -SC 1~6 Alkyl, -NR e R f and hydroxy.

[0236] In some embodiments, the compounds of the present disclosure include a compound in which each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 alkyl, phenyl, and 5-6 membered heteroaryl, halo, C 1~6 Alkyl, C 1~6 Alkylene-NR A R B , C 1~6 Haloalkyl, and C 1~6 and having a structure of formula (II') or (II''), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

[0237] In some embodiments, the compounds of the present disclosure are 2 Halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 3~6 In some embodiments, the compounds of the present disclosure have a structure of formula (II') or (II'') where R 2 is halo. In some embodiments, the compounds of the present disclosure have a structure of formula (II') or (II'') where R 2 C 1~6 It has a structure of formula (II') or (II'') in which the alkyl is alkyl.

[0238] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy, hydroxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d May be substituted with -OC 3~7 Cycloalkyl, -C(O)OC 1~6 -O-3 to 8-membered heterocyclyl optionally substituted with alkyl, and -NR A R B C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a and optionally substituted with:

[0239] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d May be substituted with -OC 3~7 Cycloalkyl, -C(O)OC 1~6 -O-3 to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d may be substituted with C 2~6 Alkyl, -O-5-6 membered heteroaryl, C 0~6 Alkylene-C(O)NR e R f , and -NR A R B C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a is substituted with R 3 Even if -N(H)C(O)CH3- It is not NH2 and has the structure of formula (II'').

[0240] In some embodiments, the compounds of the present disclosure are 3 C 1~6Alkoxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d May be substituted with -OC 3~7 Cycloalkyl, -C(O)OC 1~6 -O-(3- to 8-membered heterocyclyl) optionally substituted with alkyl, and -NR A R B C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a and optionally substituted with:

[0241] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy and C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, -NR c R d May be substituted with -OC 3~7 cycloalkyl, C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a and optionally substituted with:

[0242] In some embodiments, the compounds of the present disclosure are 3 One or more (e.g., one, two, three, or four) R 3a may be substituted with C 1~6 and (II′) or (II″) wherein the alkoxy group is alkoxy.

[0243] In some embodiments, the compounds of the present disclosure are 3 C 1~6 It has a structure of formula (II') or (II''), which is a 3- to 8-membered heterocyclyl optionally substituted with alkyl. In some embodiments, the compounds of the present disclosure are 4 H, C 1~6and halo, and has a structure of formula (II') or (II'').

[0244] In some embodiments, the compounds of the present disclosure are 4 is H. In some embodiments, compounds of the present disclosure include those in which R3 and R4, together with the atoms to which they are attached, together form an aromatic or non-aromatic 5-10 membered monocyclic or bicyclic ring fused to a phenyl, wherein the 5-10 membered ring contains at least one heteroatom, and the 5-10 membered ring is selected from the group consisting of C 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5-6 membered heteroaryl, -(C 0~6 (alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -(C 0~6 (Alkylene)-NR c R d , -(C 0~6 Alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 Alkylene)-C 1~6 It has a structure of formula (II') or (II''), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

[0245] In some embodiments, the compounds of the present disclosure are 5 is H or C 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (II') or (II'') where R 5 is H. In some embodiments, the compounds of the present disclosure have a structure of formula (II′) or (II″), wherein R 5 C 1~6 It has a structure of formula (II') or (II'') in which the alkyl is alkyl.

[0246] In some embodiments, the compounds of the present disclosure are 6 is H or C 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (II') or (II'') where R 6 is H. In some embodiments, the compounds of the present disclosure have a structure of formula (II′) or (II″), wherein R 6 C 1~6 It has a structure of formula (II') or (II'') in which the alkyl is alkyl.

[0247] In some embodiments, the compounds of the present disclosure include a compound in which each R 3a Ga-NR A R B , C 1~6 Alkoxy, hydroxy, 3- to 8-membered heterocyclyl, and -(C 0~6 alkylene)-(NR c R d may be substituted with C 3~6 cycloalkyl), wherein the 3- to 8-membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; It has the structure of formula (II') or (II'').

[0248] In some embodiments, the compounds of the present disclosure include a compound in which each R 3a Ga-NR A R B and has a structure of formula (II′) or (II″): In some embodiments, the compounds of the present disclosure include a compound in which each R 3ais a 3- to 8-membered heterocyclyl, and the 3- to 8-membered heterocyclyl is selected from halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkylene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 and having a structure of formula (II') or (II''), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

[0249] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylene-NR c R d , 3- to 6-membered heterocyclyl optionally substituted with oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy, -(C 0~6 alkylene)-phenyl, and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 The cycloalkyl has the structure of formula (II') or (II''), each optionally substituted with hydroxy.

[0250] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylene-NR c R d, oxo or -C(O)OC 1~6 3- to 6-membered heterocyclyl optionally substituted with alkyl, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy, -(C 0~6 alkylene)-phenyl, and -(C 0~6 Alkylene)-C 3~6 cycloalkyl, C 1~6 Alkyl, C 1~6 Alkylene and C 3~6 It has the structure of formula (II″), where each cycloalkyl is optionally substituted with hydroxy.

[0251] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 Alkylene-NR c R d and having a structure of formula (II′) or (II″), selected from the group consisting of:

[0252] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H or C 1~6 It has a structure of formula (II') or (II'') in which the alkyl is alkyl.

[0253] In some embodiments, the compounds of the present disclosure include a compound in which each R c and R d independently, for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl, having a structure of formula (II') or (II'').

[0254] In some embodiments, the compounds of the present disclosure include a compound in which each R c and R d independently, for each occurrence, H or C1~6 It has a structure of formula (II') or (II'') in which the alkyl is alkyl.

[0255] In some embodiments, the compounds of the present disclosure include a compound in which each R c and R d is H. In some embodiments, the compounds of the present disclosure include a compound in which each R e and R f is H.

[0256] In another embodiment, a compound of formula (III″)

[0257] [ka]

[0258] or a pharmaceutically acceptable salt thereof (In the formula, Ring A is selected from naphthyl and 8-12 membered bicyclic heteroaryl, and naphthyl and 8-12 membered bicyclic heteroaryls are selected from one or more (e.g., one, two, three, or four) R 1 may be substituted with; Y1 is N or CR 6 and; Y2 is N or CR 4 and; Y3 is N or CR 5 and; Y4 is N or CR 3 and; Y5 is N or CR 2 and; Each X is CH2, CH, or NR h and O, independently selected from the group consisting of (NH, CH, NR h (R h =H), any hydrogen atom in R x and each R h are independently H or C 1~6 is alkyl;

[0259] [ka]

[0260] is a single or double bond; each R x independently, C 1~6 is alkyl or halo; n is 1 or 2; m is 0, 1, or 2; Each R 1 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 independently selected from the group consisting of haloalkoxy, halo, and -CN; R 2 Ha, Halo, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 selected from the group consisting of alkoxy; R 3 is C 1~6 Alkyl, C 1~6 alkoxy, and hydroxy; 1~6 Alkoxy is one or more (e.g., one, two, three, or four) -NR A R B or C 1~6 optionally substituted with 3- to 8-membered heterocyclyl optionally substituted with alkyl; R 4 is H, C 1~6 selected from the group consisting of alkyl, halo, and hydroxy; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 alkyl; and Each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, and C 1~6 haloalkyl) is provided herein.

[0261] In some embodiments, compounds of the present disclosure have a structure of formula (III"), where ring A is naphthyl.

[0262] [ka]

[0263] It has a structure of formula (III″): In some embodiments, the compounds of the present disclosure are 1 , Y 2 , Y 3 , Y 4 , and Y 5 In some embodiments, at least one of Y is N. 1 is N.

[0264] In some embodiments, the compounds of the present disclosure are 2 , Y 3 , Y 4 , and Y 5 is not N. In some embodiments, Y 2 is N. In some embodiments, the compounds of the present disclosure are 1 , Y 3 , Y 4 , and Y 5 is not N. In some embodiments, Y 3 is N.

[0265] In some embodiments, the compounds of the present disclosure are 1 , Y 2 , Y 4 , and Y 5 is not N. In some embodiments, Y 2 and Y 3 is N. In some embodiments, the compounds of the present disclosure are 1 , Y4 , and Y 5 is not N, and has a structure of formula (III'').

[0266] In some embodiments, compounds of the present disclosure have the structure of Formula (III″), where X is CH 2 . In some embodiments, compounds of the present disclosure have the structure of formula (III″), where n is 1.

[0267] In some embodiments, compounds of the present disclosure have the structure of Formula (III″), where m is 0. In some embodiments, the compounds of the present disclosure are 2 C 1~6 alkyl, for example, methyl, having the structure of formula (III'').

[0268] In some embodiments, the compounds of the present disclosure are 3 one or more (e.g., one, two, three, or four) -NR A R B may be substituted with C 1~6 Alkoxy, for example, has the structure of formula (III″), which is —O—(CH 2 ) 2 —N(CH 3 ) 2 .

[0269] In some embodiments, the compounds of the present disclosure are 3 C 1~6 C optionally substituted with 3- to 8-membered heterocyclyl optionally substituted with alkyl 1~6 It has a structure of formula (III″), which is alkoxy.

[0270] In some embodiments, the compounds of the present disclosure are 4 is H. In some embodiments, the compounds of the present disclosure are 5 is H.

[0271] In another embodiment, a compound of formula (IV″)

[0272] [ka]

[0273] or a stereoisomer or a pharmaceutically acceptable salt thereof (In the formula, Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, and C 1~6 independently selected from the group consisting of alkyl; n is 0, 1, or 2; (A)R 2 is C 1~6 is alkyl or halo; R 3 is C 1~6 Alkoxy, hydroxy, -C(O)-C 1~6 alkyl; -O-(one or more (e.g., one, two, three, or four) C 1~6 3-8 membered oxygen-containing heterocyclyl optionally substituted with alkyl, -NR A R B and nitro, C 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with R 3 is hydroxy, nitro, NH2, NHCH3, or N(CH3)2, R 7 MoR 8 Also not methyl; R 4 is H, C 1~6 alkyl, halo, and hydroxy; or (B)R 2 is H, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 selected from the group consisting of alkoxy; R 3 and R 4 together with the atoms to which they are bonded, i) an aromatic or non-aromatic five-membered monocyclic ring fused to a phenyl, R 3a five-membered ring having at least one nitrogen or two oxygen atoms connected to a phenyl at the ii) an aromatic or non-aromatic 6-membered monocyclic ring fused to a phenyl, wherein R 3 A six-membered ring having one and only one nitrogen atom connected to a phenyl at the Forming The five- or six-membered ring may be oxo, hydroxy, or -NR c R d may be substituted with C 1~6 Alkyl, -(C 0~6 Alkylene)-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; R 7 is hydrogen, C 1~6 C optionally substituted with alkoxy 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Haloalkyl, cyano, and C 1~6 selected from the group consisting of 3- to 8-membered heterocyclyl optionally substituted with alkyl; R 8 is hydrogen or C 1~6 is alkyl; Each R 3a is C 1~6 Alkyl, -NR e R f and 3- to 8-membered heterocyclyl, wherein the 3- to 8-membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, and C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of haloalkyl; Each RA and R B independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O)2C 1~2 Alkyl, -C(O)-unsubstituted C 1~6 alkyl, 3- to 6-membered unsaturated heterocyclyl optionally substituted with one oxo, C 1~6 Alkyl or C 1~6 selected from the group consisting of 5-6 membered heteroaryl substituted with alkoxy, and pyrazolyl; 1~6 The alkyl may be substituted with one or more (e.g., one, two, three, or four) hydroxy and / or one NH; R A and R B One of the groups is -C(O)-unsubstituted C 1~6 If it is alkyl, R A and R B The other is not H, but R A and R B is neither -(CH2)2NH2 nor -CH2C(CH3)2NH2; Each R c and R d independently, for each occurrence, H, C 1~6 Alkyl, and -C(O)OC 1~6 alkyl, and Each R e and R f independently, for each occurrence, H, C 1~6 Alkyl, and -C(O)OC 1~6 alkyl) and the compound is

[0274] [ka]

[0275] or a stereoisomer or pharmaceutically acceptable salt thereof. In some embodiments, compounds of the present disclosure have the structure of formula (IV″), where n is 0.

[0276] In some embodiments, the compounds of the present disclosure are 2 C 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), wherein R 2 is methyl. In some embodiments, the compounds of the present disclosure have a structure of formula (IV″), where R 2 is halo. In some embodiments, the compounds of the present disclosure have a structure of formula (IV″), where R 2 is hydrogen.

[0277] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy, hydroxy, -C(O)-C 1~6 alkyl; -O-(one or more (e.g., one, two, three, or four) C 1~6 3-8 membered oxygen-containing heterocyclyl optionally substituted with alkyl, -NR A R B and nitro, C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a may be substituted with R 3 is hydroxy, nitro, NH2, NHCH3, or N(CH3)2, R 7 is not methyl;R 4 H, C 1~6 It has the structure of formula (IV''), which is alkyl, halo, and hydroxy.

[0278] In some embodiments, the compounds of the present disclosure are 3 C 1~6 Alkoxy, hydroxy, -O-(one or more (e.g., one, two, three, or four) C 1~6 3-8 membered oxygen-containing heterocyclyl optionally substituted with alkyl, -NR A R Band nitro, C 1~6 The alkoxy is selected from one or more (e.g., one, two, three, or four) R 3a may be substituted with R 3 is hydroxy, nitro, NH2, NHCH3, or N(CH3)2, R 7 is not methyl;R 4 H, C 1~6 It has the structure of formula (IV''), which is alkyl, halo, and hydroxy.

[0279] In some embodiments, the compounds of the present disclosure are 3 One or more (e.g., one, two, three, or four) R 3a may be substituted with C 1~6 It has the structure of formula (IV''), which is alkoxy.

[0280] In some embodiments, the compounds of the present disclosure are 3 is hydroxy. In some embodiments, the compounds of the present disclosure have a structure of formula (IV″), where R 3 -C(O)-C 1~6 It has the structure of formula (IV''), which is alkyl.

[0281] In some embodiments, the compounds of the present disclosure are 3 is -O-(one or more (e.g., one, two, three, or four) C 1~6 It has a structure of formula (IV″), which is a 3-8 membered oxygen-containing heterocyclyl optionally substituted with alkyl.

[0282] In some embodiments, the compounds of the present disclosure are 3 Ga-NR A R B In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), wherein R 3 is nitro.

[0283] In some embodiments, the compounds of the present disclosure are 4is H. In some embodiments, the compounds of the present disclosure are 5 is H.

[0284] In some embodiments, the compounds of the present disclosure are 6 is H. In some embodiments, the compounds of the present disclosure are 7 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (IV″), 7 C 1~6 C optionally substituted with alkoxy 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), wherein R 7 C 2~6 In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), where R 7 C 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), where R 7 is cyano. In some embodiments, the compounds of the present disclosure have a structure of formula (IV″), where R 7 C 1~6 It has a structure of formula (IV''), which is a 3- to 8-membered heterocyclyl optionally substituted with alkyl.

[0285] In some embodiments, the compounds of the present disclosure are 8 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (IV″), 8 C 1~6 It has the structure of formula (IV''), which is alkyl.

[0286] In some embodiments, the compounds of the present disclosure are 3a Ga-NR e R f In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), wherein R 3a Halo, hydroxy, C 1~6 Alkyl, and C1~6 and haloalkyl, and having a structure of formula (IV″), which is a 3-8 membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of haloalkyl.

[0287] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, S(O)2C 1~2 Alkyl, -C(O)-unsubstituted C 1~6 alkyl, 3- to 6-membered unsaturated heterocyclyl optionally substituted with one oxo, C 1~6 Alkyl or C 1~6 selected from the group consisting of 5-6 membered heteroaryl substituted with alkoxy, and pyrazolyl; 1~6 It has the structure of formula (IV″) where the alkyl is optionally substituted with one or more (eg, 1, 2, 3, or 4) hydroxy and / or one NH 2 .

[0288] In some embodiments, the compounds of the present disclosure include a compound in which each R A and R B independently, for each occurrence, H, C 1~6 Alkyl, S(O)2C 1~2 Alkyl, -C(O)-unsubstituted C 1~6 Alkyl, C 1~6 Alkyl or C 1~6 selected from the group consisting of 5-6 membered heteroaryl substituted with alkoxy, and pyrazolyl; 1~6 It has the structure of formula (IV″) where the alkyl is optionally substituted with one or more (eg, 1, 2, 3, or 4) hydroxy and / or one NH 2 .

[0289] In some embodiments, the compounds of the present disclosure are A is H and R B is H. In some embodiments, the compounds of the present disclosure have a structure of formula (IV″), where R A is H and RB C, which may be substituted with one or more (e.g., one, two, three, or four) hydroxy groups and / or one NH 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), wherein R A is H and R B is S(O)2C 1~2 In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), wherein R A is H and R B C 1~6 Alkyl or C 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), where each R A is H and R B In some embodiments, the compounds of the present disclosure have a structure of formula (IV"), where each R A C 1~6 alkyl, and R B -C(O)-unsubstituted C 1~6 alkyl, C 1~6 It has the structure of formula (IV″) where the alkyl is optionally substituted with one or more (eg, 1, 2, 3, or 4) hydroxy and / or one NH 2 .

[0290] In some embodiments, the compounds of the present disclosure are 3 and R 4 together with the atoms to which they are attached form a 5-membered aromatic or non-aromatic monocyclic ring fused to a phenyl, and R 3 and the 6-membered ring is oxo, hydroxy, or -NR c R d may be substituted with C 1~6 Alkyl, -(C 0~6 Alkylene)-C 1~6and optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl. It has the structure of '').

[0291] In some embodiments, the compounds of the present disclosure are 3 and R 4 together with the atoms to which they are attached form a 5-membered aromatic or non-aromatic monocyclic ring fused to a phenyl, and R 3 and the 6-membered ring is an oxo, hydroxy, or -NR c R d may be substituted with C 1~6 Alkyl, -(C 0~6 Alkylene)-C 1~6 and having a structure of Formula (IV″), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

[0292] In some embodiments, the compounds of the present disclosure are 3 and R 4 together with the atoms to which they are attached form an aromatic or non-aromatic six-membered monocyclic ring fused to a phenyl, and R 3 and only one nitrogen atom connected to the phenyl at the -position, forming a six-membered ring with the remaining atoms in the ring being carbon, and the six-membered ring is not oxo, hydroxy, or -NR c R d may be substituted with C 1~6 Alkyl, -(C 0~6 Alkylene)-C 1~6 and having a structure of Formula (IV″), optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

[0293] In another embodiment, a compound of formula (VI″)

[0294] [ka]

[0295] or a stereoisomer or a pharmaceutically acceptable salt thereof (In the formula,

[0296] [ka]

[0297] teeth

[0298] [ka]

[0299] or optionally substituted phenyl; X is NR 9 or is a bond; Y is NR 9 , CH2, or a bond; R 9 is H and C 1~6 alkyl;

[0300] [ka]

[0301] is a nitrogen-containing 4- to 6-membered heterocyclylene or 4- to 6-membered heterocycle fused to phenyl; X 1 , X 2 , X 3 , X 4 , X 5 , and X 6 Each of is CH or N, and CH is R 1 may be substituted with;

[0302] [ka]

[0303] but

[0304] [ka]

[0305] If

[0306] [ka]

[0307] is not a 6-membered monocyclic heterocyclylene; Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, C 1~6 Alkyl, C 1~6 Alkoxy, -NR e R f independently selected from the group consisting of 3- to 8-membered heterocyclyl, and 5- to 6-membered heteroaryl; n is 0, 1, or 2; R 2 , R 3 , R 4 , R 5 , and R 6 Each of 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, -NR e R f , C 1~6 Alkoxy, and C 1~6 independently selected from the group consisting of alkyl; R 7 is C 1~6 C optionally substituted with alkoxy 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Haloalkyl, cyano, and C 1~6 selected from the group consisting of 3- to 8-membered heterocyclyl optionally substituted with alkyl; R 8 is hydrogen; or R 7 and R 8 may be taken together with the carbons to which they are attached to form a 3- to 4-membered cycloalkyl or heterocyclyl ring; and Each R e and R f independently, for each occurrence, H, C 1~6 Alkyl, and -C(O)OC 1~6 alkyl) is provided herein.

[0308] In some embodiments, the compounds of the present disclosure are

[0309] [ka]

[0310] but

[0311] [ka]

[0312] It has a structure of formula (VI″), In some embodiments, the compounds of the present disclosure are

[0313] [ka]

[0314] C 1~6 It has the structure of formula (VI″), which is phenyl optionally substituted with alkyl. In some embodiments, compounds of the present disclosure include those in which X is NR 9 In some embodiments, compounds of the present disclosure have a structure of formula (VI"), where X is a bond.

[0315] In some embodiments, compounds of the present disclosure are those in which Y is NR 9 In some embodiments, compounds of the present disclosure have a structure of formula (VI"), where Y is CH. In some embodiments, compounds of the present disclosure have a structure of formula (VI"), where Y is a bond.

[0316] In some embodiments, the compounds of the present disclosure are 9 is H. In some embodiments, the compounds of the present disclosure have a structure of formula (VI″), where R 9 C 1~6 It has the structure of formula (VI″), which is alkyl.

[0317] In some embodiments, the compounds of the present disclosure are

[0318] [ka]

[0319] is a nitrogen-containing 4- to 6-membered heterocyclylene, for example, a 4-membered heterocyclylene, a 5-membered heterocyclylene, or a 6-membered heterocyclylene, having a structure of formula (VI''). In some embodiments, the compounds of the present disclosure are

[0320] [ka]

[0321] is a nitrogen-containing 4- to 6-membered heterocyclylene, for example, a 4- to 5-membered heterocyclylene, a 4-membered heterocyclylene, a 5-membered heterocyclylene, a 6-membered heterocyclylene, for example, a 6-membered monocyclic heterocyclylene, a 6-membered bicyclic heterocyclylene.

[0322] In some embodiments, the compounds of the present disclosure are 1 C 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (VI"), where R 1is a 5- to 6-membered heteroaryl,

[0323] In some embodiments, compounds of the present disclosure have the structure of formula (VI"), where n is 0. In some embodiments, compounds of the present disclosure have the structure of formula (VI"), where n is 1.

[0324] In some embodiments, the compounds of the present disclosure are 2 , R 3 , R 4 , R 5 , and R 6 each is independently selected from the group consisting of hydrogen and halo. In some embodiments, the compounds of the present disclosure are 7 C 1~6 C optionally substituted with alkoxy 1~6 alkyl, and R 8 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (VI″), where R 7 is methyl and R 8 is hydrogen.

[0325] In some embodiments, the compounds of the present disclosure are 7 and R 8 together with the carbon to which they are attached form a 3-4 membered cycloalkyl ring. In some embodiments, the compounds of the present disclosure have a structure of formula (VI'') 7 and R 8 are taken together with the carbon to which they are attached to form a 3- to 4-membered heterocyclyl ring, and have the structure of formula (VI'').

[0326] In another embodiment, a compound of formula (VII″):

[0327] [ka]

[0328] or a stereoisomer or a pharmaceutically acceptable salt thereof (In the formula, Ring A is

[0329] [ka]

[0330] is selected from Z is CH2 or NH, and any hydrogen atom of CH2 or NH is R 1 may be substituted with; Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, C 1~6 Alkyl, C 1~6 Alkoxy, -S(O) t C 1~6 Alkyl; -NR e R f independently selected from the group consisting of 3- to 8-membered heterocyclyl, and 5- to 6-membered heteroaryl; t is 0, 1, or 2; n is 0, 1, or 2; R 2 , R 3 , R 4 , R 5 , and R 6 Each of 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, -NR e R f , C 1~6 Alkoxy, and C 1~6 alkyl; or R 3 and R 4 together with the atoms to which they are attached, form R 3 and R 4 may form an aromatic 5- to 6-membered monocyclic ring fused to the phenyl to which Five- to six-membered rings are hydroxy or -NR c R done or more (e.g., one, two, three, or four) C optionally substituted with 1~6 optionally substituted with alkyl; R 7 is hydrogen or C 1~6 is alkyl; R 8 is hydrogen, C 1~6 Alkyl, or C 1~6 is haloalkyl; R 9 is hydrogen or C 1~6 is alkyl; R 10 is (5-6 membered heteroarylene)-(C 0~6 alkylene)-R 11 and; R 11 is 3- to 7-membered heterocyclyl or -NR g R h and; R 12 and R 13 is hydrogen; or R 7 and R 9 together with the atoms to which they are attached, form R 9 may form a 5- to 6-membered heterocyclic ring fused to the phenyl to which R 9 and R 10 together with the atoms to which they are attached, form R 9 and R 10 may form a 6-membered heterocyclic ring or a cyclohexane ring fused to the phenyl to which is attached; R 12 and R 13 together with the atoms to which they are attached, form R 12 and R 13 may form a phenyl ring fused to the ring to which is attached; Each R c and R d are independently H or C 1~6 is alkyl; and Each R e and R f is H, C 1~6 Alkyl, C3~6 independently selected from the group consisting of cycloalkyl, 3- to 7-membered heterocyclyl, and 5- to 6-membered heteroaryl; C 3~6 Cycloalkyl, 3- to 7-membered heterocyclyl and 5- to 6-membered heteroaryl are C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R g and R h is H, C 1~6 Alkyl, C 3~6 independently selected from the group consisting of cycloalkyl, 3- to 7-membered heterocyclyl, and 5- to 6-membered heteroaryl; C 3~6 Cycloalkyl, 3- to 7-membered heterocyclyl and 5- to 6-membered heteroaryl are C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 and R g is hydrogen, R h is not hydrogen; R 10 (5-6 membered heteroarylene)-(C 0~6 alkylene)-(3- to 7-membered heterocyclyl), and R 3 Ga-NR c R d If R 8 is hydrogen; and R g or R h C 3~6 cycloalkyl or 3- to 7-membered heterocyclyl, and R 3 Ga-NR e R f If R e or R f is not a 3- to 7-membered heterocyclyl) is provided herein.

[0331] In some embodiments, compounds of the present disclosure are those in which ring A is

[0332] [ka]

[0333] It has a structure of formula (VII″), In some embodiments, compounds of the present disclosure are those in which ring A is

[0334] [ka]

[0335] It has a structure of formula (VII″), In some embodiments, compounds of the present disclosure include those wherein Z is CH and CH is R 1 In some embodiments, the compounds of the present disclosure have a structure of formula (VII″), where Z is NH and NH is R 1 and has a structure of formula (VII″), optionally substituted with

[0336] In some embodiments, compounds of the present disclosure have the structure of formula (VII″), where t is 0. In some embodiments, compounds of the present disclosure have the structure of formula (VII″), where n is 0.

[0337] In some embodiments, the compounds of the present disclosure are 2 , R 3 , R 4 , R 5 , and R 6 Each of the groups is hydrogen and -NR e R f and having a structure of formula (VII″), independently selected from: In some embodiments, the compounds of the present disclosure are 3 and R 4 These, together with the atoms to which they are bonded, form R 3 and R 4forms an aromatic 5- or 6-membered monocyclic ring fused to a phenyl to which is attached, and the 5- or 6-membered ring is hydroxy or -NR c R d one or more (e.g., one, two, three, or four) C optionally substituted with 1~6 It has the structure of formula (VII″), optionally substituted with alkyl.

[0338] In some embodiments, the compounds of the present disclosure are 7 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (VII″), 7 C 1~6 It has the structure of formula (VII″), which is alkyl.

[0339] In some embodiments, the compounds of the present disclosure are 8 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (VII″), 8 C 1~6 It has the structure of formula (VII″), which is alkyl.

[0340] In some embodiments, the compounds of the present disclosure are 9 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (VII″), 9 C 1~6 It has the structure of formula (VII″), which is alkyl.

[0341] In some embodiments, the compounds of the present disclosure are 11 is a 3- to 7-membered heterocyclyl. In some embodiments, compounds of the present disclosure have a structure of Formula (VII″), where R 11 Ga-NR g R h It has a structure of formula (VII″),

[0342] In some embodiments, the compounds of the present disclosure are 7 and R 9 These, together with the atoms to which they are bonded, form R 9may form a 5- to 6-membered heterocyclic ring fused to the phenyl to which is bonded, and has a structure of formula (VII'').

[0343] In some embodiments, the compounds of the present disclosure are 9 and R 10 These, together with the atoms to which they are bonded, form R 9 and R 10 may form a 6-membered heterocyclic ring or a cyclohexane ring fused to the phenyl to which is attached, and has a structure of formula (VII'').

[0344] In some embodiments, the compounds of the present disclosure are 12 and R 13 However, these, together with the atoms to which they are bonded, form R 12 and R 13 may form a phenyl ring fused to the ring to which it is attached, and has a structure of formula (VII'').

[0345] In some embodiments, the compounds of the present disclosure include a compound in which each R e and R f However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 C optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy 3~6 and having a structure of formula (VII″), independently selected from cycloalkyl.

[0346] In some embodiments, the compounds of the present disclosure include a compound in which each R e and R f However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6and 3-7 membered heterocyclyl, each independently selected from the group consisting of alkoxy, ...

[0347] In some embodiments, the compounds of the present disclosure include a compound in which each R e and R f However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 and having a structure of Formula (VII″):

[0348] In some embodiments, the compounds of the present disclosure include a compound in which each R e and R f is H and C 1~6 and having a structure of formula (VII″), independently selected from alkyl. In some embodiments, the compounds of the present disclosure include a compound in which each R g and R h is H and C 1~6 and having a structure of formula (VII″), independently selected from alkyl.

[0349] In some embodiments, the compounds of the present disclosure include a compound in which each R g and R h However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 C optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy 3~6 and having a structure of formula (VII″), independently selected from cycloalkyl.

[0350] In some embodiments, the compounds of the present disclosure include a compound in which each R g and Rh However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 and 3-7 membered heterocyclyl, each independently selected from the group consisting of alkoxy, ...

[0351] In some embodiments, the compounds of the present disclosure include a compound in which each R g and R h However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 and 5-6 membered heteroaryl, each independently selected from the group consisting of alkoxy, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents.

[0352] In another embodiment, a compound of formula (VIII″)

[0353] [ka]

[0354] or a stereoisomer or a pharmaceutically acceptable salt thereof (In the formula, B is

[0355] [ka]

[0356] is selected from Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, and C 1~6 independently selected from the group consisting of alkyl; n is 0, 1, or 2; R 2 , R 3 , R 4 , R 5 , and R 6 Each of 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, -NR e R f , NO2, C 1~6 Alkoxy, and C 1~6 independently selected from the group consisting of alkyl; or R 4 and R 5 together with the atoms to which they are attached, form R 4 and R 5 may form a 5-membered heteroaryl fused to the phenyl to which is attached; R 9 is hydrogen or C 1~6 is alkyl; Each R 10 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, -NR e R f , NO2, C 1~6 Alkoxy, C 1~6 Alkyl, and C(O)NH(C 1~6 alkylene)Ph, wherein Ph is optionally substituted with halogen; m is 0, 1, or 2; R 6 and R 9 together with the atoms to which they are attached, form R 6 may form a piperidine ring fused to the phenyl to which is attached; R 7 and R 8 each independently represents hydrogen, C 1~6 Alkyl or C 1~6 haloalkyl or R 7 and R 8 may be taken together with the atom to which they are attached to form a 3- to 4-membered cycloalkyl or heterocyclyl ring; R 9 is methyl, R 7 and R 8 is not methyl; R 9 is hydrogen, R 2 and R 6 at least one of which is not hydrogen; R e and R f Each of 1~6 alkyl, and —C(O)CHPh is provided herein.

[0357] In some embodiments, compounds of the present disclosure are those in which B is

[0358] [ka]

[0359] It has a structure of formula (VIII″), In some embodiments, compounds of the present disclosure are those in which B is

[0360] [ka]

[0361] It has a structure of formula (VIII″), In some embodiments, compounds of the present disclosure have the structure of formula (VIII″), where n is 0.

[0362] In some embodiments, the compounds of the present disclosure are 2 , R 3 , R 4 , R 5 , and R 6 Each of the groups is hydrogen, -NR e R f , NO2, and C 1~6 and having a structure of formula (VIII″), independently selected from the group consisting of alkyl.

[0363] In some embodiments, the compounds of the present disclosure are 4 and R 5 These, together with the atoms to which they are bonded, form R 4 and R 5 may form a 5-membered heteroaryl fused to the phenyl to which is attached, having the structure of formula (VIII'').

[0364] In some embodiments, the compounds of the present disclosure are 9 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (VIII″), 9 C 1~6 It has a structure of formula (VIII″), which is alkyl.

[0365] In some embodiments, the compounds of the present disclosure are 10 is C(O)NH(C 1~6 It has a structure of formula (VIII″) wherein Ph is optionally substituted with halogen.

[0366] In some embodiments, compounds of the present disclosure have the structure of formula (VIII"), where m is 0. In some embodiments, compounds of the present disclosure have the structure of formula (VIII"), where m is 1.

[0367] In some embodiments, the compounds of the present disclosure are 6 and R 9 These, together with the atoms to which they are bonded, form R 6 has a structure of formula (VIII″) in which the phenyl group is fused to a piperidine ring.

[0368] In some embodiments, the compounds of the present disclosure are 7 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (VIII″), wherein each of R 7 Each of these is C 1~6 It has a structure of formula (VIII″), which is alkyl.

[0369] In some embodiments, the compounds of the present disclosure are 7 and R 8 which, together with the atoms to which they are attached, form a 3- to 4-membered cycloalkyl or heterocyclyl ring, have the structure of formula (VIII'').

[0370] In some embodiments, the compounds of the present disclosure are 8 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (VIII″), wherein each of R 8 Each of these is C 1~6 It has a structure of formula (VIII″), which is alkyl.

[0371] In another embodiment, a compound of formula (IX″):

[0372] [ka]

[0373] or a stereoisomer or a pharmaceutically acceptable salt thereof (In the formula, Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, and C 1~6 independently selected from the group consisting of alkyl; n is 0, 1, or 2; R 2 is C 1~6 is alkyl; R 3 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, -NR e R f , NO2, C 1~6 Alkoxy, and C 1~6 selected from the group consisting of alkyl; R 6 is hydrogen or C 1~6 is alkyl; R e and R f Each of the1~6 alkyl) is provided herein.

[0374] In some embodiments, compounds of the present disclosure have the structure of formula (IX″), where n is 0. In some embodiments, the compounds of the present disclosure are 2 is methyl.

[0375] In some embodiments, the compounds of the present disclosure are 3 Ga-NR e R f It has a structure of formula (IX″), In some embodiments, the compounds of the present disclosure are 6 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (IX″), 6 C 1~6 It has the structure of formula (IX″), which is alkyl.

[0376] In some embodiments, the compounds of the present disclosure are e and R f is hydrogen. In another embodiment, a compound of formula (X″)

[0377] [ka]

[0378] or a stereoisomer or a pharmaceutically acceptable salt thereof (In the formula, Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, and C 1~6 independently selected from the group consisting of alkyl; n is 0, 1, or 2; R 2 is C 1~6 is alkyl; and R 3is C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Halo, -CN, -NR e R f , NO2, 3- to 8-membered heterocyclyl or -NR e R f may be substituted with C 1~6 alkoxy; and R 4 is hydrogen or C 1~6 is alkyl; R 5 is hydrogen, C 1~6 Alkyl, C 1~6 is haloalkyl; R 6 is hydrogen or C 1~6 is alkyl; or R 5 and R 6 may be taken together with the carbons to which they are attached to form a 3- to 4-membered cycloalkyl or heterocyclic ring; and R e and R f Each of the 1~6 alkyl) is provided herein.

[0379] In some embodiments, compounds of the present disclosure have a structure of formula (X″), where n is 0. In some embodiments, the compounds of the present disclosure are 2 is methyl.

[0380] In some embodiments, the compounds of the present disclosure are 3 Ga-NR e R f In some embodiments, the compounds of the present disclosure have a structure of formula (X″), wherein R 3 Ga-NR e R f may be substituted with C 1~6 In some embodiments, the compounds of the present disclosure have a structure of formula (X″), where R 3C optionally substituted with 3- to 8-membered heterocyclyl 1~6 It has a structure of formula (X″), which is alkoxy.

[0381] In some embodiments, the compounds of the present disclosure are 4 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (X″), 4 C 1~6 It has the structure of formula (X″), which is alkyl.

[0382] In some embodiments, the compounds of the present disclosure are 5 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (X″), 5 C 1~6 It has the structure of formula (X″), which is alkyl.

[0383] In some embodiments, the compounds of the present disclosure are 6 is hydrogen. In some embodiments, the compounds of the present disclosure have a structure of formula (X″), 6 C 1~6 It has the structure of formula (X″), which is alkyl.

[0384] In some embodiments, the compounds of the present disclosure are 5 and R 6 are joined together with the carbon to which they are attached to form a 3- to 4-membered cycloalkyl ring, and have the structure of formula (X'').

[0385] In some embodiments, the compounds of the present disclosure are 5 and R 6 may be joined together with the carbon to which they are attached to form a 3- or 4-membered heterocycle, and have a structure of formula (X'').

[0386] In certain embodiments, the present invention provides compounds of formula I:

[0387] [ka]

[0388] or a pharmaceutically acceptable salt, isotopic derivative or prodrug thereof, or a pharmaceutical composition thereof. In another aspect, the present invention provides a compound of Formula VIII, Formula IX, Formula X, Formula XI, or Formula XIII:

[0389] [ka]

[0390] or a pharmaceutically acceptable salt, isotopic derivative, prodrug, or pharmaceutical composition thereof. In another aspect, the present invention provides a compound of Formula XIV, Formula XV, Formula XVI, Formula XVII, Formula XIX, Formula XX, Formula XXI, Formula XXII, Formula XXIII, Formula XXIV, Formula XXV, Formula XXVII, Formula XXVIII, or Formula XXIX:

[0391] [ka]

[0392] [ka]

[0393] or a pharmaceutically acceptable salt, isotopic derivative, prodrug, or pharmaceutical composition thereof, wherein Q 1 is O or NR 2 and; Q 2 is O, NR 2 , or CR 3 R 4 and; Q 3 is S, O, or NR 2 and; Q 4 is a bond, O, NR 2 , or CR 3 R 4 and; z is 0, 1, 2, or 3; x is 0, 1, 2, 3, or 4; each

[0394] [ka]

[0395] is R 10 and one R 11 an optionally substituted aryl, heteroaryl, heterocycle, cycloalkene, or bicycle;

[0396] [ka]

[0397] is R 10 and one R 11 substituted aryl, heteroaryl, heterocyclic, or bicyclic;

[0398] [ka]

[0399] is R 20 is an aryl, heteroaryl, heterocycle, or bicycle optionally substituted with 1, 2, 3, or 4 substituents independently selected from

[0400] [ka]

[0401] is R 20 and one R 11 optionally substituted cycloalkyl, aryl, heteroaryl, heterocyclic, or bicyclic;

[0402] [ka]

[0403] is R 20 is a tricyclic ring optionally substituted with 1, 2, 3, or 4 substituents independently selected from X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , and X 7 is CR 10 , CH, and N; 1 , X 2 , X 3 , X 4 , X 5 , X 6 , and X 7 ≤ 4 of which are N; X 8 , X 9 , X 10 , X 11 , and X 12 , CH, CR 10 , C.R. 11 and N, 1 , X 2 , X 3 , X 4 , X 5 , X 6 , and X 7 ≤ 4 of which are N; Each R 1 is independently hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or cycloalkyl; Each R 2 are independently hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, alkyl-heterocycle, alkyl-heteroaryl, alkyl-aryl, or —C(O)R 7 and; R 3 and R4 is hydrogen, halogen, alkyl, haloalkyl, alkenyl, alkynyl independently selected from the group consisting of aryl, aryl, heteroaryl, and cycloalkyl; R 3b is alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and cycloalkyl; or R 3 and R 4 , or R 3b and R 4 together with the carbon to which they are attached form a spirocyclopropyl, and the spirocyclopropyl group is R 6 and optionally substituted with 1, 2, 3, or 4 substituents independently selected from: R 5 is alkenyl or alkynyl; R 5b is haloalkyl; Each R 6 is independently selected from the group consisting of halogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and cycloalkyl; Each R 7 and R 8 is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, -NR 1 R 12 , -OR 12 , and S.R. 12 independently selected from the group consisting of: Each R 10 is hydrogen, halogen, alkyl, haloalkyl, cyano, nitro, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, -alkyl-NR 1 R 2 , -alkyl-OR 2 , -C(O)R 7 , -NR 2 C(O)R 7 , -OC(O)R 7 , -NR 1 R 2 , -OR 2 , S.R.2 , -S(O)R 7 , S(O)2R 7 , and -P(O)R 7 R 8 and R are independently selected from the group consisting of: 21 and optionally substituted with 1, 2, 3, or 4 substituents independently selected from: R 10b is halogen, alkyl, haloalkyl, cyano, nitro, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, -alkyl-NR 1 R 2 , -alkyl-OR 2 , -C(O)R 7 , -NR 2 C(O)R 7 , -OC(O)R 7 , -NR 1 R 2 , -OR 2 , S.R. 2 , -S(O)R 7 , S(O)2R 7 , and -P(O)R 7 R 8 each of which, excluding hydrogen, cyano, and nitro, is selected from the group consisting of R 21 and optionally substituted with 1, 2, 3, or 4 substituents independently selected from: R 11 teeth,

[0404] [ka]

[0405] or CH2CN; Each R 12 are independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and cycloalkyl; R 13 , R 14 , R 15 , and R 16is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, CH2OR 2 , and CH2NR 1 R 2 Are independently selected from; or R 13 and R 14 together with the carbon to which they are attached to form a spirocyclopropyl; or R 15 and R 16 together with the carbon to which they are attached to form a spirocyclopropyl; R 16b is alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or cycloalkyl; R 17 is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, -alkylcycloalkyl, -CH2CH2-OR 2 , -CH2CH2-NR 1 R 2 , -alkyl-aryl, -alkyl-heteroaryl, or cycloalkyl; R 18 is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or -C(O)R 7 Is it; or R 17 and R 18 together with the nitrogen to which they are attached form a heterocyclic ring; R 19 is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or -C(O)R 7 and; Each R 20 is hydrogen, halogen, alkyl, haloalkyl, cyano, nitro, oxo, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, -alkyl-NR 1 R 2 , -alkyl-OR 2 , -C(O)R 7, -NR 2 C(O)R 7 , -OC(O)R 7 , -NR 1 R 2 , -OR 2 , S.R. 2 , -S(O)R 7 , S(O)2R 7 , and -P(O)R 7 R 8 each of which, excluding hydrogen, cyano, and nitro, is independently selected from R 22 and optionally substituted with 1, 2, 3, or 4 substituents independently selected from: Each R 21 is hydrogen, halogen, alkyl, haloalkyl, cyano, nitro, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, -C(O)R 7 , -NR 2 C(O)R 7 , -OC(O)R 7 , -NR 1 R 2 , -OR 2 , S.R. 2 , -S(O)R 7 , S(O)2R 7 , and -P(O)R 7 R 8 are independently selected from; Each R 22 is hydrogen, halogen, alkyl, haloalkyl, cyano, nitro, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, -C(O)R 7 , -NR 2 C(O)R 7 , -OC(O)R 7 , -NR 1 R 2 , -OR 2 , S.R. 2 , -S(O)R 7 , S(O)2R 7 , and -P(O)R 7 R 8 (independently selected from to provide.

[0406] The present invention relates to a compound of formula (Z):

[0407] [ka]

[0408] or a pharmaceutically acceptable salt, prodrug, or pharmaceutical composition thereof. In the compound of formula (Z), A100 is selected from the group consisting of the formulas (A1), (A2), (A3), (A4), (A5), (A6), (A7), (A8), (A9), (A10), (A11), (A12), (A13), (A14), (A15), (A16), (A17), (A18), (A19), and (A20):

[0409] [ka]

[0410] may be selected from the group consisting of: In the compound of formula (Z), L 1 can be -CH2- or absent. In the compound of formula (Z), L 2 -CONH-, -NHCO-, -NHSO2-, -SO2NH-, -NH-, -CO-, -NR 114 - or may be absent.

[0411] In the compound of formula (Z), L 3 teeth

[0412] [ka]

[0413] It may be present or absent. In the compound of formula (Z), L 4 Ha-CR 120 R 121 - or may be absent.

[0414] In the compound of formula (Z), B100 is

[0415] [ka]

[0416] It could be. In the compound of formula (Z), R 101 H, halo, -OH, -CONH2, -OR 124 , N.R. 124 R 125 , -NO2, -NS(O)2CH3, C1-C6 alkoxyl, C3-C6 cycloalkoxyl, C3-C6 cycloheteroalkoxyl, C1-C6 heteroalkoxyl, -C(O)CH3,

[0417] [ka]

[0418] It could be. R 102 is H, -OH, halo, or a substituted alkyne, e.g.

[0419] [ka]

[0420] The alkyne may be an alkyne including: R 103 can be H or halo, or alkyl. R 104 can be H, halo, or alkyl.

[0421] R 106 is H, halo, or C1-C6 alkyl, or C1-C6 cycloheteroal It could be a kill. R 107 is H, Me, —COH, —CHOH, halo, C1-C3 alkyl, C1-C3 heteroalkyl, or C1-C4 cycloheteroalkyl, for example:

[0422] [ka]

[0423] It could be. R 108 is H, halo, CO2H, CONH2, aryl, C3-C6 heteroaryl (e.g., pyridine), C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 heteroalkyl, C3-C6 cycloheteroalkyl (e.g., morpholine), or

[0424] [ka]

[0425] can be, or

[0426] [ka]

[0427] It could be. R 109 can be H, halo, or Me. R 110 can be H or Me.

[0428] R 112 can be NO2 or NH2. R 114 can be Me. R 118 teeth

[0429] [ka]

[0430] It could be. R 120can be H, Me, halo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 heteroalkyl, C3-C6 cycloheteroalkyl, aryl, or heteroaryl.

[0431] R 121 can be H. In an alternative embodiment of the present invention, R1 20 and R1 21 may be taken together with the carbon atom to which they are attached to form a C3-C6 cycloalkyl or a C3-C6 cycloheteroalkyl.

[0432] R 122 is H, Me, halo, aryl, C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloheteroalkyl, such as phenyl, benzyl, or thiophene, or

[0433] [ka]

[0434] can be, or

[0435] [ka]

[0436] It could be. R 122 is OR 123 It could be. R 123 can be aryl, C3-C6 cycloalkyl, or C3-C6 cycloheteroalkyl (e.g., phenyl or benzyl).

[0437] R 124 is H, -S(O)2CH3, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 heteroalkyl, C3-C6 cycloheteroalkyl, or heteroaryl, or

[0438] [ka]

[0439] can be; or

[0440] [ka]

[0441] It could be. R 125 can be H, C(O)CH3, or absent. In compounds of formula (Z), each alkoxyl, alkyl, aryl, cycloalkoxyl, cycloalkyl, cycloheteroalkoxyl, cycloheteroalkyl, haloalkyl, heteroalkoxyl, heteroalkyl, and heteroaryl group may be optionally substituted.

[0442] Embodiments of the present invention include salt forms of compounds of formula (Z). The salt forms may include any pharmaceutically acceptable salt, such as hydrochloric acid (HCl), trifluoroacetic acid (TFA), or formic acid (FA).

[0443] In a preferred embodiment, R 106 can be -CH3. L 2 can be -NHCO-. L 4 Ha-CR 120 R 121 -It could be.

[0444] R 120 can be CH3, R 121 can be H. In an alternative embodiment, L 4 Ha-CR 120 R 121 - may be R 120 and R 121 together with the carbon atom to which they are attached form a (hetero)cycloalkyl of formula (Y1), (Y2), or (Y3):

[0445] [ka]

[0446] Form. B100 is

[0447] [ka]

[0448] It could be. In a further alternative embodiment, L 4 Ha-CR 120 R 121 - may be R 120 can be CH2F, CHF, CF3, or of formula (X6):

[0449] [ka]

[0450] It can be; R 121 can be H. In certain embodiments, the compounds of the present invention have the formula:

[0451] [ka]

[0452] or a pharmaceutically acceptable salt thereof. In certain embodiments, compounds of the present disclosure have the formula:

[0453] [ka]

[0454] or a pharmaceutically acceptable salt thereof. In certain embodiments, the compounds of the present invention have the formula:

[0455] [ka]

[0456] or a pharmaceutically acceptable salt thereof. In certain embodiments, the compounds of the present invention have the formula:

[0457] [ka]

[0458] [ka]

[0459] or a pharmaceutically acceptable salt thereof. In certain embodiments, compounds of the present disclosure have the formula:

[0460] [ka]

[0461] or a pharmaceutically acceptable salt thereof. An aspect of the present invention provides a composition comprising a compound according to the present invention. An aspect of the present invention provides pharmaceutically acceptable salts or prodrugs of the compounds of the present invention.

[0462] An aspect of the present invention provides a method of treating a subject suffering from a viral infection, the method comprising administering to the subject a compound according to the present invention. An aspect of the present invention provides a method of preventing a viral infection in a subject, the method comprising administering to the subject a compound according to the present invention.

[0463] An aspect of the present invention provides a method of preventing viral replication in a subject, the method comprising administering to the subject a compound according to the present invention. An aspect of the present invention provides a method of inhibiting PLpro in a subject, the method comprising administering to the subject a compound according to the present invention. Embodiments of the present invention In certain embodiments, the compounds of the present invention have the formula:

[0464] [ka]

[0465] or a pharmaceutically acceptable salt thereof (wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , R 1 , R 6 , R 10 , R 11 , Q 3 , ring B, and x are as defined herein).

[0466] [ka]

[0467] Embodiments of the present invention In certain embodiments,

[0468] [ka]

[0469] but,

[0470] [ka]

[0471] is selected from. In certain embodiments,

[0472] [ka]

[0473] but,

[0474] [ka]

[0475] is selected from. In certain embodiments,

[0476] [ka]

[0477] but,

[0478] [ka]

[0479] is selected from. In certain embodiments,

[0480] [ka]

[0481] but,

[0482] [ka]

[0483] is selected from. In certain embodiments,

[0484] [ka]

[0485] but,

[0486] [ka]

[0487] is selected from. In certain embodiments,

[0488] [ka]

[0489] but,

[0490] [ka]

[0491] is selected from. In certain embodiments,

[0492] [ka]

[0493] but,

[0494] [ka]

[0495] is selected from. In certain embodiments,

[0496] [ka]

[0497] but,

[0498] [ka]

[0499] is selected from. In certain embodiments,

[0500] [ka]

[0501] but,

[0502] [ka]

[0503] is selected from. In certain embodiments,

[0504] [ka]

[0505] but,

[0506] [ka]

[0507] is selected from. In certain embodiments,

[0508] [ka]

[0509] but

[0510] [ka]

[0511] is. In certain embodiments,

[0512] [ka]

[0513] but,

[0514] [ka]

[0515] is selected from. In certain embodiments,

[0516] [ka]

[0517] but,

[0518] [ka]

[0519] is selected from. In certain embodiments,

[0520] [ka]

[0521] but,

[0522] [ka]

[0523] is selected from.

[0524] [ka]

[0525] Embodiments of the present invention In certain embodiments,

[0526] [ka]

[0527] but,

[0528] [ka]

[0529] is selected from. R 1 Non-limiting embodiments of In certain embodiments, R 1 is hydrogen.

[0530] In certain embodiments, R 1 is alkyl. In certain embodiments, R 1 is haloalkyl. In certain embodiments, R 1 is alkenyl.

[0531] In certain embodiments, R 1 is alkynyl. In certain embodiments, R 1 is aryl. In certain embodiments, R 1 is heteroaryl.

[0532] In certain embodiments, R 1 is hydrogen. In certain embodiments, R 1 is cycloalkyl. R 2 Non-limiting embodiments of In certain embodiments, R 2is hydrogen.

[0533] In certain embodiments, R 2 is alkyl. In certain embodiments, R 2 is haloalkyl. In certain embodiments, R 2 is alkenyl.

[0534] In certain embodiments, R 2 is alkynyl. In certain embodiments, R 2 is aryl. In certain embodiments, R 2 is heteroaryl.

[0535] In certain embodiments, R 2 is cycloalkyl. In certain embodiments, R 2 -C(O)R 7 is. R 3 Non-limiting embodiments of In certain embodiments, R 3 is hydrogen.

[0536] In certain embodiments, R 3 is a halogen. In certain embodiments, R 3 is alkyl. In certain embodiments, R 3 is haloalkyl.

[0537] In certain embodiments, R 3 is alkenyl. In certain embodiments, R 3 is alkynyl. In certain embodiments, R 3 is aryl.

[0538] In certain embodiments, R 3 is heteroaryl. In certain embodiments, R 3 is cycloalkyl. R 3b Non-limiting embodiments of In certain embodiments, R 3b is alkyl.

[0539] In certain embodiments, R 3b is haloalkyl. In certain embodiments, R 3b is alkenyl. In certain embodiments, R 3b is alkynyl.

[0540] In certain embodiments, R 3b is aryl. In certain embodiments, R 3b is heteroaryl. In certain embodiments, R 3b is cycloalkyl.

[0541] R 4 Non-limiting embodiments of In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is a halogen.

[0542] In certain embodiments, R 4 is alkyl. In certain embodiments, R 4 is haloalkyl. In certain embodiments, R 4 is alkenyl.

[0543] In certain embodiments, R 4 is alkynyl. In certain embodiments, R 4 is aryl. In certain embodiments, R 4 is heteroaryl.

[0544] In certain embodiments, R 4 is cycloalkyl. R 5 Non-limiting embodiments of In certain embodiments, R 5 is alkenyl.

[0545] In certain embodiments, R 5 is alkynyl. In certain embodiments, R 5 but

[0546] [ka]

[0547] is. In certain embodiments, R 5 but

[0548] [ka]

[0549] is. In certain embodiments, R 5 but

[0550] [ka]

[0551] is. In certain embodiments, R 5 but

[0552] [ka]

[0553] is. In certain embodiments, R 5 but

[0554] [ka]

[0555] is. In certain embodiments, R 5 but

[0556] [ka]

[0557] is. In certain embodiments, R 5 but

[0558] [ka]

[0559] is. In certain embodiments, R 5 but

[0560] [ka]

[0561] is. In certain embodiments, R 5 but

[0562] [ka]

[0563] is. R 5b Non-limiting embodiments of In certain embodiments, R 5b is haloalkyl.

[0564] In certain embodiments, R 5b but

[0565] [ka]

[0566] is. In certain embodiments, R 5b but

[0567] [ka]

[0568] is. In certain embodiments, R 5b is -CF3. R 6 Non-limiting embodiments of In certain embodiments, R 6 is a halogen.

[0569] In certain embodiments, R 6 is alkyl. In certain embodiments, R 6 is haloalkyl. In certain embodiments, R 6 is alkenyl.

[0570] In certain embodiments, R 6 is alkynyl. In certain embodiments, R 6 is aryl. In certain embodiments, R 6 is heteroaryl.

[0571] In certain embodiments, R 6 is cycloalkyl. R 7 Non-limiting embodiments of In certain embodiments, R 7 is hydrogen.

[0572] In certain embodiments, R 7 is alkyl. In certain embodiments, R 7 is haloalkyl. In certain embodiments, R 7 is alkenyl.

[0573] In certain embodiments, R 7 is alkynyl. In certain embodiments, R 7 is aryl. In certain embodiments, R 7 is heteroaryl.

[0574] In certain embodiments, R 7 is cycloalkyl. In certain embodiments, R 7 Ga-NR 1 R 12 is. In certain embodiments, R 7 -OR 12 is.

[0575] In certain embodiments, R 7 is SR 12 is. R 8 Non-limiting embodiments of In certain embodiments, R 8 is hydrogen.

[0576] In certain embodiments, R 8 is alkyl. In certain embodiments, R 8 is haloalkyl. In certain embodiments, R 8 is alkenyl.

[0577] In certain embodiments, R 8 is alkynyl. In certain embodiments, R 8 is aryl. In certain embodiments, R 8 is heteroaryl.

[0578] In certain embodiments, R 8 is cycloalkyl. In certain embodiments, R 8 Ga-NR 1 R 12 is. In certain embodiments, R 8 -OR 12 is.

[0579] In certain embodiments, R 8 is SR 12 is. R 10 Non-limiting embodiments of In certain embodiments, R 10 is hydrogen.

[0580] In certain embodiments, R 10 is a halogen. In certain embodiments, R 10 is alkyl. In certain embodiments, R 10 is haloalkyl.

[0581] In certain embodiments, R 10 is cyano. In certain embodiments, R 10 is nitro. In certain embodiments, R 10 is alkenyl.

[0582] In certain embodiments, R 10 is alkynyl. In certain embodiments, R 10 is aryl. In certain embodiments, R 10 is heteroaryl.

[0583] In certain embodiments, R 10 is cycloalkyl. In certain embodiments, R10 -C(O)R 7 is. In certain embodiments, R 10 Ga-NR 2 C(O)R 7 is.

[0584] In certain embodiments, R 10 -OC(O)R 7 is. In certain embodiments, R 10 Ga-NR 1 R 2 is. In certain embodiments, R 10 -OR 2 is.

[0585] In certain embodiments, R 10 is SR 2 is. In certain embodiments, R 10 -S(O)R 7 is. In certain embodiments, R 10 is S(O)2R 7 is.

[0586] In certain embodiments, R 10 -P(O)R 7 R 8 is. R 10b Non-limiting embodiments of: In certain embodiments, R 10b is hydrogen.

[0587] In certain embodiments, R 10b is a halogen. In certain embodiments, R 10b is alkyl. In certain embodiments, R 10b is haloalkyl.

[0588] In certain embodiments, R 10b is cyano. In certain embodiments, R 10b is nitro. In certain embodiments, R 10b is alkenyl.

[0589] In certain embodiments, R 10b is alkynyl. In certain embodiments, R 10b is aryl. In certain embodiments, R 10b is heteroaryl.

[0590] In certain embodiments, R 10b is cycloalkyl. In certain embodiments, R 10b -C(O)R 7 is. In certain embodiments, R 10b Ga-NR 2 C(O)R 7 is.

[0591] In certain embodiments, R 10b -OC(O)R 7 is. In certain embodiments, R 10b Ga-NR 1 R 2 is. In certain embodiments, R 10b -OR 2 is.

[0592] In certain embodiments, R 10b is SR 2 is. In certain embodiments, R 10b -S(O)R 7 is. In certain embodiments, R 10b is S(O)2R 7 is.

[0593] In certain embodiments, R 10b -P(O)R 7 R8 is. R 11 Non-limiting embodiments of: In certain embodiments, R 11 but

[0594] [ka]

[0595] is. In certain embodiments, R 11 but

[0596] [ka]

[0597] is. In certain embodiments, R 11 but

[0598] [ka]

[0599] is. In certain embodiments, R 11 but

[0600] [ka]

[0601] is. In certain embodiments, R 11 but

[0602] [ka]

[0603] is. In certain embodiments, R 11 but

[0604] [ka]

[0605] is. In certain embodiments, R 11 but

[0606] [ka]

[0607] is. In certain embodiments, R 11 but

[0608] [ka]

[0609] is. In certain embodiments, R 11 but

[0610] [ka]

[0611] is. In certain embodiments, R 11 but

[0612] [ka]

[0613] is. R 12 Non-limiting embodiments of In certain embodiments, R 12 is hydrogen.

[0614] In certain embodiments, R 12 is alkyl. In certain embodiments, R 12 is haloalkyl. In certain embodiments, R 12 is alkenyl.

[0615] In certain embodiments, R 12 is alkynyl. In certain embodiments, R 12 is aryl. In certain embodiments, R 12 is heteroaryl.

[0616] In certain embodiments, R 12 is cycloalkyl. R 13 Non-limiting embodiments of In certain embodiments, R 13 is hydrogen.

[0617] In certain embodiments, R 13 is alkyl. In certain embodiments, R 13 is haloalkyl. In certain embodiments, R 13 is alkenyl.

[0618] In certain embodiments, R 13 is alkynyl. In certain embodiments, R 13 is aryl. In certain embodiments, R 13 is heteroaryl.

[0619] In certain embodiments, R 13 is cycloalkyl. R 14 Non-limiting embodiments of In certain embodiments, R 14 is hydrogen.

[0620] In certain embodiments, R 14 is alkyl. In certain embodiments, R 14 is haloalkyl. In certain embodiments, R 14 is alkenyl.

[0621] In certain embodiments, R 14 is alkynyl. In certain embodiments, R 14 is aryl. In certain embodiments, R 14 is heteroaryl.

[0622] In certain embodiments, R 14 is cycloalkyl. R 15 Non-limiting embodiments of In certain embodiments, R 15 is hydrogen.

[0623] In certain embodiments, R 15 is alkyl. In certain embodiments, R 15 is haloalkyl. In certain embodiments, R 15 is alkenyl.

[0624] In certain embodiments, R 15 is alkynyl. In certain embodiments, R 15 is aryl. In certain embodiments, R 15 is heteroaryl.

[0625] In certain embodiments, R 15 is cycloalkyl. R 16 Non-limiting embodiments of In certain embodiments, R 16 is hydrogen.

[0626] In certain embodiments, R 16is alkyl. In certain embodiments, R 16 is haloalkyl. In certain embodiments, R 16 is alkenyl.

[0627] In certain embodiments, R 16 is alkynyl. In certain embodiments, R 16 is aryl. In certain embodiments, R 16 is heteroaryl.

[0628] In certain embodiments, R 16 is cycloalkyl. R 16b Non-limiting embodiments of In certain embodiments, R 16b is alkyl.

[0629] In certain embodiments, R 16b is haloalkyl. In certain embodiments, R 16b is alkenyl. In certain embodiments, R 16b is alkynyl.

[0630] In certain embodiments, R 16b is aryl. In certain embodiments, R 16b is heteroaryl. In certain embodiments, R 16b is cycloalkyl.

[0631] R 17 Non-limiting embodiments of In certain embodiments, R 17 is hydrogen. In certain embodiments, R 17 is alkyl.

[0632] In certain embodiments, R 17 is haloalkyl. In certain embodiments, R 17 is alkenyl. In certain embodiments, R 17 is alkynyl.

[0633] In certain embodiments, R 17 is heteroaryl. In certain embodiments, R 17 is -alkylcycloalkyl. In certain embodiments, R 17 -CH2CH2-OR 2 is.

[0634] In certain embodiments, R 17 -CH2CH2-NR 1 R 2 is. In certain embodiments, R 17 is -alkyl-aryl. In certain embodiments, R 17 is -alkyl-heteroaryl.

[0635] In certain embodiments, R 17 is cycloalkyl. R 18 Non-limiting embodiments of In certain embodiments, R 18 is hydrogen.

[0636] In certain embodiments, R 18 is alkyl. In certain embodiments, R 18 is haloalkyl. In certain embodiments, R 18 is alkenyl.

[0637] In certain embodiments, R 18 is aryl. In certain embodiments, R 18is heteroaryl. In certain embodiments, R 18 is cycloalkyl.

[0638] In certain embodiments, R 18 -C(O)R 7 is. R 19 Non-limiting embodiments of In certain embodiments, R 19 is hydrogen.

[0639] In certain embodiments, R 19 is alkyl. In certain embodiments, R 19 is haloalkyl. In certain embodiments, R 19 is alkenyl.

[0640] In certain embodiments, R 19 is alkynyl. In certain embodiments, R 19 is aryl. In certain embodiments, R 19 is heteroaryl.

[0641] In certain embodiments, R 19 is cycloalkyl. In certain embodiments, R 19 is cycloalkyl. In certain embodiments, R 19 -C(O)R 7 is.

[0642] R 20 Non-limiting embodiments of In certain embodiments, R 20 is hydrogen. In certain embodiments, R 20 is a halogen.

[0643] In certain embodiments, R 20is alkyl. In certain embodiments, R 20 is haloalkyl. In certain embodiments, R 20 is cyano.

[0644] In certain embodiments, R 20 is nitro. In certain embodiments, R 20 is alkenyl. In certain embodiments, R 20 is alkynyl.

[0645] In certain embodiments, R 20 is aryl. In certain embodiments, R 20 is heteroaryl. In certain embodiments, R 20 is cycloalkyl.

[0646] In certain embodiments, R 20 -C(O)R 7 is. In certain embodiments, R 20 Ga-NR 2 C(O)R 7 is. In certain embodiments, R 20 -OC(O)R 7 is.

[0647] In certain embodiments, R 20 Ga-NR 1 R 2 is. In certain embodiments, R 20 -OR 2 is. In certain embodiments, R 20 is SR 2 is.

[0648] In certain embodiments, R 20 is S(O)R 7 is. In certain embodiments, R 20 is S(O)2R 7 is. In certain embodiments, R 20 -P(O)R 7 R 8 is.

[0649] In certain embodiments, R 20 is heteroaryl. R 21 Non-limiting embodiments of In certain embodiments, R 21 is heteroaryl.

[0650] In certain embodiments, R 21 is hydrogen. In certain embodiments, R 21 is a halogen. In certain embodiments, R 21 is alkyl.

[0651] In certain embodiments, R 21 is haloalkyl. In certain embodiments, R 21 is cyano. In certain embodiments, R 21 is nitro.

[0652] In certain embodiments, R 21 is alkenyl. In certain embodiments, R 21 is alkynyl. In certain embodiments, R 21 is aryl.

[0653] In certain embodiments, R 21 is heteroaryl. In certain embodiments, R 21 is cycloalkyl. In certain embodiments, R 21 -C(O)R 7is.

[0654] In certain embodiments, R 21 Ga-NR 2 C(O)R 7 is. In certain embodiments, R 21 -OC(O)R 7 is. In certain embodiments, R 21 Ga-NR 1 R 2 is.

[0655] In certain embodiments, R 21 -OR 2 is. In certain embodiments, R 21 is SR 2 is. In certain embodiments, R 21 is S(O)R 7 is.

[0656] In certain embodiments, R 21 is S(O)2R 7 is. In certain embodiments, R 21 -P(O)R 7 R 8 is. In certain embodiments, R 21 is heteroaryl.

[0657] R 22 Non-limiting embodiments of In certain embodiments, R 22 is hydrogen. In certain embodiments, R 22 is a halogen.

[0658] In certain embodiments, R 22 is alkyl. In certain embodiments, R 22 is haloalkyl. In certain embodiments, R 22 is cyano.

[0659] In certain embodiments, R 22 is nitro. In certain embodiments, R 22 is alkenyl. In certain embodiments, R 22 is alkynyl.

[0660] In certain embodiments, R 22 is aryl. In certain embodiments, R 22 is heteroaryl. In certain embodiments, R 22 is cycloalkyl.

[0661] In certain embodiments, R 22 -C(O)R 7 is. In certain embodiments, R 22 Ga-NR 2 C(O)R 7 is. In certain embodiments, R 22 -OC(O)R 7 is.

[0662] In certain embodiments, R 22 Ga-NR 1 R 2 is. In certain embodiments, R 22 -OR 2 is. In certain embodiments, R 22 is SR 2 is.

[0663] In certain embodiments, R 22 is S(O)R 7 is. In certain embodiments, R 22 is S(O)2R 7 is. In certain embodiments, R 22 -P(O)R7 R 8 is.

[0664] Representative Compounds of the Invention

[0665] [Table 1-1]

[0666] [Table 1-2]

[0667] [Table 1-3]

[0668] [Table 1-4]

[0669] [Table 1-5]

[0670] [Table 1-6]

[0671] [Table 1-7]

[0672] [Table 1-8]

[0673] [Table 1-9]

[0674]

Table 1-10

[0675]

Table 1-11

[0676]

Table 1-12

[0677]

Table 1-13

[0678]

Table 1-14

[0679]

Table 1-15

[0680]

Table 1-16

[0681]

Table 1-17

[0682]

Table 1-18

[0683]

Table 1-19

[0684]

Table 1-20

[0685]

Table 1-21

[0686]

Table 1-22

[0687]

Table 1-23

[0688]

Table 1-24

[0689]

Table 1-25

[0690]

Table 1-26

[0691]

Table 1-27

[0692]

Table 1-28

[0693]

Table 1-29

[0694]

Table 1-30

[0695]

Table 1-31

[0696]

Table 1-32

[0697]

Table 1-33

[0698]

Table 1-34

[0699]

Table 1-35

[0700]

Table 1-36

[0701]

Table 1-37

[0702]

Table 1-38

[0703]

Table 1-39

[0704]

Table 1-40

[0705]

Table 1-41

[0706]

Table 1-42

[0707]

Table 1-43

[0708]

Table 1-44

[0709]

Table 1-45

[0710]

Table 1-46

[0711]

Table 1-47

[0712]

Table 1-48

[0713]

Table 1-49

[0714]

Table 1-50

[0715]

Table 1-51

[0716]

Table 1-52

[0717]

Table 1-53

[0718]

Table 1-54

[0719]

Table 1-55

[0720]

Table 1-56

[0721]

Table 1-57

[0722]

Table 1-58

[0723]

Table 1-59

[0724]

Table 1-60

[0725]

Table 1-61

[0726]

Table 1-62

[0727]

Table 1-63

[0728]

Table 1-64

[0729]

Table 1-65

[0730]

Table 1-66

[0731]

Table 1-67

[0732]

Table 1-68

[0733]

Table 1-69

[0734]

Table 1-70

[0735]

Table 1-71

[0736]

Table 1-72

[0737]

Table 1-73

[0738]

Table 1-74

[0739]

Table 1-75

[0740]

Table 1-76

[0741]

Table 1-77

[0742]

Table 1-78

[0743]

Table 1-79

[0744]

Table 1-80

[0745] [Table 1-81]

[0746] [Table 1-82]

[0747] [Table 1-83]

[0748] [Table 1-84]

[0749] [Table 1-85]

[0750] [Table 1-86]

[0751] [Table 1-87]

[0752] [Table 1-88]

[0753] Pharmaceutical Composition Also disclosed herein is a pharmaceutical composition comprising the compound described herein or its pharmaceutically acceptable salt and one or more (for example, one, two, three, or four) pharmaceutically acceptable excipients.In certain embodiments, the compound of the present invention is provided in an effective amount in the pharmaceutical composition.In certain embodiments, the compound of the present invention is provided in a therapeutically effective amount.

[0754] In certain embodiments, the pharmaceutical composition comprises an effective amount of the active ingredient. In certain embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the active ingredient. "Pharmaceutically acceptable" means approved or approvable by a regulatory authority of the Federal or State government or a corresponding authority in a country other than the United States, or listed in the United States Pharmacopoeia or other generally recognized pharmacopoeias for use in animals, and more particularly in humans.

[0755] "Pharmaceutically acceptable salts" refers to salts of the compounds of the present invention that are pharmaceutically acceptable and possess the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic and can be inorganic or organic acid addition salts and base addition salts. Specifically, such salts can be formed with (1) inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, etc. or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or when coordinated with an organic base, e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc.; and, if the compound contains a basic functional group, salts of non-toxic organic or inorganic acids, e.g., hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, etc. The term "pharmaceutically acceptable cation" refers to an acceptable cationic counterion of an acidic functional group.Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like (see, e.g., Berge et al., J. Pharm. Sci. (1977) 66(1):1-79, the entire contents of which are incorporated herein by reference).

[0756] "Subjects" to which administration is contemplated include, but are not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or non-human animals, e.g., mammals such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cows, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal.

[0757] The terms "human," "patient," and "subject" are used interchangeably herein. Disease, disorder, and condition are used interchangeably herein.

[0758] As used herein, unless otherwise specified, the terms "treat," "treating," and "treatment" contemplate actions taken while a subject is suffering from the specified disease, disorder, or condition that reduce the severity of the disease, disorder, or condition or slow or decelerate the progression of the disease, disorder, or condition ("therapeutic treatment"), as well as actions taken before a subject begins to suffer from the specified disease, disorder, or condition ("prophylactic treatment").

[0759] Generally, the "effective amount" of a compound refers to the amount that induces desired biological response, for example, is sufficient to treat CNS-related disorders, and is sufficient to induce anesthesia or sedation.As understood by those skilled in the art, the effective amount of the compound of the present invention can vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease to be treated, the mode of administration, and the age, weight, health and condition of the subject.The effective amount includes therapeutic treatment and prophylactic treatment.

[0760] As used herein, unless otherwise specified, a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more (e.g., one, two, three, or four) symptoms associated with a disease, disorder, or condition. A therapeutically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" can encompass an amount that improves overall treatment, reduces or avoids the symptoms or causes of a disease or condition, or enhances the therapeutic effectiveness of another therapeutic agent.

[0761] The pharmaceutical compositions provided herein can be administered by a variety of routes, including, but not limited to, oral (enteral), parenteral (by injection), rectal, transdermal, intradermal, intrathecal, subcutaneous (SC), intravenous (IV), intramuscular (IM), and intranasal administration.

[0762] Pharmaceutically acceptable excipients include any and all diluents or other liquid vehicles, dispersing or suspending aids, surface active agents, isotonic agents, preservatives, lubricants, etc., that are appropriate for the particular dosage form desired. General considerations in the formulation and / or manufacture of pharmaceutical compositions can be found, for example, in Remington's Pharmaceutical Sciences, 16th Edition, E. W. Martin (Mack Publishing Co., Easton, PA, 1980) and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).

[0763] The compounds and pharmaceutical compositions provided herein can be administered as the sole active agent or in combination with other active agents. In one aspect, the present invention provides a combination of a compound of the present invention with another pharmacologically active agent. The administration of the combination can proceed by any technique apparent to those skilled in the art, including, for example, separate administration, sequential administration, simultaneous administration, and alternating administration. Treatment method Another aspect of the present disclosure provides a method for treating a patient suffering from a viral infection, e.g., a coronavirus infection. In particular, in certain embodiments, the present disclosure provides a method for treating the following medical indications, comprising administering a therapeutically effective amount of a compound described herein, e.g., a compound described herein, to a subject in need of treatment for the medical indication. In one aspect, the compounds described herein are contemplated as PLpro inhibitors. In certain embodiments, the present disclosure provides a method for treating a viral infection in a patient in need of treatment, comprising inhibiting PLpro by administering a compound described herein.

[0764] SARS-CoV-2 is a positive-stranded RNA betacoronavirus. The genome of SARS-CoV-2 contains 16 nonstructural proteins (Nsp1 to Nsp16) that are initially expressed as the viral polyprotein (see Thiel et al., Journal of General Virology 2003, 84(9), 2305-2315; Barretto et al., J Virol 2005, 79(24), 15189-98; and Harcourt et al., Journal of Virology 2004, 78(24), 13600-13612, the contents of each of which are incorporated by reference in their entirety). During viral replication in coronaviruses, this polyprotein is processed by a virally encoded protease to promote the formation of a membrane-bound replicase complex that replicates viral RNA (see Mielech et al., Journal of Virology 2015, 89(9), 4907-4917, the entire contents of which are incorporated herein by reference). One of the major proteases from CoVs, the 3C-like protease, is known for its ability to cleave Nsp4 through Nsp16. In addition to the 3C-like protease, CoVs can also encode up to two papain-like proteases (PLs), one of which cleaves Nsp1 through Nsp3. For example, CoVs such as mouse hepatitis virus (MHV) and other human coronaviruses, including NL63, OC43, HKU1, and 229E, encode PLP1 and PLP29. For SARS-CoV-2, its genome closely resembles that of Middle East Respiratory Syndrome CoV (MERS-CoV) and SARS-CoV by encoding a single papain-like protease. While not limited to its mechanism of action, PLpro's dual viral polypeptide cleavage and immunosuppressive roles make it a potential target for small molecule antiviral drug development. PLpro is discussed in Mclain and Vabret, Signal Transduction and Targeted Therapy 2020, 5:223; and Rut et al., Sci. Adv. 2020, 6:eabd4596, the entire contents of each of which are incorporated herein by reference.

[0765] In some embodiments, the infection is chronic. As used herein, "chronic" refers to an infection that persists or recurs over an extended period of time. In some embodiments, the infection is acute. As used herein, "acute" refers to an infection that is of short duration.

[0766] Methods for quantifying viral replication are known in the art. In some embodiments, the number of viruses is determined using a plaque assay. In some embodiments, the number of viruses is determined using a focus-forming assay (FFA). In some embodiments, the number of viruses is determined using an endpoint dilution assay. In some embodiments, the number of viruses is determined using an enzyme-linked immunosorbent assay (ELISA). In some embodiments, the number of viruses is determined using tunable resistive pulse sensing (TRPS) to detect individual viral particles. In some embodiments, viral replication is determined, for example, by quantifying the amount or percentage of dead host cells in vitro, for example, using propidium iodide (PI) to identify dead cells and quantifying the amount of morphologically rounded cells, or by immunofluorescence microscopy of apoptotic markers. In some embodiments, the number of viruses is determined by measuring the virus titer or multiplicity of infection (MOI), or by performing plaque assays, focus-forming assays, and end-point dilution assays, viral protein quantification assays (e.g., hemagglutination assays, bicinchoninic acid assays (BCA), or single radial immunodiffusion (SRID) assays), transmission electron microscopy analysis, tunable resistive pulse sensing (TRPS) assays, flow cytometry assays, quantitative PCR (qPCR) assays, or enzyme-linked immunosorbent assays (ELISA). In some embodiments, viral replication is determined by quantifying viral nucleic acid (e.g., viral DNA or viral RNA) content.

[0767] Methods for quantifying viral spread are known in the art. In some embodiments, viral spread is quantified using epidemiological modeling (see, for example, Graw F. et al., (2016) Modeling Viral Spread. Annu Rev Virol, 3(1)). In some embodiments, viral spread is assessed in vitro, for example in cell culture, for example, by using microscopy, for example, by using transmission electron microscopy (TEM).

[0768] Methods for quantifying viral assembly are known in the art. In some embodiments, viral assembly is determined using statistical modeling (see, e.g., Clement N et al. (2018) Viral Capsid Assembly: A Quantified Uncertainty Approach. J Comp Biol, 25(1)). In some embodiments, viral assembly is determined using biochemical techniques to determine capsid complex formation, such as co-immunoprecipitation, e.g., Western blotting. In some embodiments, viral assembly is determined by flow cytometry to detect co-localized viral proteins (see, e.g., Stoffel, CL et al. (2005). "Rapid Determination of Baculovirus Titer by a Dual Channel Virus Counter" American Biotechnology Laboratory. 37(22):24-25).

[0769] Viral genes encode elements necessary for the process of viral infection, a multistep process including, for example, attachment to a host cell, entry, uncoating, the viral gene transcription cascade, viral protein expression, viral genome replication, viral packaging and assembly, envelopment, transport and maturation, release and egress, and host cell-to-cell spread. The β gene is a gene corresponding to an early stage of viral infection, e.g., viral genome replication. The γ gene is a gene corresponding to a later stage of viral infection, e.g., egress. Methods for quantifying viral gene expression are known in the art. In some embodiments, viral gene expression is determined using reverse transcriptase and quantitative polymerase chain reaction (RT-qPCR). In some embodiments, RNA sequencing (RNA-Seq) is used to determine viral gene expression. In some embodiments, viral DNA is quantified using Southern blot. In some embodiments, β gene expression is quantified. In some embodiments, γ gene expression is quantified. In some embodiments, β gene expression and γ gene expression are quantified. In some embodiments, the expression of the entire viral genome is quantified.

[0770] Methods for quantifying viral release are known in the art. In some embodiments, viral release is determined by a biochemical assay, e.g., Western blotting, e.g., metabolic labeling (see, e.g., Yadav et al. (2012). "A facile quantitative assay for viral particle genesis reveals cooperativity in virion assembly and saturation of an antiviral protein." Virology. 429(2):155-162). In some embodiments, viral release is determined by ELISA. In some embodiments, viral release is determined using electron microscopy, e.g., transmission electron microscopy (TEM). In some embodiments, viral release is determined by an infectivity assay to detect virions in a sample, e.g., serum. In some embodiments, viral release is determined by quantification of viral DNA or RNA in serum in vivo or culture supernatant in vitro.

[0771] The treatment methods of the present invention can be used as monotherapy or in combination with one or more (e.g., one, two, three, or four) other therapies (e.g., anti-infective agents) that can be used to treat a disease or disorder, such as an infectious disease. The term "combination" as used herein is understood to mean that two or more different treatments are delivered to a subject during the course of the subject's illness, so that the effects of the treatments on the patient overlap at some point. In certain embodiments, the delivery of one treatment is still ongoing when the delivery of a second treatment begins, so that there is an overlap in administration. This is sometimes referred to herein as "simultaneous" or "co-delivery." In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In certain embodiments in either case, the treatments are more effective due to combined administration. For example, the second treatment is more effective than when the second treatment is administered in the absence of the first treatment, for example, a similar effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, or a similar condition is seen with the first treatment. In certain embodiments, delivery is such that the reduction in symptoms or other parameters associated with the disorder is greater than that observed when one treatment is delivered in the absence of the other treatment.The effect of the two treatments can be partially additive, totally additive, or superadditive.Delivery can be such that the effect of the first treatment delivered is still detectable when the second treatment is delivered.

[0772] Thus, in certain embodiments, the subject has received, is receiving, or will receive one or more (e.g., one, two, three, or four) other therapies suitable for use in treating a disease or disorder. In certain embodiments, the treatment methods of the present invention further include administering to the subject one or more (e.g., one, two, three, or four) other therapies suitable for use in treating a disease or disorder, e.g., an infectious disease. In certain embodiments, the one or more (e.g., one, two, three, or four) other therapies include an agent that ameliorate one or more (e.g., one, two, three, or four) symptoms of infection by an intracellular pathogen. In certain embodiments, the one or more (e.g., one, two, three, or four) other therapies include surgical removal of infected tissue.

[0773] Thus, in certain embodiments, the subject has received, is receiving, or will receive one or more (e.g., one, two, three, or four) other therapies suitable for use in treating a disease or disorder. In certain embodiments, the treatment methods of the present invention further include administering to the subject one or more (e.g., one, two, three, or four) other therapies suitable for use in treating a disease or disorder, e.g., an infectious disease. In certain embodiments, the one or more (e.g., one, two, three, or four) other therapies include an agent that ameliorate one or more (e.g., one, two, three, or four) symptoms of infection by an intracellular pathogen. In certain embodiments, the one or more (e.g., one, two, three, or four) other therapies include surgical removal of infected tissue.

[0774] It is understood that the methods of use disclosed herein can be used in combination with drugs, such as anti-infective drugs that ameliorate one or more (e.g., one, two, three, or four) symptoms of a disease or disorder associated with an intracellular pathogen. For example, the methods of use disclosed herein can be used in combination with another antiviral drug.

[0775] In some embodiments, the additional therapeutic agent may be a therapeutic antiviral vaccine. [Example]

[0776] Synthesis procedure

[0777] [Table 2-1]

[0778] [Table 2-2]

[0779] Example 1: 5-(Azetidin-3-ylamino)-2-methyl-N-(1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl)benzamide (Compound 172)

[0780] [ka]

[0781] Step 1: tert-Butyl 3-((3-(methoxycarbonyl)-4-methylphenyl)amino)azetidine-1-carboxylate (1A-2) To a solution of methyl 5-amino-2-methylbenzoate (1.10 g, 6.66 mmol, 1.1 equiv.) and tert-butyl 3-oxoazetidine-1-carboxylate (1.00 g, 5.84 mmol, 1.0 equiv.) in DME (30 mL) was added NaBH(OAc) (1.49 g, 7.01 mmol, 1.2 equiv.). The mixture was stirred at 20 °C for 12 h. LCMS showed complete consumption of the starting material. The mixture was treated with water (40 mL) and extracted with DCM (20 mL × 2). The combined organic layers were dried over Na SO , filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 2 EtOAc / petroleum ether. tert-Butyl 3-((3-(methoxycarbonyl)-4-methylphenyl)amino)azetidine-1-carboxylate (700 mg, 2.18 mmol, 37% yield) was obtained as a white solid. + =265.2.

[0782] Step 2: 5-((1-(tert-butoxycarbonyl)azetidin-3-yl)amino)-2-methylbenzoic acid (1A-3) To a solution of tert-butyl 3-((3-(methoxycarbonyl)-4-methylphenyl)amino)azetidine-1-carboxylate (700 mg, 2.18 mmol, 1.0 equiv.) in a mixture of HO (10 mL) and THF (30 mL), LiOH·HO (458 mg, 10.9 mmol, 5.0 equiv.) was added. The mixture was stirred at 70 °C for 16 h. TLC showed that the starting material was completely consumed and a major spot was detected. The reaction mixture was cooled to room temperature, poured into HO (10 mL), and washed with TMBE (10 mL × 2). The aqueous layer was acidified to pH 5 with HCl (1 M aqueous solution). The product was extracted with 2-methyltetrahydrofuran (10 mL × 3). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the crude product 5-((1-(tert-butoxycarbonyl)azetidin-3-yl)amino)-2-methylbenzoic acid (700 mg) as a white solid.

[0783] Step 3: N-Methoxy-N-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxamide (1A-5) To a solution of N,O-dimethylhydroxylamine hydrochloride (775 mg, 7.95 mmol, 2.0 equiv) in DCM (15 mL) was added 5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (700 mg, 3.97 mmol, 1.0 equiv), followed by HATU (1.81 g, 4.76 mmol, 1.2 equiv) and DIEA (1.95 g, 15.1 mmol, 2.63 mL, 3.8 equiv). The resulting mixture was stirred at 20 °C for 16 h. LCMS showed complete consumption of the starting material. The mixture was treated with saturated aqueous NaHCO (10 mL) and extracted with DCM (5.0 mL × 2). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 2 EtOAc / petroleum ether. N-Methoxy-N-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxamide (440 mg, 2.01 mmol, 51% yield) was obtained as a colorless oil. + =220.3(LCMS); 1 H NMR (400 MHz, CDCl3) δ 7.15 - 7.01 (m, 3H), 4.00 - 2.96 (m, 7H), 2.85 - 2.68 (m, 4H), 1.81 - 1.77 (m, 3H). Step 4: 1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethanone (1A-6) To a solution of N-methoxy-N-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxamide (400 mg, 1.82 mmol, 1.0 equiv.) in THF (10 mL) was added MeMgBr (3 M in EtO, 912 μL, 1.5 equiv.) at 0 °C. The resulting mixture was stirred at 20 °C under a N atmosphere for 16 h. LCMS indicated that the starting material had been consumed and the desired mass had been detected. The mixture was treated with water (10 mL) and extracted with DCM (10 mL × 5). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 5 EtOAc / petroleum ether. 1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethanone (120 mg, 689 μmol, 38% yield) was obtained as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 7.49 - 7.41 (m, 1H), 7.24 - 7.12 (m, 2H), 3.00 - 2.92 (m, 2H), 2.88 - 2.76 (m, 2H), 2.60 - 2.52 (m, 3H), 1.85 - 1.70 (m, 4H). Step 5: 1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethanamine (1A-7) To a solution of 1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethanone (100 mg, 574 μmol, 1.0 equiv) in MeOH (6.0 mL) was added NHOAc (531 mg, 6.88 mmol, 12 equiv), followed by NaBHCN (144 mg, 2.30 mmol, 4.0 equiv). The resulting mixture was stirred at 60 °C for 16 h. LCMS showed complete consumption of the starting material. The mixture was treated with water (10 mL) and extracted with DCM (5.0 mL × 5). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give 1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethanamine (90.0 mg, 513 μmol, 89% yield) as a colorless oil. M-17+H + =159.0(LCMS).

[0784] Step 6: tert-butyl 3-((4-methyl-3-((1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl)carbamoyl)phenyl)amino)azetidine-1-carboxylate (1A-8) To a solution of 1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethanamine (60.0 mg, 342 μmol, 1.0 equiv) and 5-((1-(tert-butoxycarbonyl)azetidin-3-yl)amino)-2-methylbenzoic acid (94.4 mg, 308 μmol, 0.9 equiv) in DCM (5.0 mL) was added EDCI (98.4 mg, 514 μmol, 1.5 equiv), HOBt (69.4 mg, 514 μmol, 1.5 equiv), and TEA (69.3 mg, 685 μmol, 95.3 μL, 2.0 equiv). The mixture was stirred at 20° C. for 16 hours. LCMS showed that the starting material was completely consumed. The mixture was treated with water (10 mL) and extracted with DCM (5.0 mL × 5). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 2 EtOAc / petroleum ether to give tert-butyl 3-((4-methyl-3-((1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl)carbamoyl)phenyl)amino)azetidine-1-carboxylate (80.0 mg, 162 μmol, 47%) as a yellow solid. M+Na + =486.1(LCMS); 1 H NMR (400 MHz, CD3OD) δ 7.23 (d, J = 7.1 Hz, 1H), 7.12 - 7.07 (m, 1H), 7.03 - 6.95 (m, 2H), 6.56 - 6.49 (m, 2H), 5.43 - 5.36 (m, 1H), 4.61 - 4.58 (m, 1H), 4.29 - 4.17 (m, 3H), 3.74 - 3.69 (m, 2H), 3.10 - 3.02 (m, 1H), 2.83 - 2.77 (m, 3H), 2.21 - 2.18 (m, 3H), 1.95 - 1.87 (m, 2H), 1.83 - 1.77 (m, 2H), 1.48 (m, 11H). Step 7: 5-(azetidin-3-ylamino)-2-methyl-N-(1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl)benzamide (Compound 172) To a solution of tert-butyl 3-((4-methyl-3-((1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl)carbamoyl)phenyl)amino)azetidine-1-carboxylate (60.0 mg, 129 μmol, 1.0 equiv) in DCM (8.0 mL) was added TFA (4.62 g, 40.5 mmol, 3.00 mL, 313 equiv). The mixture was stirred at 20° C. for 1 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The mixture was concentrated in vacuo at 30°C to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (150 x 30 mm, 5 µm); flow rate: 25 mL / min; gradient: 10% to 45% B over 8 min; mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile) to give 5-(azetidin-3-ylamino)-2-methyl-N-(1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl)benzamide (22.7 mg, 47.6 µmol, 37% yield, TFA salt) as a yellow solid. M+H + =364.3(LCMS); 1 H NMR (400 MHz, CD3OD) δ 7.22 - 7.18 (m, 1H), 7.10 - 7.00 (m, 2H), 6.98 - 6.94 (m, 1H), 6.58 - 6.53 (m, 1H), 6.50 - 6.48 (m, 1H), 5.41 - 5.38 (m, 1H), 4.50 - 4.45 (m, 1H), 4.38 - 4.32 (m, 2H), 3.96 - 3.89 (m, 2H), 3.12 - 2.98 (m, 1H), 2.82 - 2.76 (m, 3H), 2.21 - 2.18 (m, 3H), 1.92 - 1.84 (m, 2H), 1.82 - 1.76 (m, 2H), 1.46 - 1.42 (m, 3H). Example 2: 5-(Azetidin-3-ylamino)-N-(1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)-2-methylbenzamide (Compound 168)

[0785] [ka]

[0786] Step 1: N-Methoxy-N-methyl-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide (2A-2) To a solution of 2,3-dihydro-1,4-benzodioxine-5-carboxylic acid (1.00 g, 5.55 mmol, 1.0 equiv.) and N,O-dimethylhydroxylamine hydrochloride (596 mg, 6.11 mmol, 1.1 equiv.) in DCM (20 mL) was added TEA (1.69 g, 16.7 mmol, 2.32 mL, 3.0 equiv.), EDCI (1.28 g, 6.66 mmol, 1.2 equiv.), and HOBt (900 mg, 6.66 mmol, 1.2 equiv.). The mixture was stirred at 20 °C for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (20 mL) and extracted with DCM (10 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 3 EtOAc / petroleum ether to give N-methoxy-N-methyl-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide (600 mg, 2.69 mmol, 48% yield) as a white solid. M+H + =224.0(LCMS).

[0787] Step 2: 1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanone (2A-3) A mixture of N-methoxy-N-methyl-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide (200 mg, 896 μmol, 1.0 equiv.) in THF (3.0 mL) was degassed and purged with N three times, and to this mixture was added MeMgBr (3 M in EtO, 388 μL, 1.3 equiv.) at 0 °C. The mixture was warmed to 20 °C and stirred at the same temperature for 2 h under a N atmosphere. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was poured into H O (10 mL) and extracted with EtOAc (4.0 mL × 3). The combined organic layers were dried over Na SO , filtered, and concentrated in vacuo to give the crude product, 1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanone (150 mg), which was used in the next step without any further purification.

[0788] Step 3: 1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanamine (2A-4) To a solution of 1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanone (100 mg, 561 μmol, 1.0 equiv.) in MeOH (1.0 mL) was added NHOAc (519 mg, 6.73 mmol, 12 equiv.) followed by NaBHCN (141 mg, 2.24 mmol, 4.0 equiv.) at 20 °C. The mixture was stirred at the same temperature for 16 h. LCMS showed that the starting material was completely consumed and the desired compound was detected as the major peak. The reaction mixture was poured into H0 (5.0 mL) and extracted with DCM (3.0 mL × 2). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give crude 1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanamine (150 mg), which was used in the next step without any further purification. M+H + =180.0(LCMS).

[0789] Step 4: tert-Butyl-((3-((1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)carbamoyl)-4-methylphenyl)amino)azetidine-1-carboxylate (2A-5) To a solution of 1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanamine (130 mg, 725 μmol, 1.1 equiv) and 5-((1-(tert-butoxycarbonyl)azetidin-3-yl)amino)-2-methylbenzoic acid (202 mg, 659 μmol, 1.0 equiv) in DCM (5.0 mL) was added TEA (267 mg, 2.64 mmol, 367 μL, 4.0 equiv), EDCI (379 mg, 1.98 mmol, 3.0 equiv), and HOBt (267 mg, 1.98 mmol, 3.0 equiv). The mixture was stirred at 20 °C for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (3.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 3 EtOAc / petroleum ether to give tert-butyl-((3-((1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)carbamoyl)-4-methylphenyl)amino)azetidine-1-carboxylate (123 mg, 263 μmol, 40% yield) as a white oil. M+H + =468.0(LCMS).

[0790] Step 5: 5-(azetidin-3-ylamino)-N-(1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)-2-methylbenzamide (Compound 168) To a solution of tert-butyl 3-((3-((1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)carbamoyl)-4-methylphenyl)amino)azetidine-1-carboxylate (20.0 mg, 42.8 μmol, 1.0 equiv) in DCM (3.0 mL) was added TFA (1.54 g, 13.5 mmol, 1.00 mL, 316 equiv). The mixture was stirred at 20° C. for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The mixture was concentrated in vacuo at 20°C to give a residue that was purified by preparative HPLC (Phenomenex Luna C18 column (150 x 30 mm, 5 µm); flow rate: 25 mL / min; gradient: 10% to 45% B over 8 min; mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile) to give 5-(azetidin-3-ylamino)-N-(1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)-2-methylbenzamide (12.0 mg, 24.6 µmol, 58% yield, TFA salt) as a white solid. M+H + =368.0(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.54 - 8.47 (m, 1H), 7.04 (d, J = 8.1 Hz, 1H), 6.88 - 6.86 (m, 1H), 6.81 - 6.73 (m, 2H), 6.59 - 6.54 (m, 2H), 5.48 - 5.40 (m, 1H), 4.53 - 4.45 (m, 1H), 4.39 - 4.30 (m, 4H), 4.27 - 4.24 (m, 2H), 3.96 - 3.91 (m, 2H), 2.22 (s, 3H), 1.46 (d, J = 7.0 Hz, 3H). Example 3: (R)-5-acetyl-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 155)

[0791] [ka]

[0792] Step 1: 5-Acetyl-2-methylbenzoic acid (3A-2) To a solution of 5-bromo-2-methylbenzoic acid (300 mg, 1.40 mmol, 1.0 equiv) in THF (10 mL) was added n-BuLi (2.5 M in hexanes, 1.12 mL, 2.0 equiv) at −78° C. The mixture was stirred at −78° C. for 30 minutes. To the mixture was added a solution of N-methoxy-N-methylacetamide (158 mg, 1.53 mmol, 163 μL, 1.1 equiv) in THF (3.0 mL). The mixture was stirred at −78° C. for 1 hour, then warmed to 20° C. and stirred at 20° C. for an additional 1 hour. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HCl (1 M aqueous solution, 10 mL) and extracted with MTBE (10 mL × 2). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 5-acetyl-2-methylbenzoic acid (70.0 mg), which was used in the next step without any further purification. M+H + =179.1(LCMS); 1 H NMR (400 MHz, DMSO-d6) δ 13.1 (br d, J = 5.4 Hz, 1H), 8.3 (d, J = 2.0 Hz, 1H), 8.0 (dd, J = 8.0, 2.0 Hz, 1H), 7.5 (d, J = 8.0 Hz, 1H), 2.6 (s, 6H). Step 2: (R)-5-acetyl-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (compound 155) To a solution of 5-acetyl-2-methylbenzoic acid (60.0 mg, 337 μmol, 1.0 equiv) in DCM (3.0 mL) was added (R)-1-(naphthalen-1-yl)ethanamine (57.7 mg, 337 μmol, 53.9 μL, 1.0 equiv), EDCI (77.5 mg, 404 μmol, 1.2 equiv), HOBt (54.6 mg, 404 μmol, 1.2 equiv), and TEA (102 mg, 1.01 mmol, 141 μL, 3.0 equiv). The mixture was stirred at 20 °C for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (10 mL) and extracted with EtOAc (5.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Luna C18 column (150 x 30 mm, 5 μm); flow rate: 25 mL / min; gradient: 35% to 70% B over 8 min; mobile phase A: 0.2% FA in water, mobile phase B: acetonitrile). (R)-5-acetyl-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (11.5 mg, 34.5 μmol, 10% yield) was obtained as a white solid. M+H + =332.1(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.3 (d, J = 8.4 Hz, 1H), 7.9 - 8.0 (m, 3H), 7.8 (d, J = 8.1 Hz, 1H), 7.6 - 7.7 (m, 2H), 7.5 - 7.5 (m, 2H), 7.4 (d, J = 8.0 Hz, 1H), 6.1 (q, J = 6.9 Hz, 1H), 2.5 - 2.6 (m, 3H), 2.4 (s, 3H), 1.7 (d, J = 7.0 Hz, 3H). Example 4: (R)-5-hydroxy-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 101)

[0793] [ka]

[0794] Step 1: (R)-5-hydroxy-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 101) To a mixture of (R)-1-(naphthalen-1-yl)ethanamine (56.3 mg, 329 μmol, 52.6 μL, 1.0 equiv.) and 5-hydroxy-2-methylbenzoic acid (50.0 mg, 329 μmol, 1.0 equiv.) in DCM (3.0 mL) was added HATU (250 mg, 657 μmol, 2.0 equiv.) and DIEA (127 mg, 986 μmol, 172 μL, 3.0 equiv.). The resulting mixture was stirred at 20 °C for 3 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Waters Xbridge BEH C18 column (100 x 30 mm, 10 μm); flow rate: 25 mL / min; gradient: 30% to 60% B over 8 min; mobile phase A: water (10 mM NH4HCO3), mobile phase B: acetonitrile) to give (R)-5-hydroxy-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (50.2 mg, 164 μmol, 50% yield) as a white solid. M+H + =306.2(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.19 (br d, J = 8.3 Hz, 1H), 7.91 - 7.76 (m, 2H), 7.60 - 7.40 (m, 4H), 6.97 (d, J = 8.3 Hz, 1H), 6.78 (s, 1H), 6.73 (br d, J = 8.3 Hz, 1H), 6.09 (br s, 2H), 2.29 (s, 3H), 1.76 (br d, J = 5.7 Hz, 3H). Example 5: (R)-5-Methoxy-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 136)

[0795] [ka]

[0796] Step 1: (R)-5-Methoxy-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 136) To a mixture of (R)-1-(naphthalen-1-yl)ethanamine (50 mg, 292 μmol, 47.0 μL, 1.0 equiv.) and 5-methoxy-2-methylbenzoic acid (48.6 mg, 292 μmol, 1.0 equiv.) in DCM (2.0 mL) was added EDCI (67.2 mg, 350 μmol, 1.2 equiv.), HOBt (47.4 mg, 350 μmol, 1.2 equiv.), and TEA (88.6 mg, 876 μmol, 100 μL, 3.0 equiv.). The resulting mixture was stirred at 20 °C for 3 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Waters Xbridge BEH C18 column (100 x 30 mm, 10 μm); flow rate: 25 mL / min; gradient: 45% to 75% B over 8 min; mobile phase A: water (10 mM NH4HCO3), mobile phase B: acetonitrile). (R)-5-Methoxy-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (36.1 mg, 112 μmol, 38% yield) was obtained as a white solid. M+H + =320.1(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.63 - 7.43 (m, 4H), 7.09 (d, J = 8.3 Hz, 1H), 6.87 - 6.78 (m, 2H), 6.19 - 6.08 (m, 1H), 3.74 (s, 3H), 2.35 (s, 3H), 1.80 (d, J = 6.7 Hz, 3H). Example 6: (R)-2-chloro-5-methoxy-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 132)

[0797] [ka]

[0798] Step 1: (R)-2-chloro-5-methoxy-N-(1-(naphthalen-1-yl)ethyl)benzamide (compound 132) To a mixture of (R)-1-(naphthalen-1-yl)ethanamine (60.0 mg, 350 μmol, 56.0 μL, 1.0 equiv) and 2-chloro-5-methoxybenzoic acid (65.4 mg, 350 μmol, 1.0 equiv) in DCM (3.0 mL) was added EDCI (80.6 mg, 420 μmol, 1.2 equiv), HOBt (56.8 mg, 420 μmol, 1.2 equiv), and TEA (106 mg, 1.05 mmol, 146 μL, 3.0 equiv). The resulting mixture was stirred at 20 °C for 3 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Waters Xbridge BEH C18 column (100 x 30 mm, 10 μm); flow rate: 25 mL / min; gradient: 50% to 80% B over 8 min; mobile phase A: water (10 mM NH4HCO3), mobile phase B: acetonitrile). (R)-2-chloro-5-methoxy-N-(1-(naphthalen-1-yl)ethyl)benzamide (56.3 mg, 161 μmol, 46% yield) was obtained as a white solid. M+H + =340.0(LCMS); 1H NMR (400 MHz, CDCl3) δ 8.23 ​​(d, J = 8.5 Hz, 1H), 7.89 (d, J = 7.7 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.63 - 7.42 (m, 4H), 7.25 (d, J = 8.9 Hz, 1H), 7.22 (d, J = 3.0 Hz, 1H), 6.88 (dd, J = 3.1, 8.8 Hz, 1H), 6.14 (q, J = 6.9 Hz, 1H), 3.79 (s, 3H), 1.82 (d, J = 6.8 Hz, 3H). Example 7: (R)-tert-butyl (2-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)ethyl)carbamate (Compound 158)

[0799] [ka]

[0800] Step 1: Methyl 5-(2-((tert-butoxycarbonyl)amino)ethoxy)-2-methylbenzoate (7A-2) A mixture of tert-butyl (2-hydroxyethyl)carbamate (2.43 g, 15.0 mmol, 2.33 mL, 1.0 equiv.), methyl 5-hydroxy-2-methylbenzoate (2.50 g, 15.0 mmol, 1.0 equiv.), and PPh3 (4.34 g, 16.6 mmol, 1.1 equiv.) in THF (30 mL) was degassed and purged with N2 three times. To the mixture was added dropwise DIAD (3.35 g, 16.6 mmol, 3.22 mL, 1.1 equiv.) at 20 °C. The resulting mixture was stirred at 70 °C under a N2 atmosphere for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into HO (30 mL), and extracted with EtOAc (10 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 2 EtOAc / petroleum ether to give methyl 5-(2-((tert-butoxycarbonyl)amino)ethoxy)-2-methylbenzoate (2.50 g, 8.08 mmol, 54% yield) as a yellow oil. M+Na + =332.0(LCMS); 1 H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 2.8 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.94 (dd, J = 2.8, 8.3 Hz, 1H), 5.11 - 4.95 (m, 1H), 4.02 (s, 2H), 3.88 (s, 3H), 3.53 (br d, J = 5.1 Hz, 2H), 2.51 (s, 3H), 1.45 (s, 9H). Step 2: 5-(2-((tert-butoxycarbonyl)amino)ethoxy)-2-methylbenzoic acid (7A-3) To a solution of methyl 5-(2-((tert-butoxycarbonyl)amino)ethoxy)-2-methylbenzoate (1.60 g, 5.17 mmol, 1.0 equiv) in a mixture of MeOH (8.0 mL) and THF (24 mL), NaOH (2 M aqueous solution, 10 mL, 4.0 equiv) was added. The mixture was stirred at 70 °C for 8 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was cooled to room temperature, HO (30 mL) was added, and the mixture was washed with MTBE (15 mL × 2). The aqueous layer was acidified to pH 5 with HCl (1 M aqueous solution). The product was extracted with EtOAc (8.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 5-(2-((tert-butoxycarbonyl)amino)ethoxy)-2-methylbenzoic acid (1.1 g), which was used in the next step without any further purification. M+Na + =318.2(LCMS); 1 H NMR (400 MHz, DMSO-d6) δ 13.49 (br s, 1H), 9.33 (s, 1H), 8.45 (d, J = 7.5 Hz, 1H), 7.28 (br s, 1H), 7.00 - 6.92 (m, 1H), 6.70 (t, J = 8.4 Hz, 2H), 5.18 - 5.11 (m, 1H), 2.64 - 2.54 (m, 2H), 2.00 - 1.90 (m, 1H), 1.87 - 1.72 (m, 3H). Step 3: (R)-tert-butyl (2-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)ethyl)carbamate (Compound 158) To a solution of 5-(2-((tert-butoxycarbonyl)amino)ethoxy)-2-methylbenzoic acid (50.0 mg, 169 μmol, 1.0 equiv) and (R)-1-(naphthalen-1-yl)ethanamine (34.8 mg, 203 μmol, 32.5 μL, 1.2 equiv) in DCM (3.0 mL) was added TEA (51.4 mg, 508 μmol, 70.7 μL, 3.0 equiv), EDCI (48.7 mg, 254 μmol, 1.5 equiv), and HOBt (34.3 mg, 254 μmol, 1.5 equiv). The mixture was stirred at 20 °C for 16 h. TLC showed complete consumption of the starting material. The reaction mixture was poured into HO (3.0 mL) and extracted with EtOAc (3.0 mL × 3). The combined organic layers were washed with brine (3.0 mL × 3), dried over Na2SO4, and concentrated in vacuo to give a residue, which was purified by preparative TLC (EtOAc / petroleum ether = 1 / 3, R f =0.5) to obtain (R)-tert-butyl (2-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)ethyl)carbamate (77.2 mg, 143 μmol, 84% yield) as a white oil. M-56+H + =393.0(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 8.6 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.62 - 7.45 (m, 4H), 7.09 (d, J = 8.4 Hz, 1H), 6.85 - 6.77 (m, 2H), 6.18 - 6.09 (m, 1H), 5.98 - 5.91 (m, 1H), 4.94 (br d, J = 4.9 Hz, 1H), 3.98 - 3.90 (m, 2H), 3.52 - 3.43 (m, 2H), 2.35 (s, 3H), 1.81 (d, J = 6.7 Hz, 3H), 1.44 (s, 9H). Example 8: (R)-5-(2-aminoethoxy)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 159)

[0801] [ka]

[0802] Step 1: (R)-5-(2-aminoethoxy)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (compound 159) To a mixture of (R)-tert-butyl (2-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)ethyl)carbamate (20.0 mg, 44.6 μmol, 1.0 equiv) in EtOAc (2.0 mL) was added HCl / EtOAc (4 M, 2.0 mL). The mixture was stirred at 20 °C for 30 min. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was concentrated in vacuo to give a residue, which was purified by preparative HPLC (Phenomenex Luna column (80 × 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 10% to 45% B over 8 min; mobile phase A: 0.04% aqueous HCl, mobile phase B: acetonitrile). (R)-5-(2-aminoethoxy)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (6.21 mg, 16.1 μmol, 36% yield, HCl salt) was obtained as a white solid. + =349.1(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.26 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.70 - 7.44 (m, 4H), 7.17 (d, J = 8.5 Hz, 1H), 6.97 (dd, J = 2.8, 8.4 Hz, 1H), 6.92 (d, J = 2.6 Hz, 1H), 6.06 (q, J = 7.0 Hz, 1H), 4.59 (br s, 2H), 4.28 - 4.11 (m, 2H), 3.33 (d, J = 5.1 Hz, 2H), 2.27 (s, 3H), 1.71 (d, J = 6.9 Hz, 3H). Example 9: (R)-5-(2-(dimethylamino)ethoxy)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 160)

[0803] [ka]

[0804] Step 1: (R)-5-(2-(dimethylamino)ethoxy)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (compound 160) To a solution of (R)-5-(2-aminoethoxy)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (20.0 mg, 57.4 μmol, 1.0 equiv., HCl salt) in MeOH (3.0 mL) was added TEA (900 μL), followed by formaldehyde (9.32 mg, 115 μmol, 8.55 μL, 37% purity in water, 2.0 equiv.). The resulting mixture was adjusted to pH 6 with a small amount of AcOH. The mixture was stirred at 20° C. for 30 min, and then NaBH3CN (7.21 mg, 115 μmol, 2.0 equiv.) was added. The resulting mixture was stirred at 20° C. for an additional 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (3.0 mL) at 25° C. and extracted with EtOAc (3.0 mL × 3). The combined organic layers were washed with brine (3.0 mL x 3), dried over NaSO, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Luna column (80 x 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 5% to 50% B over 8 min; mobile phase A: 0.04% aqueous HCl, mobile phase B: acetonitrile). (R)-5-(2-(dimethylamino)ethoxy)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (15.9 mg, 42.2 μmol, 74% yield, HCl salt) was obtained as a white solid. M+H + =377.1(LCMS); 1H NMR (400 MHz, CD3OD) δ 8.85 (br d, J = 7.8 Hz, 1H), 8.25 (d, J = 8.3 Hz, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.63 (d, J = 6.8 Hz, 1H), 7.60 - 7.43 (m, 3H), 7.18 (d, J = 8.4 Hz, 1H), 6.98 (dd, J = 2.8, 8.4 Hz, 1H), 6.93 (d, J = 2.7 Hz, 1H), 6.11 - 5.97 (m, 1H), 4.35 - 4.25 (m, 2H), 3.61 - 3.51 (m, 2H), 2.95 (s, 6H), 2.28 (s, 3H), 1.71 (d, J = 6.8 Hz, 3H). Example 10: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(oxetan-3-yloxy)benzamide (Compound 152)

[0805] [ka]

[0806] Step 1: Methyl 2-methyl-5-(oxetan-3-yloxy)benzoate (10A-1) To a solution of methyl 5-hydroxy-2-methylbenzoate (150 mg, 903 μmol, 1.0 equiv.) and 3-iodooxetane (199 mg, 1.08 mmol, 1.2 equiv.) in DMF (4 mL) was added CsCO (588 mg, 1.81 mmol, 2.0 equiv.). The mixture was stirred at 110 °C for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into H2O (5.0 mL), and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give methyl 2-methyl-5-(oxetan-3-yloxy)benzoate (1.10 g), which was used in the next step without any further purification.

[0807] Step 2: 2-Methyl-5-(oxetan-3-yloxy)benzoic acid (10A-2) To a solution of methyl 2-methyl-5-(oxetan-3-yloxy)benzoate (80.0 mg, 360 μmol, 1.0 equiv.) in a mixture of THF (3.0 mL) and HO (1.0 mL), LiOH·HO (45.3 mg, 1.08 mmol, 3.0 equiv.) was added. The mixture was stirred at 20 °C for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (3.0 mL) and extracted with petroleum ether (3.0 mL × 2). The aqueous phase was adjusted to pH 4 with HCl (1 M aqueous solution) and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 2-methyl-5-(oxetan-3-yloxy)benzoic acid (60.0 mg) as a colorless oil, which was used in the next step without any further purification. M+H + =209.2(LCMS).

[0808] Step 3: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(oxetan-3-yloxy)benzamide (compound 152) To a solution of 2-methyl-5-(oxetan-3-yloxy)benzoic acid (50.0 mg, 240 μmol, 1.0 equiv.) and (R)-1-(naphthalen-1-yl)ethanamine (41.1 mg, 240 μmol, 38.4 μL, 1.0 equiv.) in DCM (3.0 mL) was added TEA (48.6 mg, 480 μmol, 2.0 equiv.), EDCI (55.2 mg, 288 μmol, 1.2 equiv.), and HOBt (38.9 mg, 288 μmol, 1.2 equiv.). The mixture was stirred at 20 °C for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue. The residue was purified by preparative TLC (EtOAc / petroleum ether = 2 / 1) to give (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(oxetan-3-yloxy)benzamide (12.2 mg, 33.2 μmol) as a white solid. M+H + =362.1(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.66 - 7.43 (m, 4H), 7.10 - 7.04 (m, 1H), 6.66 - 6.62 (m, 1H), 6.62 - 6.56 (m, 1H), 6.18 - 6.06 (m, 1H), 5.98 - 5.88 (m, 1H), 5.16 - 5.05 (m, 1H), 4.93 - 4.82 (m, 2H), 4.72 - 4.62 (m, 2H), 2.40 - 2.31 (m, 3H), 1.84 - 1.75 (m, 3H). Example 11: (R)-5-(azetidin-3-yloxy)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 141)

[0809] [ka]

[0810] Step 1: tert-Butyl 3-(3-(methoxycarbonyl)-4-methylphenoxy)azetidine-1-carboxylate (11A-1) To a stirred solution of methyl 5-hydroxy-2-methylbenzoate (300 mg, 1.81 mmol, 1.0 equiv) in DMF (10 mL) was added CsCO (1.18 g, 3.61 mmol, 2.0 equiv) and tert-butyl 3-iodoazetidine-1-carboxylate (613 mg, 2.17 mmol, 1.2 equiv). The mixture was stirred at 110 °C for 16 h. TLC showed complete consumption of the starting material. The reaction mixture was cooled to room temperature, poured into water (30 mL), and extracted with EtOAc (10 mL × 3). The combined organic layers were dried and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 5 EtOAc / petroleum ether. tert-Butyl 3-(3-(methoxycarbonyl)-4-methylphenoxy)azetidine-1-carboxylate (450 mg, 1.40 mmol, 78% yield) was obtained as a colorless oil. 1 H NMR (400 MHz, CD3Cl) δ 7.29 (s, 1H), 7.19 - 7.17 (d, J = 8.4 Hz, 1H), 6.87 - 6.84 (m, 1H), 4.93 - 4.89 (m, 1H), 4.35 - 4.31 (m, 2H), 4.03 - 4.01 (m, 2H), 3.91 (s, 3H), 2.54 (s, 3H), 1.47 (s, 9H). Step 2: 5-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-2-methylbenzoic acid (11A-2) To a stirred solution of tert-butyl 3-(3-(methoxycarbonyl)-4-methylphenoxy)azetidine-1-carboxylate (200 mg, 622 μmol, 1.0 equiv) in a mixture of THF (5.0 mL) and HO (1.0 mL) was added LiOH·HO (52.2 mg, 1.24 mmol, 2.0 equiv) at 20 °C for 2 h and then at 70 °C for an additional 14 h. Additional LiOH·HO (10 mg) was added, and the reaction mixture was stirred at 70 °C for an additional 1 h. LCMS indicated complete consumption of the starting material. The reaction mixture was cooled to room temperature, poured into HO (3.0 mL), and washed with TBME (5.0 mL × 2). The aqueous layer was acidified to pH 5 with HCl (1 M aqueous solution). The product was extracted with DCM (3.0 mL x 5) and the combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the product 5-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-2-methylbenzoic acid (150 mg, 488 μmol, 78% yield) as a colorless oil, which was used in the next step without any further purification. - =306.1(LCMS).

[0811] Step 3: (R)-tert-butyl 3-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)azetidine-1-carboxylate (11A-3) To a mixture of 5-(1-tert-butoxycarbonylazetidin-3-yl)oxy-2-methylbenzoic acid (90.0 mg, 292 μmol, 1.0 equiv.) in DCM (5.0 mL), (1R)-1-(1-naphthyl)ethanamine (55.2 mg, 322 μmol, 51.6 μL, 1.1 equiv.) was added, followed by TEA (88.9 mg, 879 μmol, 122 μL, 3.0 equiv.) and T3P (280 mg, 439 μmol, 261 μL, 50% in EtOAc, 1.5 equiv.). The resulting mixture was stirred at 20 °C for 1.5 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The mixture was poured into HO (3.0 mL). The product was extracted with DCM (8.0 mL × 5). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 3 EtOAc / petroleum ether to give (R)-tert-butyl 3-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)azetidine-1-carboxylate (120 mg, 261 μmol, 89% yield) as a colorless oil. M+H + =461.4(LCMS).

[0812] Step 4: (R)-tert-butyl 3-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)azetidine-1-carboxylate (compound 141) To a mixture of (R)-tert-butyl 3-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)azetidine-1-carboxylate (50.0 mg, 109 μmol, 1.0 equiv) in EtOAc (5.0 mL) was added HCl / EtOAc (4 M, 10 mL) at 0 °C. The mixture was stirred at 25 °C for 1 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was concentrated in vacuo at 30 °C to give a residue, which was purified by preparative HPLC (Phenomenex Gemini C18 column (75 × 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 10% to 40% B over 8 min; mobile phase A: 0.04% aqueous HCl, mobile phase B: acetonitrile). (R)-tert-butyl 3-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)azetidine-1-carboxylate (14.0 mg, 38.8 μmol, 36% yield) was obtained as a white solid. + =361.1(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.27 - 8.21 (m, 1H), 7.94 - 7.89 (m, 1H), 7.85 - 7.78 (m, 1H), 7.64 - 7.45 (m, 4H), 7.20 - 7.16 (m, 1H), 6.84 - 6.79 (m, 1H), 6.77 - 6.71 (m, 1H), 6.10 - 6.00 (m, 1H), 5.15 - 5.06 (m, 1H), 4.55 - 4.43 (m, 2H), 4.13 - 4.04 (m, 2H), 2.31 - 2.20 (m, 3H), 1.76 - 1.65 (m, 3H). Example 12: (R)-tert-butyl 4-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)piperidine-1-carboxylate (Compound 164)

[0813] [ka]

[0814] Step 1: tert-butyl 4-(3-(methoxycarbonyl)-4-methylphenoxy)piperidine-1-carboxylate (12A-1) To a solution of methyl 5-hydroxy-2-methylbenzoate (200 mg, 1.20 mmol, 1.0 equiv.) in THF (20 mL) under a N atmosphere at 0 °C, tert-butyl 4-hydroxypiperidine-1-carboxylate (266 mg, 1.32 mmol, 1.1 equiv.) and PPh3 (379 mg, 1.44 mmol, 1.2 equiv.) were added, followed by DIAD (316 mg, 1.56 mmol, 304 μL, 1.3 equiv.). The resulting mixture was stirred at 20 °C for 16 h. TLC showed complete consumption of the starting material. The mixture was poured into HO (10 mL) and extracted with DCM (10 mL × 5). The combined organic layers were dried over NaSO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 2 EtOAc / petroleum ether. tert-Butyl 4-(3-(methoxycarbonyl)-4-methylphenoxy)piperidine-1-carboxylate (200 mg, 572 μmol, 48% yield) was obtained as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 7.48 - 7.45 (m, 1H), 7.18 - 7.12 (m, 1H), 7.00 - 6.95 (m, 1H), 4.50 - 4.44 (m, 1H), 3.92 - 3.87 (m, 3H), 3.74 - 3.65 (m, 2H), 3.40 - 3.31 (m, 2H), 2.55 - 2.50 (m, 3H), 1.96 - 1.86 (m, 2H), 1.80 - 1.69 (m, 2H), 1.51 - 1.46 (m, 9H). Step 2: 5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-2-methylbenzoic acid (12A-2) To a stirred solution of tert-butyl 4-(3-methoxycarbonyl-4-methyl-phenoxy)piperidine-1-carboxylate (120 mg, 343 μmol, 1.0 equiv) in a mixture of THF (6.0 mL) and HO (2.0 mL) was added LiOH·HO (36.0 mg, 859 μmol, 2.5 equiv) at 20 °C for 8 h, then at 70 °C for an additional 2 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into HO (10 mL), and washed with MTBE (5.0 mL × 3). The aqueous solution was acidified to pH 5 with HCl (1 M aqueous solution), and the product was extracted with DCM (5.0 mL × 8). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-2-methylbenzoic acid (85.0 mg) as a colorless oil, which was used in the next step without any further purification. - =334.2(LCMS).

[0815] Step 3: (R)-tert-butyl 4-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)piperidine-1-carboxylate (Compound 164) To a suspension of (1R)-1-(1-naphthyl)ethanamine (65.1 mg, 380 μmol, 60.8 μL, 1.5 equiv) in DCM (5.0 mL), 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-2-methyl-benzoic acid (85.0 mg, 253 μmol, 1.0 equiv) and TEA (76.9 mg, 760 μmol, 106 μL, 3.0 equiv) were added, followed by EDCI (72.9 mg, 380 μmol, 1.5 equiv) and HOBt (51.4 mg, 380 μmol, 1.5 equiv). The mixture was stirred at 20 °C for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The mixture was poured into HO (10 mL) and extracted with DCM (5.0 mL × 8). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (EtOAc / petroleum ether = 1 / 2, R f=0.5) to obtain (R)-tert-butyl 4-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)piperidine-1-carboxylate (110 mg, 218 μmol, 86% yield) as a white solid. M-56+H + =433.1; 1 H NMR (400 MHz, CDCl3) δ 8.26 - 8.22 (m, 1H), 7.91 - 7.88 (m, 1H), 7.86 - 7.81 (m, 1H), 7.60 (s, 5H), 7.10 - 7.06 (m, 1H), 6.85 (s, 1H), 4.39 - 4.33 (m, 1H), 3.71 - 3.62 (m, 2H), 3.31 - 3.23 (m, 2H), 2.36 - 2.33 (m, 3H), 1.83 - 1.78 (m, 4H), 1.47 - 1.46 (m, 9H), 1.31 - 1.20 (m, 3H). Example 13: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(piperidin-4-yloxy)benzamide (Compound 162)

[0816] [ka]

[0817] Step 1: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(piperidin-4-yloxy)benzamide (Compound 162) To a mixture of (R)-tert-butyl 4-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenoxy)piperidine-1-carboxylate (80.0 mg, 164 μmol, 1.0 equiv) in EtOAc (3.0 mL) was added HCl / EtOAc (4 M, 40.9 μL). The resulting mixture was stirred at 20 °C for 1 h. LCMS indicated complete consumption of the starting material and detection of the desired mass. The reaction mixture was concentrated in vacuo at 30 °C to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (75 × 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 10% to 40% B over 8 min; mobile phase A: 0.04% aqueous HCl, mobile phase B: acetonitrile). (R)-2-Methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(piperidin-4-yloxy)benzamide (40.0 mg, 103 μmol, 63% yield, HCl salt) was obtained as a white solid. + =389.1; 1 H NMR (400 MHz, CD3OD) δ 8.29 - 8.13 (m, 1H), 7.92 - 7.83 (m, 1H), 7.82 - 7.73 (m, 1H), 7.62 - 7.57 (m, 1H), 7.57 - 7.53 (m, 1H), 7.53 - 7.49 (m, 1H), 7.49 - 7.45 (m, 1H), 7.45 - 7.42 (m, 1H), 7.15 - 7.09 (m, 1H), 6.97 - 6.90 (m, 1H), 6.87 - 6.84 (m, 1H), 6.04 - 5.94 (m, 1H), 4.64 - 4.56 (m, 1H), 3.29 (br d, J = 3.2 Hz, 2H), 3.19 - 3.09 (m, 2H), 2.24 - 2.20 (m, 3H), 2.14 - 2.01 (m, 2H), 2.01 - 1.83 (m, 2H), 1.69 - 1.62 (m, 3H). Example 14: (R)-2-Methyl-5-(methylsulfonamido)-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 100)

[0818] [ka]

[0819] Step 1: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-nitrobenzamide (14A-2) To a solution of 2-methyl-5-nitrobenzoic acid (1.00 g, 5.52 mmol, 1.0 equiv.) and (R)-1-(naphthalen-1-yl)ethanamine (940 mg, 5.52 mmol, 880 μL, 1.0 equiv.) in DCM (20 mL) at 0 °C, TEA (1.12 g, 11.0 mmol, 1.54 mL, 2.0 equiv.) and T3P (10.5 g, 16.6 mmol, 10.0 mL, 50% in EtOAc, 3.0 equiv.) were added. The resulting mixture was stirred at 20 °C for 3 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (10 mL) and extracted with DCM (5.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 1 EtOAc / petroleum ether to give (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-nitrobenzamide (1.50 g, 4.49 mmol, 81% yield) as a white solid. M+H + =335.2(LCMS).

[0820] Step 2: (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (14A-3) A solution of (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-nitrobenzamide (1.00 g, 2.99 mmol, 1.0 equiv.), 10% palladium on carbon (200 mg) in a mixture of EtOAc (20 mL) and MeOH (20 mL) was degassed and purged with H 3 times, then the mixture was stirred at 20° C. under an atmosphere of H 2 (1.02 atm (15 psi)) for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The suspension was filtered through a pad of Celite, and the filter cake was washed with EtOAc (5.0 mL × 3). The combined filtrate was concentrated in vacuo to give (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (800 mg, 2.58 mmol, 86% yield) as a white solid. M+H + =305.2(LCMS).

[0821] Step 3: (R)-2-Methyl-5-(methylsulfonamido)-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 100) To a solution of (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (100 mg, 329 μmol, 1.0 equiv) in Py (2.0 mL) was added MsCl (41.4 mg, 361 μmol, 28 μL, 1.1 equiv) at 0° C. The resulting mixture was stirred at 20° C. for 3 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Waters Xbridge BEH C18 column (100 x 30 mm, 10 μm); flow rate: 25 mL / min; gradient: 30% to 60% B over 8 min; mobile phase A: 10 mM aqueous NH4HCO3, mobile phase B: acetonitrile). (R)-2-methyl-5-(methylsulfonamido)-N-(1-(naphthalen-1-yl)ethyl)benzamide (38.5 mg, 100 μmol, 30% yield) was obtained as a white solid. M+H + =383.1(LCMS); 1H NMR (400 MHz, CDCl3) δ 8.21 (d, J = 8.5 Hz, 1H), 7.91 - 7.86 (m, 1H), 7.81 (d, J = 8.3 Hz, 1H), 7.61 - 7.42 (m, 4H), 7.17 - 7.09 (m, 3H), 6.80 (br s, 1H), 6.17 - 6.06 (m, 2H), 2.88 (s, 3H), 2.37 (s, 3H), 1.83 - 1.73 (m, 3H) Example 15: (R)-5-((1H-pyrazol-4-yl)amino)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 121)

[0822] [ka]

[0823] Step 1: 2-methyl-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)benzoic acid (15A-2) To a stirred solution of methyl 5-amino-2-methylbenzoate (50.0 mg, 303 μmol, 1.0 equiv.) and 4-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (83.9 mg, 363 μmol, 1.2 equiv.) in dioxane (2.0 mL) under a N atmosphere was added tBuXPhos Pd G3 (24.0 mg, 30.3 μmol, 0.1 equiv.) and sodium t-butanolate (145 mg, 1.51 mmol, 5.0 equiv.). The mixture was stirred at 100 °C for 16 h. LCMS indicated complete consumption of the starting material and detection of the desired compound. The reaction mixture was cooled to room temperature, poured into HO (5.0 mL), and washed with MTBE (3.0 mL × 2). The aqueous solution was acidified to pH 6 with HCl (1M aqueous solution) and extracted with DCM (3.0 mL x 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give 2-methyl-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)benzoic acid (100 mg) as a yellow oil, which was used in the next step without any further purification. M+H + =302.3(LCMS).

[0824] Step 2: 2-methyl-N-((R)-1-(naphthalen-1-yl)ethyl)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)benzamide (15A-3) To a stirred solution of 2-methyl-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)benzoic acid (130 mg, 431 μmol, 1.0 equiv) and (R)-1-(naphthalen-1-yl)ethanamine (111 mg, 647 μmol, 104 μL, 1.5 equiv) in DCM (5 mL) was added EDCI (124 mg, 647 μmol, 1.5 equiv) and HOBt (87.4 mg, 647 μmol, 1.5 equiv), followed by TEA (131 mg, 1.29 mmol, 180 μL, 3.0 equiv). The mixture was stirred at 20° C. for 2 hours. TLC showed complete consumption of the starting material. The mixture was poured into water (5.0 mL) and extracted with DCM (5.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (EtOAc / petroleum ether = 1 / 2, R f =0.2) to give 2-methyl-N-((R)-1-(naphthalen-1-yl)ethyl)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)benzamide (90.0 mg, 198 μmol, 46% yield) as a yellow oil.

[0825] Step 3: (R)-5-((1H-pyrazol-4-yl)amino)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 121) To a stirred solution of 2-methyl-N-((R)-1-(naphthalen-1-yl)ethyl)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)benzamide (90.0 mg, 198 μmol, 1.0 equiv) in MeOH (2.0 mL) was added 4-methylbenzenesulfonic acid hydrate (113 mg, 594 μmol, 3.0 equiv). The mixture was stirred at 20° C. for 2 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The mixture was poured into HO (3.0 mL) and extracted with EtOAc (3.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (150 x 40 mm, 10 μm); flow rate: 60 mL / min; gradient: 30% to 60% B over 8 min; mobile phase A: 10 mM aqueous NH4HCO3, mobile phase B: acetonitrile). (R)-5-((1H-pyrazol-4-yl)amino)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (30.0 mg, 80.7 μmol, 41% yield) was obtained as a white solid. M+H + =371.0(LCMS); 1 H NMR (400 MHz, DMSO-d6) δ 12.57 (br s, 1H), 8.83 (d, J = 8.1 Hz, 1H), 8.23 ​​(d, J = 8.3 Hz, 1H), 8.01 - 7.92 (m, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.68 - 7.45 (m, 6H), 7.37 (br s, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.76 (d, J = 2.4 Hz, 1H), 6.71 (dd, J = 2.4, 8.2 Hz, 1H), 5.89 (quintet, J = 7.1 Hz, 1H), 2.14 (s, 3H), 1.55 (d, J = 6.8 Hz, 3H). Example 16: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(thiazol-2-ylamino)benzamide (Compound 107)

[0826] [ka]

[0827] Step 1: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(thiazol-2-ylamino)benzamide (Compound 107) To a mixture of (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (100 mg, 329 μmol, 1.5 equiv.) and 2-chlorothiazole (26.2 mg, 219 μmol, 1.0 equiv.) in propan-2-ol (2.0 mL) was added TsOH·HO (62.5 mg, 329 μmol, 1.5 equiv.). The resulting mixture was stirred at 20 °C for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Waters Xbridge BEH C18 column (100 x 30 mm, 10 μm); flow rate: 25 mL / min; gradient: 25% to 55% B over 8 min; mobile phase A: water (10 mM NH4HCO3), mobile phase B: acetonitrile). (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-(thiazol-2-ylamino)benzamide (16.8 mg, 43.4 μmol, 20% yield) was obtained as an off-white solid. M+H + =388.2(LCMS); 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 8.3 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.62 - 7.43 (m, 5H), 7.33 - 7.27 (m, 2H), 7.20 (d, J = 3.5 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 6.59 (d, J = 3.7 Hz, 1H), 6.19 - 6.10 (m, 1H), 6.02 (br d, J = 8.4 Hz, 1H), 2.40 (s, 3H), 1.82 (d, J = 6.7 Hz, 3H). Example 17: (R)-5-((2-methoxypyridin-3-yl)amino)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 115)

[0828] [ka]

[0829] Step 1: Methyl 5-((2-methoxypyridin-3-yl)amino)-2-methylbenzoate (17A-1) A mixture of methyl 5-amino-2-methylbenzoate (400 mg, 2.42 mmol, 1.2 equiv.), 3-bromo-2-methoxypyridine (379 mg, 2.02 mmol, 1.0 equiv.), and CsCO (1.31 g, 4.04 mmol, 2.0 equiv.) in dioxane (6.0 mL) was degassed and purged with N three times. To the mixture was added Pd(dba) (185 mg, 202 μmol, 0.1 equiv.) and Xantphos (234 mg, 404 μmol, 0.2 equiv.) at 20 °C. The resulting mixture was stirred at 120 °C under a N atmosphere for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into H2O (5.0 mL), and extracted with EtOAc (10 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 3 EtOAc / petroleum ether to give methyl 5-((2-methoxypyridin-3-yl)amino)-2-methylbenzoate (400 mg, 1.47 mmol, 73% yield) as a yellow solid. M+H + =273.3(LCMS).

[0830] Step 2: 5-((2-methoxypyridin-3-yl)amino)-2-methylbenzoic acid (17A-2) To a solution of methyl 5-((2-methoxypyridin-3-yl)amino)-2-methylbenzoate (400 mg, 1.47 mmol, 1.0 equiv) in a mixture of MeOH (9.0 mL) and THF (27 mL) was added LiOH·HO (185 mg, 4.41 mmol, 3.0 equiv). The mixture was stirred at 70 °C for 5 h. TLC showed that most of the starting material still remained. The mixture was cooled to room temperature, and NaOH (58.75 mg, 1.47 mmol, 1.0 equiv) was added. The resulting mixture was stirred at 70 °C for an additional 16 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was cooled to room temperature and poured into HO (18 mL), and the mixture was washed with petroleum ether (6.0 mL × 5). The aqueous layer was acidified to pH 5 with HCl (1 M aqueous solution). The product was extracted with EtOAc (6.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 5-((2-methoxypyridin-3-yl)amino)-2-methylbenzoic acid (210 mg) as a yellow oil, which was used in the next step without any further purification. M+H + =259.3(LCMS).

[0831] Step 3: (R)-5-((2-methoxypyridin-3-yl)amino)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (Compound 115) To a solution of (R)-1-(naphthalen-1-yl)ethanamine (66.3 mg, 387 μmol, 1.0 equiv.) and 5-((2-methoxypyridin-3-yl)amino)-2-methylbenzoic acid (100 mg, 387 μmol, 1.0 equiv.) in DCM (4.0 mL) was added TEA (206 mg, 2.03 mmol, 283 μL, 3.0 equiv.), EDCI (325 mg, 1.69 mmol, 2.5 equiv.), and HOBt (229 mg, 1.69 mmol, 2.5 equiv.). The mixture was stirred at 20 °C for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (4.0 mL) and extracted with DCM (2.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (EtOAc / petroleum ether = 1 / 2, R f =0.6), (R)-5-((2-methoxypyridin-3-yl)amino)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (90.0 mg, 219 μmol, 57% yield) was obtained as a yellow solid. M+H + =412.2(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.28 - 8.21(m, 1H), 7.92 - 7.81 (m, 2H), 7.69 - 7.63 (m, 1H), 7.61 - 7.42 (m, 4H), 7.30 - 7.15 (m, 1H), 7.20 - 7.15 (m, 1H), 7.13 - 7.06 (m, 2H), 6.78 - 5.72 (m, 1H), 6.19 -6.12 (m, 1H), 6.01 - 5.92 (m, 2H), 4.03 (s, 3H), 2.38 (s, 3H), 1.77 - 1.84 (m, 3H). Example 18: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-((2-oxo-1,2-dihydropyridin-3-yl)amino)benzamide (Compound 119)

[0832] [ka]

[0833] Step 1: (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-((2-oxo-1,2-dihydropyridin-3-yl)amino)benzamide (Compound 119) A mixture of (R)-5-((2-methoxypyridin-3-yl)amino)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (45 mg, 109 μmol, 1.0 equiv) in DCM (5.0 mL) was degassed and purged with N three times. To the mixture was added BBr3 (219 mg, 875 μmol, 8.0 equiv) in DCM (2 mL) at −78 °C. The mixture was stirred at 20 °C under a N2 atmosphere for 2 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The mixture was concentrated in vacuo to give a residue. The residue was diluted with MeOH (2 mL) and basified to pH 8 using NH3·H2O (37% aqueous solution). The mixture was concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (80 × 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 35% to 65% B over 8 min; mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile). (R)-2-methyl-N-(1-(naphthalen-1-yl)ethyl)-5-((2-oxo-1,2-dihydropyridin-3-yl)amino)benzamide (11.5 mg, 28.8 μmol, 26% yield, TFA salt) was obtained as a white solid. M+H + =398.0(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.32 - 8.19 (m, 1H), 7.98 - 7.77 (m, 2H), 7.69 - 7.43 (m, 4H), 7.25 - 7.10 (m, 4H), 6.98 - 6.78 (m, 1H), 6.32 - 6.21 (m, 1H), 6.13 - 5.93 (m, 1H), 2.34 - 2.24 (m, 3H), 1.79 - 1.59 (m, 3H). Example 19: 5-(N-(1-amino-3-hydroxypropan-2-yl)acetamido)-2-methyl-N-((R)-1-(naphthalen-1-yl)ethyl)benzamide (Compound 165)

[0834] [ka]

[0835] Step 1: (R)-tert-butyl 3-((4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenyl)amino)azetidine-1-carboxylate (19A-1) To a solution of 5-((1-(tert-butoxycarbonyl)azetidin-3-yl)amino)-2-methylbenzoic acid (100 mg, 326 μmol, 1.0 equiv.) and (R)-1-(naphthalen-1-yl)ethanamine (61.5 mg, 359 μmol, 1.1 equiv.) in DCM (5.0 mL) was added TEA (99.1 mg, 979 μmol, 136 μL, 3.0 equiv.), EDCI (75.1 mg, 392 μmol, 1.2 equiv.), and HOBt (52.9 mg, 392 μmol, 1.2 equiv.). The mixture was stirred at 20° C. for 3 h. TLC showed that the starting material was completely consumed. The reaction mixture was poured into HO (5.0 mL) and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give crude product (R)-tert-butyl 3-((4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenyl)amino)azetidine-1-carboxylate (150 mg), which was used in the next step without any further purification. M+H + =460.4(LCMS).

[0836] Step 2: (R)-tert-butyl 3-(N-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenyl)acetamido)azetidine-1-carboxylate (19A-2) To a solution of (R)-tert-butyl 3-((4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenyl)amino)azetidine-1-carboxylate (40.0 mg, 87.0 μmol, 1.0 equiv) and acetyl chloride (7.52 mg, 95.7 μmol, 6.83 μL, 1.1 equiv) in DCM (1.0 mL) was added pyridine (6.88 mg, 87.0 μmol, 7.03 μL, 1.0 equiv). The mixture was stirred at 20° C. for 3 hours. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was poured into HO (1.0 mL) and extracted with EtOAc (1.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give crude product (R)-tert-butyl 3-(N-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenyl)acetamido)azetidine-1-carboxylate (38.2 mg), which was used in the next step without any further purification. M+H + =502.4(LCMS).

[0837] Step 3: 5-(N-(1-amino-3-hydroxypropan-2-yl)acetamido)-2-methyl-N-((R)-1-(naphthalen-1-yl)ethyl)benzamide (Compound 165) To a solution of (R)-tert-butyl 3-(N-(4-methyl-3-((1-(naphthalen-1-yl)ethyl)carbamoyl)phenyl)acetamido)azetidine-1-carboxylate (10.0 mg, 19.9 μmol, 1.0 equiv) in DCM (1.0 mL) was added TFA (154 mg, 1.35 mmol, 100 μL). The mixture was stirred at 20° C. for 30 min. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was poured into HO (1.0 mL) and extracted with EtOAc (1.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Luna column (80 x 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 1% to 30% B over 8 min; mobile phase A: 0.04% aqueous HCl, mobile phase B: acetonitrile). 5-(N-(1-amino-3-hydroxypropan-2-yl)acetamido)-2-methyl-N-((R)-1-(naphthalen-1-yl)ethyl)benzamide (3.00 mg, 6.58 μmol, 33% yield, HCl salt) was obtained as a yellow gum. M+H + =420.1(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.25 (d, J = 8.2 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.60 - 7.42 (m, 3H), 7.03 (d, J = 8.2 Hz, 1H), 6.79 - 6.66 (m, 2H), 6.05 (q, J = 7.3 Hz, 1H), 4.20 (dd, J = 4.0, 11.2 Hz, 1H), 4.04 - 3.89 (m, 2H), 3.23 (br dd, J = 3.5, 13.1 Hz, 1H), 3.04 - 2.90 (m, 1H), 2.22 (s, 3H), 2.01 (d, J = 4.4 Hz, 3H), 1.70 (dd, J = 2.8, 6.9 Hz, 3H). Example 20: (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (Compound 153)

[0838] [ka]

[0839] Step 1: Methyl 5-amino-4-iodo-2-methylbenzoate (20A-1) To a solution of methyl 5-amino-2-methylbenzoate (15.0 g, 90.8 mmol, 1.0 equiv.) in AcOH (80 mL) was added NIS (22.5 g, 99.9 mmol, 1.1 equiv.). The mixture was stirred at 20 °C for 1 h. TLC showed that the starting material had been consumed. The reaction mixture was poured into H2O (200 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 9 EtOAc / petroleum ether. Methyl 5-amino-4-iodo-2-methylbenzoate (2.40 g, 9.18 mmol, 89% yield) was obtained as a brown oil. M+H + =293.0(LCMS).

[0840] Step 2: Methyl 5-amino-2-methyl-4-((trimethylsilyl)ethynyl)benzoate (20A-2) A mixture of methyl 5-amino-4-iodo-2-methylbenzoate (3.00 g, 10.3 mmol, 1.0 equiv.), TEA (2.09 g, 20.6 mmol, 2.87 mL, 2.0 equiv.), Pd(PPh3)2Cl2 (217 mg, 309 μmol, 0.03 equiv.), CuI (19.6 mg, 103 μmol, 0.01 equiv.), and ethynyltrimethylsilane (1.52 g, 15.5 mmol, 2.14 mL, 1.5 equiv.) in toluene (80 mL) and HO (40 mL) was degassed and purged with N2 three times. The resulting mixture was stirred at 70 °C under a N2 atmosphere for 3 h. TLC showed complete consumption of the starting material. The reaction mixture was cooled to room temperature, poured into HO (30 mL), and extracted with EtOAc (20 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 4 EtOAc / petroleum ether to give methyl 5-amino-2-methyl-4-((trimethylsilyl)ethynyl)benzoate (2.40 g, 9.18 mmol, 89% yield) as a brown oil. M+H + =262.1(LCMS).

[0841] Step 3: Methyl 5-methyl-1H-indole-6-carboxylate (20A-3) A mixture of methyl 5-amino-2-methyl-4-((trimethylsilyl)ethynyl)benzoate (1.00 g, 3.83 mmol, 1.0 equiv.), Cu(OAc) (1.39 g, 7.65 mmol, 2.0 equiv.) in DCE (50 mL) was degassed and purged with N three times, then the mixture was stirred at 130 °C under N atmosphere for 1 h. TLC showed complete consumption of the starting material. The reaction mixture was cooled to room temperature, poured into H O (100 mL), and extracted with DCM (50 mL × 3). The combined organic layers were dried over Na SO , filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 3 EtOAc / petroleum ether. Methyl 5-methyl-1H-indole-6-carboxylate (500 mg, 2.64 mmol, 18% yield) was obtained as a yellow solid. M+H + =190.1(LCMS).

[0842] Step 4: 5-Methyl-1H-indole-6-carboxylic acid (20A-4) To a solution of methyl 5-methyl-1H-indole-6-carboxylate (40.0 mg, 211 μmol, 1.0 equiv.) in a mixture of EtOH (2.0 mL) and THF (2.0 mL), NaOH (2 M aqueous solution, 529 μL, 5.0 equiv.) was added. The mixture was stirred at 20° C. for 30 min. The mixture was stirred at 80° C. for 3 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into H2O (5.0 mL), and washed with MTBE (3.0 mL × 3). The aqueous layer was acidified to pH 5 using HCl (1 M aqueous solution). The product was extracted with EtOAc (4.0 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give 5-methyl-1H-indole-6-carboxylic acid (30.0 mg, 171 μmol, 81% yield) as a white solid, which was used in the next step without any further purification.

[0843] Step 5: (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (compound 153) To a solution of 5-methyl-1H-indole-6-carboxylic acid (30.0 mg, 171 μmol, 1.0 equiv.) and (R)-1-(naphthalen-1-yl)ethanamine (35.2 mg, 206 μmol, 33.0 μL, 1.2 equiv.) in DCM (2.0 mL) was added EDCI (39.4 mg, 206 μmol, 1.2 equiv.), HOBt (30.1 mg, 223 μmol, 1.3 equiv.), and TEA (52.0 mg, 514 μmol, 72.0 μL, 3.0 equiv.). The resulting mixture was stirred at 20 °C for 3 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (EtOAc / petroleum ether = 1:1, R f =0.6), (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (13.2 mg, 35.8 μmol, 21% yield) was obtained as a yellow solid. M+H + =329.0(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 8.5 Hz, 1H), 8.18 - 8.09 (m, 1H), 7.90 (d, J = 7.9 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.62 - 7.45 (m, 4H), 7.43 (s, 1H), 7.38 - 7.33 (m, 1H), 7.22 - 7.17 (m, 1H), 6.49 - 6.39 (m, 1H), 6.22 - 6.13 (m, 1H), 6.02 (br d, J = 8.4 Hz, 1H), 2.53 (s, 3H), 1.82 (d, J = 6.8 Hz, 3H). Example 21: (R)-tert-butyl ((5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-indol-2-yl)methyl)carbamate (Compound 189)

[0844] [ka]

[0845] Step 1: Methyl 5-amino-4-(3-((tert-butoxycarbonyl)amino)prop-1-yn-1-yl)-2-methylbenzoate (21A-1) To a mixture of methyl 5-amino-4-iodo-2-methylbenzoate (1.00 g, 3.44 mmol, 1.0 equiv.), tert-butyl prop-2-yn-1-ylcarbamate (533 mg, 3.44 mmol, 1.0 equiv.), CuI (262 mg, 1.37 mmol, 0.4 equiv.), and Pd(PPh3)2Cl2 (482 mg, 687 μmol, 0.2 equiv.) was added TEA (10 mL) under a N2 atmosphere. The mixture was stirred at 20 °C for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The mixture was poured into H2O (20 mL) and extracted with DCM (15 mL x 8). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 1 EtOAc / petroleum ether. Methyl 5-amino-4-(3-((tert-butoxycarbonyl)amino)prop-1-yn-1-yl)-2-methylbenzoate (1.50 g, 4.71 mmol, 51% yield) was obtained as a white solid. M+H + =319.2(LCMS); 1 H NMR (400 MHz, CDCl3) δ 7.13 - 7.10 (m, 1H), 4.86 - 4.78 (m, 1H), 4.23 - 4.17 (m, 2H), 3.89 - 3.85 (m, 3H), 2.45 - 2.40 (m, 3H), 1.48 (s, 9H). Step 2: Methyl 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-indole-6-carboxylate (21A-2) To a solution of methyl 5-amino-4-(3-((tert-butoxycarbonyl)amino)prop-1-yn-1-yl)-2-methylbenzoate (500 mg, 1.57 mmol, 1.0 equiv) in DCE (30 mL) was added Cu(OAc) (713 mg, 3.93 mmol, 2.5 equiv). The mixture was stirred at 130 °C under a N atmosphere for 1 h. TLC showed complete consumption of the starting material. The heated reaction mixture was poured into HO (20 mL) and extracted with EtOAc (20 mL × 5). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 2 EtOAc / petroleum ether. Methyl 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-indole-6-carboxylate (1.10 g, 3.46 mmol, 73% yield) was obtained as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 9.08 - 9.00 (m, 1H), 8.06 - 8.01 (m, 1H), 7.38 (s, 1H), 6.29 - 6.24 (m, 1H), 4.40 - 4.36 (m, 2H), 3.91 - 3.89 (m, 3H), 2.67 (s, 3H), 1.49 (s, 9H). Step 3: 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-indole-6-carboxylic acid (21A-3) To a solution of methyl 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-indole-6-carboxylate (800 mg, 2.51 mmol, 1.0 equiv) in a mixture of THF (10 mL) and MeOH (3.0 mL), NaOH (2 M in aqueous solution, 8.0 mL, 6.4 equiv) was added. The mixture was stirred at 20 °C for 1 h and then at 60 °C for an additional 16 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The mixture was poured into HO (10 mL) and washed with MTBE (10 mL × 2). The aqueous solution was acidified to pH 5 with HCl (1 M aqueous solution). The product was extracted with DCM (15 mL × 5). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-indole-6-carboxylic acid (750 mg, 1.97 mmol, 78% yield) as a red solid, which was used in the next step without any further purification. - =303.1(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.46 - 8.40 (m, 1H), 7.81 - 7.77 (m, 1H), 6.79 - 6.76 (m, 1H), 6.33 - 6.30 (m, 1H), 3.27 - 3.08 (m, 2H), 2.07 - 2.05 (m, 3H), 1.46 - 1.40 (m, 9H). Step 4: (R)-tert-butyl ((5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-indol-2-yl)methyl)carbamate (Compound 189) To a solution of (R)-1-(naphthalen-1-yl)ethanamine (186 mg, 1.08 mmol, 174 μL, 1.1 equiv) and 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-indole-6-carboxylic acid (300 mg, 986 μmol, 1.0 equiv) in DCM (8.0 mL) was added TEA (299 mg, 2.96 mmol, 412 μL, 3.0 equiv), EDCI (283 mg, 1.48 mmol, 1.5 equiv), and HOBt (200 mg, 1.48 mmol, 1.5 equiv). The mixture was stirred at 20 °C for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (10 mL) and extracted with DCM (10 mL × 4). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (150 x 40 mm, 10 μm); flow rate: 30 mL / min; gradient: 45% to 75% B over 8 min; mobile phase A: 0.04% aqueous NH4HCO3, mobile phase B: acetonitrile). (R)-tert-butyl ((5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-indol-2-yl)methyl)carbamate (280 mg, 612 μmol, 62% yield) was obtained as a white solid. M+H + =458.1(LCMS); 1 H NMR (400 MHz,CDCl3) δ 8.89 - 8.82 (m, 1H), 8.32 - 8.26 (m, 1H), 7.92 - 7.87 (m, 1H), 7.85 - 7.81 (m, 1H), 7.62 - 7.45 (m, 4H), 7.34 - 7.28 (m, 2H), 6.22 - 6.12 (m, 2H), 6.04 - 5.98 (m, 1H), 5.07 - 5.00 (m, 1H), 4.35 - 4.30 (m, 2H), 2.53 - 2.50 (m, 3H), 1.84 - 1.79 (m, 3H), 1.48 - 1.44 (m, 9H). Example 22: (R)-2-(aminomethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (Compound 148)

[0846] [ka]

[0847] Step 1: (R)-2-(aminomethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (compound 148) To a stirred solution of (R)-tert-butyl ((5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-indol-2-yl)methyl)carbamate (220 mg, 481 μmol, 1.0 equiv) in DCM (8.0 mL) was added TFA (6.16 g, 54.0 mmol, 4.00 mL, 112 equiv). The mixture was stirred at 20 °C for 1 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The mixture was concentrated in vacuo to give a residue, which was purified by preparative HPLC (Phenomenex Gemini C18 column (75 × 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 10% to 40% B over 8 min; mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile). (R)-2-(aminomethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (150 mg, 420 μmol, 87% yield, TFA salt) was obtained as a pink powder. + =358.1(LCMS); 1H NMR (400 MHz, CD3OD) δ 8.29 (d, J = 8.6 Hz, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 7.1 Hz, 1H), 7.63 - 7.56 (m, 1H), 7.55 - 7.46 (m, 2H), 7.38 (d, J = 5.4 Hz, 2H), 6.51 (s, 1H), 6.14 - 6.01 (m, 1H), 4.26 (s, 2H), 2.42 (s, 3H), 1.73 (d, J = 6.9Hz, 3H). Example 23: (R)-2-(azetidin-3-yl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (Compound 156)

[0848] [ka]

[0849] Step 1: tert-butyl 3-((2-amino-4-(methoxycarbonyl)-5-methylphenyl)ethynyl)azetidine-1-carboxylate (23A-1) To a stirred solution of methyl 5-amino-4-iodo-2-methylbenzoate (300 mg, 1.03 mmol, 1.0 equiv.) in THF (6.0 mL) was added tert-butyl 3-ethynylazetidine-1-carboxylate (243 mg, 1.34 mmol, 1.3 equiv.), Pd(PPh3)4 (23.8 mg, 20.6 μmol, 0.02 equiv.), CuI (3.93 mg, 20.6 μmol, 0.02 equiv.), and TEA (261 mg, 2.58 mmol, 358.63 μL, 2.5 equiv.). The mixture was then degassed and purged with N2 three times and stirred at 20 °C under a N2 atmosphere for 16 h. TLC indicated complete consumption of the starting material. The reaction mixture was poured into HO (5.0 mL) and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (EtOAc / petroleum ether = 1:1, Rf =0.7) to give tert-butyl 3-((2-amino-4-(methoxycarbonyl)-5-methylphenyl)ethynyl)azetidine-1-carboxylate (300 mg, 871 μmol, 85% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 7.29 (s, 1H), 7.14 (s, 1H), 4.17 - 3.99 (m, 5H), 3.87 (s, 3H), 2.44 (s, 3H), 1.49 - 1.41 (m, 9H). Step 2: Methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-indole-6-carboxylate (23A-2) To a solution of tert-butyl 3-((2-amino-4-(methoxycarbonyl)-5-methylphenyl)ethynyl)azetidine-1-carboxylate (160 mg, 465 μmol, 1.0 equiv.) in DCE (10 mL) was added Cu(OAc) (169 mg, 929 μmol, 2.0 equiv.). The mixture was stirred at 130° C. for 2 h. TLC showed complete consumption of the starting material. The reaction mixture was cooled to room temperature, poured into HO (10 mL), and extracted with EtOAc (4.0 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give the crude product, methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-indole-6-carboxylate (130 mg) as a brown oil, which was used in the next step without any further purification.

[0850] Step 3: 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-indole-6-carboxylic acid (23A-3) To a solution of methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-indole-6-carboxylate (80.0 mg, 42.1 μmol, 1.0 equiv.) in a mixture of EtOH (2.0 mL) and THF (2.0 mL), NaOH (2 M aqueous solution, 2.0 mL, 24 equiv.) was added. The mixture was stirred at 80° C. for 16 hours. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into H2O (5.0 mL), and washed with MTBE (3.0 mL × 2). The aqueous layer was acidified to pH 5 with HCl (1 M aqueous solution). The product was extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-indole-6-carboxylic acid (80.0 mg) as a white oil, which was used in the next step without any further purification. M-56+H + =275.2(LCMS).

[0851] Step 4: (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-indol-2-yl)azetidine-1-carboxylate (23A-4) To a solution of 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-indole-6-carboxylic acid (100 mg, 303 μmol, 1.0 equiv.) and (R)-1-(naphthalen-1-yl)ethanamine (57.0 mg, 333 μmol, 53.3 μL, 1.1 equiv.) in DCM (4.0 mL) was added EDCI (69.6 mg, 363 μmol, 1.2 equiv.), HOBt (49.1 mg, 363 μmol, 1.2 equiv.), and TEA (91.9 mg, 909 μmol, 126 μL, 3.0 equiv.). The resulting mixture was stirred at 20° C. for 3 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into H2O (5.0 mL) and extracted with DCM (2.0 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue, which was analyzed by preparative TLC (EtOAc / petroleum ether = 1:1, R f =0.6), (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-indol-2-yl)azetidine-1-carboxylate (50.0 mg, 103 μmol, 34% yield) was obtained as a white solid. + =484.1(LCMS).

[0852] Step 5: (R)-2-(azetidin-3-yl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (compound 156) To a solution of (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-indol-2-yl)azetidine-1-carboxylate (50.0 mg, 103 μmol, 1.0 equiv) in EtOAc (3.0 mL) was added HCl / EtOAc (4 M, 1.0 mL). The resulting mixture was stirred at 20 °C for 1 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was concentrated in vacuo to give a residue, which was purified by preparative HPLC (Phenomenex Luna C18 column (80 × 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 15% to 30% B over 8 min; mobile phase A: 0.04% aqueous HCl, mobile phase B: acetonitrile). (R)-2-(azetidin-3-yl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (5.95 mg, 14.2 μmol, 14% yield, HCl salt) was obtained as a white gum. + =384.1(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.28 (d, J = 8.3 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.66 (d, J = 7.0 Hz, 1H), 7.62 - 7.43 (m, 3H), 7.34 (d, J = 13.0 Hz, 2H), 6.46 (s, 1H), 6.07 (q, J = 6.7 Hz, 1H), 4.48 - 4.23 (m, 5H), 2.42 (s, 3H), 1.73 (d, J = 7.0 Hz, 3H). Example 24: (R)-2-((dimethylamino)methyl)-1-(hydroxymethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (Compound 192)

[0853] [ka]

[0854] Step 1: (R)-2-((dimethylamino)methyl)-1-(hydroxymethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (compound 192) To a solution of (R)-2-(aminomethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (90.0 mg, 252 μmol, 1.0 equiv) in MeOH (6.0 mL) was added TEA (50.0 μL), followed by formaldehyde (2.94 g, 36.3 mmol, 2.70 mL, 37% purity in water, 144 equiv). The resulting mixture was adjusted to pH 6 with a small amount of AcOH. The mixture was stirred at 20 °C for 30 min, and then NaBH CN (134 mg, 2.13 mmol, 2.0 equiv) was added. The resulting reaction mixture was stirred at 20 °C for an additional 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The mixture was treated with HO (10 mL) and extracted with DCM (10 mL × 5). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (200 x 40 mm, 10 μm); flow rate: 50 mL / min; gradient: 5% to 40% B over 8 min; mobile phase A: 0.2% FA in water, mobile phase B: acetonitrile). (R)-2-((dimethylamino)methyl)-1-(hydroxymethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (22.3 mg, 48.1 μmol, 19% yield, FA salt) was obtained as a white solid. M+H + =416.1(LCMS); 1H NMR (400 MHz, DMSO-d6) δ 8.78 - 8.73 (m, 1H), 8.30 - 8.25 (m, 1H), 8.21 - 8.18 (m, 1H), 7.98 - 7.94 (m, 1H), 7.86 - 7.81 (m, 1H), 7.68 - 7.65 (m, 1H), 7.63 - 7.49 (m, 4H), 7.32 - 7.28 (m, 1H), 6.35 - 6.33 (m, 1H), 5.98 - 5.90 (m, 1H), 5.62 - 5.54 (m, 2H), 3.65 - 3.60 (m, 2H), 2.35 - 2.33 (m, 3H), 2.20 - 2.14 (m, 6H), 1.63 - 1.57 (m, 3H). Example 25: (R)-5-Methyl-2-(morpholinomethyl)-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (Compound 206)

[0855] [ka]

[0856] Step 1: Methyl 4-iodo-2-methyl-5-(2,2,2-trifluoroacetamido)benzoate (25A-1) To a stirred solution of methyl 5-amino-4-iodo-2-methylbenzoate (300 mg, 1.03 mmol, 1.0 equiv) and TEA (125 mg, 1.24 mmol, 172 μL, 1.2 equiv) in THF (3.5 mL) was added dropwise a solution of TFAA (238 mg, 1.13 mmol, 158 μL, 1.1 equiv) in THF (1.0 mL) at −15° C. The mixture was stirred at the same temperature for 1 hour and then at 25° C. for 16 hours. LCMS showed that the starting material was completely consumed and the desired compound was detected. The mixture was poured into water (10 mL) and extracted with EtOAc (5.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give crude methyl 4-iodo-2-methyl-5-(2,2,2-trifluoroacetamido)benzoate (400 mg) as a yellow solid, which was used in the next step without any further purification. - =386.0(LCMS).

[0857] Step 2: Methyl 5-methyl-2-(morpholinomethyl)-1H-indole-6-carboxylate (25A-2) To a mixture of CuI (4.92 mg, 25.8 μmol, 0.04 equiv.) and Pd(PPh3)2Cl2 (2.27 mg, 3.23 μmol, 0.005 equiv.) in DMF (4.5 mL) was added methyl 4-iodo-2-methyl-5-(2,2,2-trifluoroacetamido)benzoate (250 mg, 646 μmol, 1.0 equiv.), morpholine (113 mg, 1.29 mmol, 114 μL, 2.0 equiv.), prop-2-yn-1-ol (54.3 mg, 969 μmol, 57.2 μL, 1.5 equiv.), and K2CO3 (179 mg, 1.29 mmol, 2.0 equiv.), followed by DMF (2.0 mL) under a N2 atmosphere. The mixture was stirred at 80 °C for 2 h. TLC showed complete consumption of the starting material. The reaction mixture was cooled to room temperature and diluted with MTBE (10 mL). The resulting mixture was washed with saturated aqueous NaHCO (5.0 mL × 2). The organic layer was dried over NaSO, filtered, and concentrated in vacuo to give a residue, which was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 1 EtOAc / petroleum ether. Methyl 5-methyl-2-(morpholinomethyl)-1H-indole-6-carboxylate (170 mg, 85% yield) was obtained as a yellow oil.

[0858] Step 3: 5-Methyl-2-(morpholinomethyl)-1H-indole-6-carboxylic acid (25A-3) To a solution of methyl 5-methyl-2-(morpholinomethyl)-1H-indole-6-carboxylate (170 mg, 590 μmol, 1.0 equiv.) in a mixture of THF (10 mL) and HO (2.5 mL), NaOH (2 M aqueous solution, 7.37 mL, 25 equiv.) was added. The mixture was stirred at 20 °C for 1 h and then at 70 °C for 16 h. LCMS indicated that half of the starting material remained, so additional aqueous NaOH (2 M aqueous solution, 5.0 mL) was added and the mixture was stirred for an additional 5 h. The reaction mixture was cooled to room temperature and washed with MTBE (10 mL). The aqueous solution was acidified to pH 5 with HCl (1 M aqueous solution) and extracted with DCM (5.0 mL × 5). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to give 5-methyl-2-(morpholinomethyl)-1H-indole-6-carboxylic acid (175 mg, 90% pure) as a brown gum.

[0859] Step 4: (R)-5-Methyl-2-(morpholinomethyl)-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (compound 206) To a mixture of 5-methyl-2-(morpholinomethyl)-1H-indole-6-carboxylic acid (140 mg, 510 μmol, 1.0 equiv.) and (R)-1-(naphthalen-1-yl)ethanamine (87.4 mg, 510 μmol, 81.7 μL, 1.0 equiv.) in DCM (2.0 mL), EDCI (147 mg, 766 μmol, 1.5 equiv.) and HOBt (103 mg, 766 μmol, 1.5 equiv.) were added, followed by TEA (155 mg, 1.53 mmol, 213 μL, 3.0 equiv.). The mixture was stirred at 20 °C for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (5.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (75 x 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 20% to 60% B over 8 min; mobile phase A: 0.2% FA in water, mobile phase B: acetonitrile). (R)-5-methyl-2-(morpholinomethyl)-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-6-carboxamide (18.4 mg, 43.0 μmol, 8% yield, FA salt) was obtained as a white solid. M+H + =428.2(LCMS); 1 H NMR (400 MHz, CDCl3) δ 9.43 - 9.32 (m, 1H), 8.41 - 8.37 (m, 1H), 8.32 - 8.25 (m, 1H), 7.93 - 7.87 (m, 1H), 7.86 - 7.79 (m, 1H), 7.63 - 7.44 (m, 4H), 7.37 - 7.31 (m, 2H), 6.35 - 6.27 (m, 1H), 6.22 - 6.12 (m, 1H), 6.07 - 5.96 (m, 1H), 3.84 - 3.69 (m, 6H), 2.63 - 2.49 (m, 7H), 1.82 (d, J = 6.8 Hz, 3H). Example 26: (R)—N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (Compound 125)

[0860] [ka]

[0861] Step 1: (R)—N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (compound 125) To a solution of (R)-1-(naphthalen-1-yl)ethanamine (100 mg, 584 μmol, 1.0 equiv.) and 1H-benzo[d]imidazole-6-carboxylic acid (94.7 mg, 584 μmol, 1.0 equiv.) in DCM (4.0 mL) was added TEA (118 mg, 1.17 mmol, 163 μL, 2.0 equiv.), EDCI (134 mg, 701 μmol, 1.2 equiv.), and HOBT (94.7 mg, 701 μmol, 1.2 equiv.). The mixture was stirred at 20 °C for 3 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (4.0 mL) and extracted with DCM (4.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (100 x 30 mm, 10 μm); flow rate: 25 mL / min; gradient: 20% to 50% B over 8 min; mobile phase A: 10 mM aqueous NH4HCO3, mobile phase B: acetonitrile). (R)-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (40.7 mg, 121 μmol, 21% yield) was obtained as a white solid. M+H + =316.3(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.11 - 8.07 (m, 2H), 7.84 - 7.78 (m, 1H), 7.76 (s, 1H), 7.71 - 7.66 (m, 1H), 7.56 - 7.48 (m, 2H), 7.44 - 7.31 (m, 4H), 7.14 - 7.02 (m, 1H), 6.11 - 6.02 (m, 1H), 1.77 - 1.65 (m, 3H). Example 27: (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (Compound 102)

[0862] [ka]

[0863] Step 1: (R)-5-Methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (Compound 102) To a mixture of (R)-1-(naphthalen-1-yl)ethanamine (40.3 mg, 235 μmol, 37.6 μL, 1.0 equiv.) and 5-methyl-1H-benzo[d]imidazole-6-carboxylic acid (50.0 mg, 235 μmol, 1.0 equiv., HCl salt) in DCM (3.0 mL) was added EDCI (67.6 mg, 353 μmol, 1.5 equiv.), HOBt (47.7 mg, 353 μmol, 1.5 equiv.), and TEA (71.4 mg, 705 μmol, 98.2 μL, 3.0 equiv.). The resulting mixture was stirred at 20 °C for 3 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Waters Xbridge BEH C18 column (100 x 30 mm, 10 μm); flow rate: 25 mL / min; gradient: 25% to 55% B over 8 min; mobile phase A: 10 mM aqueous NH4HCO3, mobile phase B: acetonitrile). (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (16.1 mg, 48.0 μmol, 20% yield) was obtained as a white solid. M+H + =330.2(LCMS); 1H NMR (400 MHz, DMSO-d6) δ 12.42 (s, 1H), 8.95 - 8.78 (m, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.23 ​​- 8.17 (m, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.84 (br d, J = 7.9 Hz, 1H), 7.69 - 7.49 (m, 4H), 7.47 (s, 1H), 7.34 (s, 1H), 6.00 - 5.86 (m, 1H), 2.44 - 2.36 (m, 3H), 1.60 (d, J = 7.0 Hz, 3H). Example 28: (R)-2-(aminomethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (Compound 128)

[0864] [ka]

[0865] Step 1: Methyl 2-methyl-4,5-dinitrobenzoate (28A-2) To a solution of methyl 2-methyl-4-nitrobenzoate (1.00 g, 5.12 mmol, 1.0 equiv.) in HSO (10 mL, 98% purity) was added KNO (596 mg, 5.89 mmol, 1.2 equiv.) at 0 °C. The resulting mixture was stirred at 20 °C for 16 h. TLC showed complete consumption of the starting material. The reaction mixture was poured into ice water (20 mL) and neutralized with saturated aqueous NaHCO to adjust the pH to 7. The product was extracted with EtOAc (10 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 5 EtOAc / petroleum ether. Methyl 2-methyl-4,5-dinitrobenzoate (700 mg, 2.91 mmol, 57% yield) was obtained as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 8.54 (s, 1H), 8.26 (s, 1H), 3.98 - 3.84 (m, 3H), 2.73 - 2.58 (m, 3H). Step 2: Methyl 4,5-diamino-2-methylbenzoate (28A-3) A solution of methyl 2-methyl-4,5-dinitrobenzoate (1.50 g, 6.25 mmol, 1.0 equiv) and 10% palladium on carbon (100 mg) in a mixture of MeOH (20 mL) and dioxane (20 mL) was degassed and purged with H three times. The mixture was stirred at 20 °C under an atmosphere of H (1.02 atm (15 psi)) for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The suspension was filtered through a pad of Celite, and the filter cake was washed with EtOAc (2.0 mL × 3). The combined filtrate was concentrated in vacuo to give methyl 4,5-diamino-2-methylbenzoate (600 mg, 3.33 mmol, 53% yield) as a brown solid. M+H + =181.2(LCMS).

[0866] Step 3: Methyl 4-amino-5-(2-((tert-butoxycarbonyl)amino)acetamido)-2-methylbenzoate (28A-4) To a solution of methyl 4,5-diamino-2-methylbenzoate (170 mg, 943 μmol, 1.0 equiv.) and 2-((tert-butoxycarbonyl)amino)acetic acid (165 mg, 943 μmol, 1.0 equiv.) in THF (5.0 mL) was added DCC (389 mg, 1.89 mmol, 382 μL, 2.0 equiv.). The resulting mixture was stirred at 20 °C for 16 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 50 to 1 / 5 EtOAc / petroleum ether. Methyl 4-amino-5-(2-((tert-butoxycarbonyl)amino)acetamido)-2-methylbenzoate (200 mg, 593 μmol, 63% yield) was obtained as a white solid. + =338.3(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.09 (br s, 1H), 7.85 - 7.72 (m, 1H), 6.67 - 6.56 (m, 1H), 5.43 (br s, 1H), 4.01 - 3.91 (m, 2H), 3.84 - 3.73 (m, 3H), 2.56 - 2.37 (m, 3H), 1.54 - 1.43 (m, 9H). Step 4: Methyl 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-benzo[d]imidazole-6-carboxylate (28A-5) To a solution of methyl 4-amino-5-(2-((tert-butoxycarbonyl)amino)acetamido)-2-methylbenzoate (100 mg, 296 μmol, 1.0 equiv) in AcOH (1.0 mL). The resulting mixture was stirred at 80° C. for 2 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into H2O (5.0 mL), and extracted with EtOAc (2.0 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product methyl 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-benzo[d]imidazole-6-carboxylate (90.0 mg) as a colorless oil, which was used in the next step without any further purification. M+H + =320.3(LCMS).

[0867] Step 5: 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-benzo[d]imidazole-6-carboxylic acid (28A-6) To a solution of methyl 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-benzo[d]imidazole-6-carboxylate (90.0 mg, 282 μmol, 1.0 equiv.) in a mixture of THF (9.0 mL) and HO (3.0 mL), NaOH (2 M aqueous solution, 423 μL, 3.0 equiv.) was added. The mixture was stirred at 80 °C for 16 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into HO (10.0 mL), and washed with MTBE (5.0 mL × 2). The aqueous layer was acidified to pH 5 using HCl (1 M aqueous solution). The product was extracted with EtOAc (4.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-benzo[d]imidazole-6-carboxylic acid (90.0 mg) as a colorless oil, which was used in the next step without any further purification. M+H + =306.3(LCMS).

[0868] Step 6: (R)-tert-butyl ((5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-benzo[d]imidazol-2-yl)methyl)carbamate (28A-7) To a solution of 1-(naphthalen-1-yl)cyclopropanamine (33.7 mg, 197 μmol, 31.5 μL, 1.0 equiv.) and 2-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-1H-benzo[d]imidazole-6-carboxylic acid (60.0 mg, 197 μmol, 1.0 equiv.) in DCM (2.0 mL) was added TEA (59.7 mg, 590 μmol, 82.1 μL, 3.0 equiv.), EDCI (45.2 mg, 236 μmol, 1.2 equiv.), and HOBt (31.9 mg, 236 μmol, 1.2 equiv.). The mixture was stirred at 20 °C for 3 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (3.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (EtOAc / petroleum ether = 1:1, R f =0.5), (R)-tert-butyl ((5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-benzo[d]imidazol-2-yl)methyl)carbamate (40.0 mg, 87.0 μmol, 44% yield) was obtained as a white solid. + =459.4(LCMS).

[0869] Step 7: (R)-2-(aminomethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (compound 128) To a stirred solution of (R)-tert-butyl ((5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-benzo[d]imidazol-2-yl)methyl)carbamate (40.0 mg, 87.0 μmol, 1.0 equiv) in EtOAc (2.0 mL) was added HCl / EtOAc (4 M, 1.0 mL). The mixture was stirred at 20 °C for 1 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The mixture was concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Luna C18 column (150 × 30 mm, 5 μm); flow rate: 25 mL / min; gradient: 5% to 40% B over 8 min; mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile). (R)-2-(aminomethyl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (9.70 mg, 20.5 μmol, 24% yield, TFA salt) was obtained as a white solid. + =359.0(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.32 (d, J = 8.7 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.69 (d, J = 7.3 Hz, 1H), 7.65 - 7.50 (m, 4H), 7.47 (s, 1H), 6.12 (q, J = 6.7 Hz, 1H), 4.42 (s, 2H), 2.50 (s, 3H), 1.77 (d, J = 7.0 Hz, 3H). Example 29: (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (Compound 131)

[0870] [ka]

[0871] Step 1: tert-butyl 3-((2-amino-5-(methoxycarbonyl)-4-methylphenyl)carbamoyl)azetidine-1-carboxylate (29A-1) To a solution of methyl 1-(tert-butoxycarbonyl)azetidine-3-carboxylate (223 mg, 1.11 mmol, 1.0 equiv.) in DMF (1.5 mL) was added pyridine (1.5 mL) and CDI (185 mg, 1.11 mmol, 1.0 equiv.). The mixture was stirred at 45 °C for 30 min. Then, methyl 4,5-diamino-2-methylbenzoate (200 mg, 1.11 mmol, 1.0 equiv.) was added to the mixture, and the resulting mixture was stirred at 20 °C for 16 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was poured into H2O (6.0 mL) and extracted with EtOAc (3.0 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 1 EtOAc / petroleum ether. tert-Butyl 3-((2-amino-5-(methoxycarbonyl)-4-methylphenyl)carbamoyl)azetidine-1-carboxylate (400 mg, 1.10 mmol, 50% yield) was obtained as a white solid. + =264.3(LCMS); 1 H NMR (400 MHz, DMSO-d6) δ 9.14 (s, 1H), 7.86 - 7.69 (m, 1H), 6.54 (s, 1H), 5.64 (s, 2H), 3.96 (br s, 4H), 3.71 (s, 3H), 3.54 - 3.42 (m, 1H), 2.40 (s, 3H), 1.39 (s, 9H). Step 2: Methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-benzo[d]imidazole-6-carboxylate (29A-2) A solution of tert-butyl 3-((2-amino-5-(methoxycarbonyl)-4-methylphenyl)carbamoyl)azetidine-1-carboxylate (400 mg, 1.10 mmol, 1.0 equiv) in AcOH (0.5 mL) was stirred at 70 °C for 1 h. TLC showed that the starting material was completely consumed and a major spot was detected. The reaction mixture was cooled to room temperature, poured into H2O (5.0 mL), and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue, which was analyzed by preparative TLC (EtOAc / petroleum ether = 1:1, R f =0.4) to give methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-benzo[d]imidazole-6-carboxylate (350 mg, 1.01 mmol, 92% yield) as a yellow oil. + =346.3(LCMS).

[0872] Step 3: Methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-6-carboxylate (29A-3) To a solution of methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1H-benzo[d]imidazole-6-carboxylate (200 mg, 420 μmol, 1.0 equiv.) in DMF (6.0 mL) was added sodium hydride (25.2 mg, 631 μmol, 60% purity, 1.5 equiv.) at 0° C. The mixture was stirred at 0° C. for 30 minutes. SEM-Cl (105 mg, 631 μmol, 112 μL, 1.5 equiv.) was added to the mixture, and the resulting mixture was stirred at 20° C. for 1 hour. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was poured into HO (6.0 mL) and extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (DCM / MeOH=10:1, R f=0.5) to give methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 315 μmol, 75% yield) as a yellow oil. + =476.3(LCMS).

[0873] Step 4: 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (29A-4) To a solution of methyl 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-6-carboxylate (80.0 mg, 42.1 μmol, 1.0 equiv.) in a mixture of EtOH (2.0 mL) and THF (2.0 mL), NaOH (2 M aqueous solution, 2.0 mL, 24 equiv.) was added. The mixture was stirred at 80° C. for 16 hours. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into HO (5.0 mL), and washed with MTBE (3.0 mL × 2). The aqueous layer was acidified to pH 5 using HCl (1 M aqueous solution). The product was extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (80.0 mg) as a yellow oil, which was used in the next step without any further purification. M+H + =462.4(LCMS).

[0874] Step 5: (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)azetidine-1-carboxylate (29A-5) To a solution of 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (70.0 mg, 152 μmol, 1.0 equiv.) and (R)-1-(naphthalen-1-yl)ethanamine (26.0 mg, 152 μmol, 24.0 μL, 1.0 equiv.) in DCM (4.0 mL) was added EDCI (34.9 mg, 182 μmol, 1.2 equiv.), HOBt (24.6 mg, 182 μmol, 1.2 equiv.), and TEA (46.0 mg, 455 μmol, 63.0 μL, 3.0 equiv.). The resulting mixture was stirred at 20° C. for 3 hours. TLC showed complete consumption of the starting material. The reaction mixture was poured into H2O (5.0 mL) and extracted with DCM (2.0 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue, which was analyzed by preparative TLC (DCM / MeOH = 10:1, R f =0.7) to give (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)azetidine-1-carboxylate (70.0 mg, 114 μmol, 75% yield) as a yellow solid.

[0875] Step 6: (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-benzo[d]imidazol-2-yl)azetidine-1-carboxylate (29A-6) To a solution of (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-2-yl)azetidine-1-carboxylate (65.0 mg, 106 μmol, 1.0 equiv.) in DMF (1.0 mL) was added ethane-1,2-diamine (28.6 mg, 476 μmol, 31.84 μL, 4.5 equiv.) and TBAF (1 M in THF, 317 μL, 3.0 equiv.). The resulting mixture was stirred at 20° C. for 3 hours. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (2.0 mL) and extracted with EtOAc (2.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (DCM / MeOH=10:1, R f =0.6), (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-benzo[d]imidazol-2-yl)azetidine-1-carboxylate (50.0 mg, 103 μmol, 98% yield) was obtained as a yellow solid. + =485.4(LCMS).

[0876] Step 7: (R)-2-(azetidin-3-yl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (compound 131) To a solution of (R)-tert-butyl 3-(5-methyl-6-((1-(naphthalen-1-yl)ethyl)carbamoyl)-1H-benzo[d]imidazol-2-yl)azetidine-1-carboxylate (50.0 mg, 103 μmol, 1.0 equiv) in EtOAc (3.0 mL) was added HCl / EtOAc (4 M, 1.0 mL). The resulting mixture was stirred at 20 °C for 3 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was concentrated in vacuo to give a residue, which was purified by preparative HPLC (Phenomenex Luna C18 column (150 × 30 mm, 5 μm); flow rate: 25 mL / min; gradient: 1% to 40% B over 8 min; mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile). (R)-2-(azetidin-3-yl)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-benzo[d]imidazole-6-carboxamide (11.0 mg, 28.5 μmol, 28% yield, TFA salt) was obtained as a white solid. + =385.1(LCMS); 1 H NMR (400 MHz, CD3OD) δ 8.93 (br d, J = 7.9 Hz, 1H), 8.29 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.66 - 7.43 (m, 6H), 6.18 - 5.96 (m, 1H), 4.55 - 4.41 (m, 5H), 2.48 (s, 3H), 1.74 (d, J = 7.0 Hz, 3H). Example 30: (R)—N-(1-(naphthalen-1-yl)ethyl)-1H-indazole-6-carboxamide (Compound 124)

[0877] [ka]

[0878] Step 1: (R)-N-(1-(naphthalen-1-yl)ethyl)-1H-indazole-6-carboxamide (compound 124) To a solution of (R)-1-(naphthalen-1-yl)ethanamine (100 mg, 584 μmol, 1.0 equiv.) and 1H-indazole-6-carboxylic acid (94.7 mg, 584 μmol, 1.0 equiv.) in DCM (4.0 mL), TEA (118 mg, 1.17 mmol, 163 μL, 2.0 equiv.) and T3P (2.23 g, 3.50 mmol, 2.08 mL, 50% in EtOAc, 6.0 equiv.) were added. The mixture was stirred at 20 °C for 3 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (4.0 mL) and extracted with DCM (2.0 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (100 x 30 mm, 10 μm); flow rate: 25 mL / min; gradient: 25% to 50% B over 8 min; mobile phase A: 10 mM aqueous NH4HCO3, mobile phase B: acetonitrile). (R)-N-(1-(naphthalen-1-yl)ethyl)-1H-indazole-6-carboxamide (28.2 mg, 89.4 μmol, 15% yield) was obtained as a white solid. M+H + =316.2(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.21 - 8.19 (m, 1H), 8.15 - 8.09 (m, 1H), 8.03 (s, 1H), 7.93 - 7.84 (m, 2H), 7.78 - 7.75 (m, 1H), 7.64 - 7.61 (m, 1H), 7.55 - 7.43 (m, 4H), 6.48 - 6.46 (m, 1H), 6.22 - 6.14 (m, 1H), 1.84 - 1.83 (d, J = 4, 3H), Example 31: (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indazole-6-carboxamide (Compound 142)

[0879] [ka]

[0880] Step 1: Methyl 5-methyl-1H-indazole-6-carboxylate (31A-2) To a solution of 6-bromo-5-methyl-1H-indazole (200 mg, 948 μmol, 1.0 equiv.) in MeOH (3.0 mL) under a N atmosphere, Pd(dppf)Cl (139 mg, 190 μmol, 0.2 equiv.) and TEA (767 mg, 7.58 mmol, 1.10 mL, 8.0 equiv.) were added. The mixture was degassed and purged with CO three times. The resulting mixture was stirred at 70 °C under a CO atmosphere (3.40 atm (50 psi)) for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was cooled to room temperature and then concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 1 / 100 to 1 / 10 EtOAc / petroleum ether. Methyl 5-methyl-1H-indazole-6-carboxylate (150 mg, 789 μmol, 83% yield). M+H + =191.1(LCMS).

[0881] Step 2: 5-Methyl-1H-indazole-6-carboxylic acid (31A-3) To a solution of methyl 5-methyl-1H-indazole-6-carboxylate (100 mg, 526 μmol, 1.0 equiv.) in a mixture of THF (3.0 mL) and HO (1.0 mL), LiOH (66.2 mg, 1.58 mmol, 3.0 equiv.) was added. The mixture was stirred at 20° C. for 18 hours. LCMS showed complete consumption of the starting material and the desired mass was detected. HO (5.0 mL) was added, and the mixture was washed with MTBE (2.0 mL × 3). The aqueous layer was acidified to pH 5 using HCl (1 M aqueous solution). The product was extracted with EtOAc (2.0 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give 5-methyl-1H-indazole-6-carboxylic acid (70.0 mg, 397 μmol, 76% yield) as a white solid, which was used in the next step without any further purification. M+H + =177.2(LCMS).

[0882] Step 3: (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indazole-6-carboxamide (compound 142) To a solution of 5-methyl-1H-indazole-6-carboxylic acid (30.0 mg, 170 μmol, 1.0 equiv.) and (R)-1-(naphthalen-1-yl)ethanamine (29.2 mg, 170 μmol, 27.3 μL, 1.0 equiv.) in DCM (2.0 mL) was added EDCI (39.2 mg, 204 μmol, 1.2 equiv.), HOBt (27.6 mg, 204 μmol, 1.2 equiv.), and TEA (34.5 mg, 341 μmol, 47.4 μL, 2.0 equiv.). The resulting mixture was stirred at 20 °C for 3 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (5.0 mL) and extracted with DCM (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (100 x 40 mm, 5 μm); flow rate: 25 mL / min; gradient: 45% to 90% B over 8 min; mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile). (R)-5-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indazole-6-carboxamide (8.51 mg, 25.8 μmol, 16% yield, TFA salt) was obtained as a white solid. M+H + =330.0(LCMS); 1 H NMR (400 MHz, CD3OD) δ 9.00 (br d, J = 7.8 Hz, 1H), 8.29 (d, J = 8.5 Hz, 1H), 8.10 (br s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 7.1 Hz, 1H), 7.63 - 7.46 (m, 5H), 6.09 (quintet, J = 7.1 Hz, 1H), 2.43 (s, 3H), 1.74 (d, J = 7.0 Hz, 3H). Example 32: (R)-6-methyl-N-(1-(naphthalen-1-yl)ethyl)quinoline-7-carboxamide (Compound 150)

[0883] [ka]

[0884] Step 1: 7-Bromo-6-methylquinoline (32A-2) To a mixture of 3-bromo-4-methyl-aniline (18.0 g, 96.8 mmol, 1.0 equiv.) and sodium 3-nitrobenzenesulfonate (26.1 g, 116 mmol, 1.2 equiv.) in HSO (60 mL, 98% purity) and HO (25 mL) was added propane-1,2,3-triol (26.7 g, 290 mmol, 21.7 mL, 3.0 equiv.). The mixture was stirred at 130 °C for 2 h. TLC showed complete consumption of the starting material. The reaction mixture was cooled to room temperature, poured into HO (30 mL), and neutralized with KCO to pH 8. The product was extracted with EtOAc (30 mL × 5). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 2 EtOAc / petroleum ether. 7-Bromo-6-methylquinoline (10.4 g, 46.8 mmol, 48% yield) was obtained as a white solid. 1 H NMR (400 MHz, CDCl3) δ 8.87 - 8.85 (m, 1H), 8.63 - 8.56 (m, 1H), 8.01 - 7.96 (m, 1H), 7.62 - 7.58 (m, 1H), 7.41 - 7.35 (m, 1H), 2.60 - 2.56 (m, 3H). Step 2: Methyl 6-methylquinoline-7-carboxylate (32A-3) To a solution of 7-bromo-6-methylquinoline (6.00 g, 27.0 mmol, 1.0 equiv.) and TEA (10.9 g, 108 mmol, 15.0 mL, 4.0 equiv.) in MeOH (50 mL) was added Pd(dppf)Cl (1.98 g, 2.70 mmol, 0.1 equiv.). The mixture was stirred at 70 °C under a CO atmosphere (3.40 atm (50 psi)) for 16 h. TLC showed complete consumption of the starting material. The reaction mixture was concentrated in vacuo to give a residue, which was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 2 EtOAc / petroleum ether. Methyl 6-methylquinoline-7-carboxylate (6.00 g, 29.8 mmol, 37% yield) was obtained as a white solid. 1 H NMR (400 MHz, CDCl3) δ 8.98 - 8.89 (m, 1H), 8.72 - 8.64 (m, 1H), 8.14 - 8.06 (m, 1H), 7.71 - 7.63 (m, 1H), 7.49 - 7.39 (m, 1H), 4.16 - 3.89 (m, 3H), 2.85 - 2.68 (m, 3H). Step 3: 6-Methylquinoline-7-carboxylic acid (32A-4) To a solution of methyl 6-methylquinoline-7-carboxylate (300 mg, 1.49 mmol, 1.0 equiv.) in a mixture of THF (8.0 mL), HO (4.0 mL), and MeOH (2.0 mL) was added LiOH·HO (125 mg, 2.98 mmol, 2.0 equiv.). The mixture was stirred at 20 °C for 30 min and then at 70 °C for 16 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was cooled to room temperature, poured into HO (8.0 mL), and washed with MTBE (8.0 mL × 2). The aqueous layer was acidified to pH 5 with HCl (1 M aqueous solution). The product was extracted with EtOAc (8.0 mL × 6). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give 6-methylquinoline-7-carboxylic acid (270 mg, 1.44 mmol, 97% yield) as a white solid, which was used in the next step without any further purification. - =186.1(LCMS).

[0885] Step 4: (R)-6-methyl-N-(1-(naphthalen-1-yl)ethyl)quinoline-7-carboxamide (compound 150) To a solution of (R)-1-(naphthalen-1-yl)ethanamine (89.2 mg, 521 μmol, 83.0 μL, 1.5 equiv.) and 6-methylquinoline-7-carboxylic acid (65.0 mg, 347 μmol, 1.0 equiv.) in DCM (5.0 mL) was added TEA (70.3 mg, 694 μmol, 96.7 μL, 2.0 equiv.) and T3P (331 mg, 521 μmol, 310 μL, 50% purity in EtOAc, 1.5 equiv.). The mixture was stirred at 20 °C for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (10 mL) and extracted with DCM (10 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (EtOAc / petroleum ether = 1 / 3, R f =0.5), (R)-6-methyl-N-(1-(naphthalen-1-yl)ethyl)quinoline-7-carboxamide (26.0 mg, 76.4 μmol, 22% yield) was obtained as a white solid. M+H + =341.1(LCMS); 1 H NMR (400 MHz, CDCl3) δ 8.82 (br d, J = 2.1 Hz, 1H), 8.32 - 8.23 ​​(m, 1H), 8.12 - 7.98 (m, 2H), 7.90 (d, J = 8.0 Hz, 1H), 7.86 - 7.79 (m, 1H), 7.67 - 7.57 (m, 3H), 7.57 - 7.44 (m, 2H), 7.44 - 7.36 (m, 1H), 6.36 - 6.14 (m, 2H), 2.69 - 2.59 (m, 3H), 1.90 - 1.80 (m, 3H). Example 33: (R)-6-methyl-N-(1-(naphthalen-1-yl)ethyl)-2-oxo-1,2-dihydroquinoline-7-carboxamide (Compound 167)

[0886] [ka]

[0887] Step 1: 7-(methoxycarbonyl)-6-methylquinoline 1-oxide (33A-1) To a mixture of methyl 6-methylquinoline-7-carboxylate (240 mg, 1.19 mmol, 1.0 equiv.) in DCM (5.0 mL) was added m-CPBA (308 mg, 1.43 mmol, 80% purity, 1.2 equiv.) at 0 °C. The mixture was stirred at 20 °C under a N atmosphere for 2 h. LCMS showed complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into saturated aqueous NaSO (10 mL) and extracted with DCM (5.0 mL × 3). The combined organic layers were dried and concentrated in vacuo to give 7-(methoxycarbonyl)-6-methylquinoline 1-oxide (300 mg, 968 μmol, 81% yield) as a yellow solid. M+H + =218.1(LCMS); 1 H NMR (400 MHz, CDCl3) δ 9.33 - 9.23 (m, 1H), 8.56 - 8.46 (m, 1H), 7.80 - 7.70 (m, 1H), 7.69 - 7.60 (m, 1H), 7.38 - 7.30 (m, 1H), 4.04 - 3.91 (m, 3H), 2.82 - 2.70 (m, 3H). Step 2: Methyl 2-chloro-6-methylquinoline-7-carboxylate (33A-2) To a solution of 7-(methoxycarbonyl)-6-methylquinoline 1-oxide (230 mg, 1.06 mmol, 1.0 equiv) in DCM (8.0 mL) was added POCl (244 mg, 1.59 mmol, 148 μL, 1.5 equiv) followed by DMF (39.0 mg, 529 μmol, 40.7 μL, 0.5 equiv) at 0 °C. The mixture was stirred at 20 °C for 16 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. Saturated aqueous NaCO was slowly added to the reaction mixture at 0 °C to adjust the pH to 8. The resulting mixture was separated, and the aqueous phase was extracted with DCM (10 mL × 5). The combined organic layers were washed with brine (10 mL), dried over NaSO, and concentrated in vacuo to give the crude product, which was purified by flash silica gel chromatography using a gradient of 0 / 1 to 1 / 2 EtOAc / petroleum ether. Methyl 2-chloro-6-methylquinoline-7-carboxylate (120 mg, 509 μmol, 48% yield) was obtained as a white solid. + =236.0(LCMS); 1 H NMR (400 MHz, CDCl3)δ 8.69 - 8.62 (m, 1H), 8.17 - 7.96 (m, 1H), 7.77 - 7.59 (m, 1H), 7.47 (d, J = 8.5 Hz, 1H), 3.98 (s, 3H), 2.80 - 2.70 (m, 3H). Step 3: 6-methyl-2-oxo-1,2-dihydroquinoline-7-carboxylic acid (33A-3) To a solution of methyl 2-chloro-6-methylquinoline-7-carboxylate (120 mg, 509 μmol, 1.0 equiv.) in dioxane (5.0 mL) was added HCl (6 M in aqueous solution, 962 μL, 11 equiv.). The mixture was stirred at 100° C. for 16 hours. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was cooled to room temperature, diluted with HO (3.0 mL), and acidified to pH 5 with NaOH (2 M aqueous solution). The product was extracted with EtOAc (8.0 mL × 5). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give the product, 6-methyl-2-oxo-1,2-dihydroquinoline-7-carboxylic acid (160 mg, 472 μmol, 93% yield), as a white solid, which was used in the next step without any further purification. M+H + =204.0(LCMS); 1 H NMR (400 MHz, DMSO-d6) δ 11.83 - 11.74 (m, 1H), 7.91 - 7.83 (m, 1H), 7.81 - 7.76 (m, 1H), 7.58 - 7.54 (m, 1H), 6.63 - 6.52 (m, 1H), 1.25 - 1.20 (m, 3H). Step 4: (R)-6-methyl-N-(1-(naphthalen-1-yl)ethyl)-2-oxo-1,2-dihydroquinoline-7-carboxamide (compound 167) To a solution of (R)-1-(naphthalen-1-yl)ethanamine (75.8 mg, 443 μmol, 70.9 μL, 1.5 equiv.) and 6-methyl-2-oxo-1,2-dihydroquinoline-7-carboxylic acid (100 mg, 295 μmol, 1.0 equiv.) in DCM (10 mL) was added TEA (89.6 mg, 886 μmol, 123 μL, 3.0 equiv.), EDCI (84.9 mg, 443 μmol, 1.5 equiv.), and HOBt (59.9 mg, 442 μmol, 1.5 equiv.). The mixture was stirred at 20 °C for 16 h. LCMS indicated complete consumption of the starting material and the desired mass was detected. The reaction mixture was poured into HO (10 mL) and extracted with DCM (10 mL × 5). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that was purified by preparative HPLC (Phenomenex Gemini C18 column (75 x 30 mm, 3 μm); flow rate: 25 mL / min; gradient: 25% to 65% B over 8 min; mobile phase A: 0.04% aqueous HCl, mobile phase B: acetonitrile). (R)-6-methyl-N-(1-(naphthalen-1-yl)ethyl)-2-oxo-1,2-dihydroquinoline-7-carboxamide (8.00 mg, 21.9 μmol, 7% yield) was obtained as a white solid. M+H + =357.1(LCMS); 1 H NMR (400 MHz, DMSO-d6) δ 11.84 - 11.57 (m, 1H), 9.13 - 8.98 (m, 1H), 8.37 - 8.13 (m, 1H), 8.00 - 7.93 (m, 1H), 7.91 - 7.80 (m, 2H), 7.65 - 7.47 (m, 5H), 7.29 - 7.21 (m, 1H), 6.54 - 6.44 (m, 1H), 5.98 - 5.87 (m, 1H), 2.30 - 2.24 (m, 3H), 1.62 - 1.53 (m, 3H). Example 34: (R)-6-methyl-N-(1-(naphthalen-1-yl)ethyl)benzo[d][1,3]dioxole-5-carboxamide (Compound 145)

[0888] [ka]

[0889] Step 1: 6-Methylbenzo[d][1,3]dioxole-5-carbaldehyde (34A-2) To a solution of 5-methylbenzo[d][1,3]dioxole (200 mg, 1.47 mmol, 175 μL, 1.0 equiv) in DCM (2.0 mL) was added dichloro(methoxy)methane (338 mg, 2.94 mmol, 260 μL, 2.0 equiv) at 0°C. The mixture was stirred at 0°C for 15 min, and a solution of TiCl4 (334 mg, 1.76 mmol, 1.2 equiv) in DCM (2.0 mL) was added dropwise. The resulting mixture was stirred at 20°C for 1 h. TLC showed that the starting material was completely consumed. The mixture was poured into HO (10 mL) and extracted with MTBE (10 mL × 2). The combined organic layers were dried and concentrated in vacuo to give a residue that was purified by flash silica gel chromatography using a gradient of 0 / 100 to 1 / 50 EtOAc / petroleum ether. 6-Methylbenzo[d][1,3]dioxole-5-carbaldehyde (220 mg, 1.34 mmol, 91% yield) was obtained as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 10.24 - 10.05 (m, 1H), 7.29 (s, 1H), 6.70 (s, 1H), 6.03 (s, 2H), 2.62...

Claims

1. Compound of formula (I') 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof (In the formula, Ring A is selected from the group consisting of naphthyl, anthracenyl, 8- to 12-membered bicyclic or tricyclic heteroaryl, 8- to 12-membered bicyclic or tricyclic heterocyclyl, and 8- to 12-membered partially unsaturated bicyclic carbocyclyl, wherein said naphthyl, 8- to 12-membered bicyclic or tricyclic heteroaryl, and 8- to 12-membered partially unsaturated bicyclic carbocyclyl have one or more (e.g., one, two, three, or four) R 1 may be substituted by; Each X is CH 2 , C.H., N.R. h and O; R x When R is substituted on a carbon atom, each R x is independent, C 1~6 alkyl or halo, or R x When R is substituted on a nitrogen atom, each R x is independent, C 1~6 is alkyl; m is 0, 1, or 2; 【Chemistry 2】 is a single bond or a double bond; n is 1 or 2; Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, 3- to 7-membered heterocyclyl, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 C optionally substituted with alkynyl or phenyl 1~6 Alkoxy, —O—C 1~6 Alkylene-C 1~6 Alkoxy, -C(O)OR i , -S(O) t C 1~6 Alkyl, -S-C 1~6 Haloalkyl, -NR e R f , -C(O)NR g R h , —O-phenyl, and hydroxy, wherein said phenyl and 5-6 membered heteroaryl are independently selected from the group consisting of halo, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 alkoxy; R 2 Ha, Haro, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~6 Alkoxy, Hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 alkylene-OH), and -NR e R f -NR c R d -O-C 3~7 Cycloalkyl, -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)O-C 1~6 alkyl, -NR c R d C which may be substituted with 1~6 Alkyl, -O-(5-6 membered heteroaryl), C 0~6 Alkylene-CN,C 0~6 Alkylene-C(O)O(C 1~6 Alkyl), C 0~6 Alkylene-C(O)NR e R f and -NR A R B wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; R 4 is H, C 1~6 Alkyl, halo, hydroxy, and -NR e R f or R 3 and R 4 together with the atoms to which they are attached form together an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to phenyl, said 5- to 10-membered ring containing at least one heteroatom, and said 5- to 10-membered ring is -NR c R d C which may be substituted with 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5- to 6-membered heteroaryl, -(C 0~6 alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, —C(O)—NCH 3 OCH 3 , -(C 0~6 alkylene)-NR c R d , -(C 0~6 (alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 (alkylene)-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; Each R 3a is C 1~6 Alkyl, -NR A R B , C 1~6 Alkoxy, hydroxy, -C(O)NR c R d , 3- to 8-membered heterocyclyl, phenyl, 5- to 6-membered heteroaryl, and -(C 0~6 alkylene)-(NR c R d C which may be substituted with 3~6 cycloalkyl), wherein the 3- to 8-membered heterocyclyl and 5- to 6-membered heteroaryl are independently selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-C 3~7 Cycloalkyl, phenyl, benzyl, C 1~6 Alkylene-OH, and C 0~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently for each occurrence, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O) 2 C 1~6 Alkyl, —C(O)—C 1~6 Alkyl, C 1~6 Alkylene -NR c R d , 3- to 6-membered heterocyclyl optionally substituted by oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy; -(C 0~6 alkylene)-phenyl, and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Cycloalkyl is hydroxy or C 1~6 each optionally substituted with alkoxy; Each R c and R d independently for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and R d may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; Each R e and R f independently for each occurrence, H, C 1~6 Alkyl, -C(O)C 1~6 Alkyl, and -C(O)OC 1~6 alkyl; and Each R g , R h , and R i is independently, for each occurrence, H or C 1~6 (alkyl).

2. Compounds of formula (I'') 【Chemistry 3】 or a pharma- ceutically acceptable salt thereof (In the formula, Ring A is selected from the group consisting of naphthyl, anthracenyl, phenanthrenyl, 8- to 14-membered bicyclic or tricyclic heteroaryl, 8- to 12-membered bicyclic or tricyclic heterocyclyl, and 8- to 12-membered partially unsaturated bicyclic carbocyclyl, wherein said naphthyl, 8- to 14-membered bicyclic or tricyclic heteroaryl, and 8- to 12-membered partially unsaturated bicyclic carbocyclyl have one or more (e.g., one, two, three, or four) R 1 may be substituted by; When Ring A is an 8- to 12-membered bicyclic heterocyclyl or an 8- to 12-membered partially unsaturated bicyclic carbocyclyl, R 3 is one or more (e.g., one, two, three, or four) R 3a C which may be substituted with 1~6 is alkoxy; Each X is CH 2 , C.H., N.R. h and O; R x When R is substituted on a carbon atom, each R x are independent, D, C 1~6 alkyl or halo, or R x When R is substituted on a nitrogen atom, each R x is independent, C 1~6 is alkyl; m is 0, 1, 2, 3, or 4; 【Chemistry 4】 is a single bond or a double bond; n is 1 or 2; Each R 1 is phenyl, 5- to 9-membered heteroaryl, C 3~7 carbocyclyl, one or more (e.g., one, two, three, or four) R 1a 3- to 7-membered heterocyclyl optionally substituted by 1~6 Haloalkyl, C 1~6 C optionally substituted with haloalkoxy, halo, -CN, hydroxy 1~6 Alkyl, C 3~6 Cycloalkyl or C 0~6 C optionally substituted with phenyl substituted with alkyl 2~6 alkenyl, optionally substituted with one or more (e.g., one, two, three, or four) halo; 2~6 C optionally substituted with alkynyl or phenyl 1~6 Alkoxy, —O—C 1~6 Alkylene-C 1~6 Alkoxy, —C(O)—C 1~6 Alkyl, -C(O)OR i , -S(O) t C 1~6 Alkyl, -S-C 1~6 Haloalkyl, -OS(O) t C 1~6 Haloalkyl, -NR j R k , -C(O)NR g R h , —O-phenyl, —B(OR m ) 2 and hydroxy, wherein said phenyl and 5-9 membered heteroaryl are independently selected from the group consisting of halo, cyano, phenyl, 3- to 7-membered heterocyclyl, C 1~6 Alkyl, C 1~6 alkylene-(3- to 7-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) halo), C substituted with hydroxy 1~6 Alkylene, C 1~6 Alkylene -NR A R B , —C(O)-3 to 6-membered heterocyclyl, hydroxy, C 1~6 Haloalkyl, C 1~6 Alkoxy, and -C(O)-C 1~6 alkyl; R 1a is oxo, halo, C 1~6 Haloalkyl, and C 1~6 alkoxy; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; R 7 is H and C 1~6 alkyl; R 2 Ha, Haro, C 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~20 Alkoxy, Hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 alkylene-OH), -C(O)O-C 1~6 Alkyl, and -NR e R f -NR c R d -O-C 3~7 Cycloalkyl, -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)O-C 1~6 alkyl, -NR c R d C which may be substituted with 1~6 Alkyl, -O-(5-6 membered heteroaryl), C 0~6 Alkylene-CN,C 0~6 Alkylene-C(O)O(C 1~6 Alkyl), C 0~6 Alkylene-C(O)NR e R f and -NR AA R BB wherein C is selected from the group consisting of 1~20 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; R 4 is H, C 1~6 C optionally substituted with alkyl, phenyl or 5- to 6-membered heteroaryl 2~6 Alkynyl, halo, hydroxy, and -NR e R f or R 3 and R 4 together with the atoms to which they are attached form together an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to phenyl, said 5- to 10-membered ring containing at least one heteroatom, and said 5- to 10-membered ring is -NR c R d C which may be substituted with 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5- to 6-membered heteroaryl, -(C 0~6 alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, —C(O)—NCH 3 OCH 3 , -(C 0~6 alkylene)-NR c R d , -(C 0~6 (alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and C 1~6 may be substituted with alkyl (C 0~6 alkylene)-3- to 7-membered heterocyclyl, wherein the aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to said phenyl is not imidazole; R AA and R BB is H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O) 2 C 1~6 Alkyl, —C(O)—C 1~6 Alkyl, C 1~20 Alkylene -NR c R d , 3- to 6-membered heterocyclyl optionally substituted by oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy; -(C 0~6 alkylene)-phenyl, -(C 0~20 alkylene)-(3- to 10-membered heterocyclyl), and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 alkylene, 3- to 10-membered heterocyclyl, and C 3~6 Cycloalkyl is C 1~6 Alkyl, hydroxy and C 1~6 each optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently for each occurrence, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O) 2 C 1~6 Alkyl, —C(O)—C 1~6 Alkyl, C 1~6 Alkylene -NR c R d , 3- to 6-membered heterocyclyl optionally substituted by oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy; -(C 0~6 alkylene)-phenyl, and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Cycloalkyl is hydroxy or C 1~6 each optionally substituted with alkoxy; Each R c and R d independently for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and R d may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; Each R e and R f independently for each occurrence, H, C 1~6 Alkyl, -C(O)C 1~6 Alkyl, -C(O)OC 1~6 Alkyl, and -S(O) 2 C 1~6 selected from the group consisting of alkyl; Each R g , R h , and R i is independently, for each occurrence, H or C 1~6 is alkyl; and Each R j and R k is independently, for each occurrence, H, C optionally substituted with phenyl 1~6 Alkyl, C 1~6 Haloalkyl, —C(O)C 1~6 Alkyl, -S(O) 2 C 1~6 Alkyl, and -C(O)OC 1~6 selected from the group consisting of alkyl; Each R 3a D, C 1~6 Alkyl, -NR A R B , C 1~6 Alkoxy, hydroxy, -C(O)NR c R d , 3- to 10-membered heterocyclyl, phenyl, 5- to 6-membered heteroaryl, and -(C 0~6 alkylene)-(NR c R d C which may be substituted with 3~6 wherein the 3- to 10-membered heterocyclyl and the 5- to 6-membered heteroaryl are independently selected from the group consisting of halo, hydroxy, C optionally substituted with one or more (e.g., 1, 2, 3, or 4) D. 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-C 3~7 Cycloalkyl, phenyl, benzyl, C 1~6 Alkylene-OH, and C 0~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R m is hydrogen and C 1~6 alkyl, or two (OR m ) groups together with the boron atom to which they are attached may form a pinacol ester; However, when ring A is naphthyl, R 4 is hydrogen, -F, -Cl, C 1~6 Alkyl, and -NR e R f R 5 is hydrogen; R 6 is hydrogen or halo; X is CH 2 n is 1; R 2 Ha, Haro, C 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~6 Alkoxy, Hydroxy, C 1~6 alkylene-(one or more (e.g., one, two, three, or four) R XX 3- to 10-membered heterocyclyl optionally substituted with one or more (e.g., one, two, three, or four) R XX 3-membered heterocyclyl optionally substituted with one or more (e.g., one, two, three, or four) R XX a 4-membered heterocyclyl substituted with R XX 5-membered saturated heterocyclyl substituted with at least two (e.g., two, three, or four) R substituted on a carbon atom of the heterocyclyl XX 6-membered heterocyclyl having the formula -NR c R d -O-C 3~7 Cycloalkyl, -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)O-C 1~6 alkyl, -NR c R d C which may be substituted with 1~6 Alkyl, —O-5 to 6 membered heteroaryl, C 0~6 Alkylene-CN,C 0~6 Alkylene-C(O)O(C 1~6 Alkyl), C 0~6 Alkylene-C(O)NR e R f and -NR AA R BB wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; Each R XX is C 1~6 Alkyl, (C 1~6 alkylene)-OH, -C(O)O-C 1~6 Alkyl, and -NR e R f are independently selected from the group consisting of: R AA and R BB is H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, —C(O)—C 1~6 Alkyl, -(C 0~6 alkylene)-phenyl, and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Cycloalkyl is hydroxy or C 1~6 Each of R may be substituted with alkoxy. AA and R BB at least one of is not hydrogen; or R AA is hydrogen, R BB is C 1~6 Alkylene -NR c R d (It is.)

3. Compound of formula (Ia'): 【Chemistry 5】 3. The compound of claim 1 or 2, which is: or a pharma- ceutically acceptable salt thereof, wherein the variables are as defined in claim 1 or 2.

4. Compound of formula (Ib'): 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof (In the formula, G 1 , G 2 , G 3 , G 4 , G 5 , G 6 , and G 7 each is independently selected from CH and N; s is 0, 1, 2, or 3; X, n, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is as defined in claim 1 or 2) 4. The compound according to claim 1 , wherein

5. Compound of formula (Ic'): 【Chemistry 7】 5. The compound of any one of claims 1 to 4, which is: or a pharma- ceutically acceptable salt thereof, wherein the variables are as defined in claim 4.

6. Compound of formula (Id'): 【Chemistry 8】 6. The compound of any one of claims 1 to 5, which is: or a pharma- ceutically acceptable salt thereof, wherein the variables are as defined in claim 4.

7. G 1 , G 2 , G 3 , G 4 , G 5 , G 6 , and G 7 7. The compound according to claim 4, wherein is CH.

8. G 1 is N and G 2 , G 3 , G 4 , G 5 , G 6 , and G 7 is CH; or G 2 is N and G 1 , G 3 , G 4 , G 5 , G 6 , and G 7 7. The compound according to claim 4, wherein is CH.

9. G 3 is N and G 1 , G 2 , G 4 , G 5 , G 6 , and G 7 is CH; or G 4 is N and G 1 , G 2 , G 3 , G 5 , G 6 , and G 7 7. The compound according to claim 4, wherein is CH.

10. G 5 is N and G 1 , G 2 , G 3 , G 4 , G 6 , and G 7 is CH; or G 6 is N and G 1 , G 2 , G 3 , G 4 , G 5 , and G 7 7. The compound according to claim 4, wherein is CH.

11. G 7 is N and G 1 , G 2 , G 3 , G 4 , G 5 , and G 6 7. The compound according to claim 4, wherein is CH.

12. 7. The compound according to any one of claims 4 to 6, wherein s is 0.

13. 7. The compound according to any one of claims 4 to 6, wherein s is 1.

14. 7. The compound according to any one of claims 4 to 6, wherein s is 2.

15. 4. The compound according to claim 1, wherein Ring A is naphthyl.

16. Ring A is 【Chemistry 9】 16. The compound of claim 15, selected from:

17. The compound of claim 2, wherein Ring A is anthracenyl.

18. The compound of claim 2, wherein Ring A is phenanthrenyl.

19. The compound of any one of claims 1 to 3, wherein Ring A is an 8-14 membered bicyclic or tricyclic heteroaryl.

20. 20. The compound of any one of claims 1 to 3 and 19, wherein Ring A is a 10-membered bicyclic heteroaryl.

21. 21. The compound of any one of claims 1 to 3, 19, and 20, wherein Ring A is quinolinyl.

22. Ring A is 【Chemistry 10】 22. The compound of claim 21 selected from the group consisting of:

23. Ring A is 【Chemistry 11】 23. The compound of claim 22, wherein

24. Ring A is isoquinolinyl, 【Chemistry 12】 21. The compound of any one of claims 1 to 3, 19, and 20, wherein

25. Ring A is 【Chemistry 13】 25. The compound of claim 24, selected from the group consisting of:

26. Compound of formula (Ie'): 【Chemistry 14】 or a pharma- ceutically acceptable salt thereof (In the formula, 【Chemistry 15】 is cyclopropylene or oxetan-3-ylene (i.e. 【Chemistry 16】 ) represents; R 1aa Ha, Haro, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -NH(C 1~6 alkyl), -N(C 1~6 Alkyl) 2 , 5- or 6-membered monocyclic heteroaryl, 4- or 5-membered heterocyclyl; R 1bb H, halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 haloalkyl; R 2 Ha, Haro, C 1~6 Alkyl, and C 1~6 haloalkyl; R 4 is H, hydroxy, -NH 2 , -NH(C 1~6 alkyl), -N(C 1~6 Alkyl) 2 , C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 haloalkyl; E is -O-, -N(H)-, or -N(C 1~6 is selected from the group consisting of aryl, arylalkyl, arylsulfonyl, arylsulfur ... R CC is H or C 1~6 is alkyl; R DD is H or C 1~6 is alkyl; R c is H or C 1~6 is alkyl; or R CC is H, and R DD and R c may, together with the carbon atom and nitrogen atom to which they are attached, form a 4- to 5-membered heterocyclic ring; and R d is H or C 1~6 is alkyl) 3. The compound of claim 2,

27. 【Fig. 17】 is cyclopropylene (i.e., 【Chemistry 18】 27. The compound of claim 26, wherein

28. 【Fig. 19】 is oxetan-3-ylene (i.e. 【Chemistry 20】 27. The compound according to claim 26, wherein

29. R 1aa C 1~6 29. The compound of any one of claims 26 to 28, which is alkoxy.

30. R 1aa C 2~6 29. The compound of any one of claims 26 to 28, which is alkenyl.

31. R 1bb The compound according to any one of claims 26 to 30, wherein is H.

32. R 1bb C 1~6 31. The compound of any one of claims 26 to 30, which is alkyl.

33. R 2 C 1~6 33. The compound of any one of claims 26 to 32, which is alkyl.

34. 34. The compound of any one of claims 26 to 33, wherein E is -O-.

35. 34. The compound of any one of claims 26 to 33, wherein E is -N(H)-.

36. E is -N (C 1~6 34. The compound of any one of claims 26 to 33, wherein the aryl group is aryl, aryl, or aryl.

37. R CC is H, and R DD and R c together with the carbon atom and nitrogen atom to which they are attached form a 4-5 membered heterocyclic ring.

38. R d 38. The compound of any one of claims 26 to 37, wherein is H.

39. R d C 1~6 38. The compound of any one of claims 26 to 37, which is alkyl.

40. X is CH 2 26. The compound according to any one of claims 1 to 4 and 7 to 25,

41. 26. The compound of any one of claims 1, 2, or 7-25, wherein X is CH.

42. 26. The compound of any one of claims 1 to 4 or 7 to 25, wherein X is NH.

43. 26. The compound of any one of claims 1 to 4 and 7 to 25, wherein X is O.

44. n is 2, one X is O, and the other X is CH 2 26. The compound according to any one of claims 1 to 4 and 7 to 25,

45. 45. The compound of any one of claims 1, 2, 7-25, and 40-44, wherein m is 0.

46. 45. The compound of any one of claims 1, 2, 7-25, and 40-44, wherein m is 1.

47. 45. The compound of any one of claims 1, 2, 7-25, and 40-44, wherein m is 2.

48. 45. The compound of any one of claims 2, 7-25, and 40-44, wherein m is 3.

49. 45. The compound of any one of claims 2, 7-25, and 40-44, wherein m is 4.

50. 【Fig. 21】 50. The compound of any one of claims 1, 2, 7-25, and 40-47, wherein is a single bond.

51. 【Fig. 22】 50. The compound of any one of claims 1, 2, 7-25, and 40-47, wherein is a double bond.

52. 52. The compound of any one of claims 1 to 4, 7 to 25, 40 to 43, and 45 to 51, wherein n is 1.

53. 52. The compound of any one of claims 1 to 4, 7 to 25, 40 to 43, and 45 to 51, wherein n is 2.

54. Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, halo, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 1~6 Alkoxy, -S(O) t -C 1~6 Alkyl, -NR e R f 54. The compound of any one of claims 1, 3-6, 13, 14, 19, 20, and 40-53, wherein each of the groups is independently selected from the group consisting of:

55. Each R 1 is phenyl, 5- to 9-membered heteroaryl, C 3~7 carbocyclyl, one or more (e.g., one, two, three, or four) R 1a 3- to 7-membered heterocyclyl optionally substituted by 1~6 C optionally substituted with haloalkyl, halo, -CN, hydroxy 1~6 Alkyl, C 3~6 Cycloalkyl or C 0~6 C optionally substituted with phenyl substituted with alkyl 2~6 alkenyl, optionally substituted with one or more (e.g., one, two, three, or four) halo; 2~6 C optionally substituted with alkynyl or phenyl 1~6 Alkoxy, -S(O) t -C 1~6 Alkyl, —C(O)—C 1~6 Alkyl, OS(O) t C 1~6 Haloalkyl, -NR j R k 54. The compound of any one of claims 2 to 6, 13, 14, 19, 20, and 40 to 53, wherein each of the following is independently selected from the group consisting of:

56. Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, halo, and C 1~6 alkyl, wherein said phenyl and 5-6 membered heteroaryl are independently selected from the group consisting of halo, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 54. The compound of any one of claims 1, 3-6, 13, 14, 19, 20, and 40-53, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

57. Each R 1 is phenyl, 5- to 9-membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, halo, and C 1~6 alkyl, wherein said phenyl and 5-9 membered heteroaryl are independently selected from the group consisting of halo, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 54. The compound of any one of claims 2 to 6, 13, 14, 19, 20, and 40 to 53, optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy.

58. Each R 1 is a 5-9 membered heteroaryl, one or more (e.g., one, two, three, or four) R 1a 3- to 7-membered heterocyclyl optionally substituted by 1~6 C optionally substituted with haloalkyl, halo, or hydroxy 1~6 Alkyl, C 3~6 Cycloalkyl or C 0~6 C optionally substituted with phenyl substituted with alkyl 2~6 alkenyl, optionally substituted with one or more (e.g., one, two, three, or four) halo; 2~6 C optionally substituted with alkynyl or phenyl 1~6 Alkoxy, -NR j R k wherein the 5-9 membered heteroaryl is independently selected from the group consisting of halo, cyano, phenyl, 3- to 7-membered heterocyclyl, C 1~6 Alkyl, C 1~6 alkylene-(3- to 7-membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) halo), C substituted with hydroxy 1~6 Alkylene, C 1~6 Alkylene -NR A R B , —C(O)-3 to 6-membered heterocyclyl, hydroxy, C 1~6 Haloalkyl, C 1~6 Alkoxy, and -C(O)-C 1~6 54. The compound of any one of claims 2 to 6, 13, 14, 19, 20, and 40 to 53, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each selected from the group consisting of alkyl.

59. Each R 1 is 5- to 9-membered heteroaryl, 3- to 7-membered heterocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, and -NR j R k 54. The compound of any one of claims 2 to 6, 13, 14, 19, 20, and 40 to 53, independently selected from the group consisting of:

60. Each R 1 Halo, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -NH(C 1~6 alkyl), -N(C 1~6 Alkyl) 2 54. The compound of any one of claims 2 to 6, 13, 14, 19, 20, and 40 to 53, wherein the ring is selected from the group consisting of: 5- or 6-membered monocyclic heteroaryl, and 4- or 5-membered heterocyclyl.

61. Each R 1 H, halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 54. The compound of any one of claims 2 to 6, 13, 14, 19, 20, and 40 to 53, selected from the group consisting of haloalkyl.

62. R 2 Halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 3~6 62. The compound of any one of claims 1 to 5, 7 to 25, and 40 to 61, selected from the group consisting of cycloalkyl.

63. R 2 Halo, C 1~6 Alkyl, C 1~6 Alkoxy, C 2~6 Alkynyl, and C 3~6 62. The compound of any one of claims 2 to 5, 7 to 25, and 40 to 61, selected from the group consisting of cycloalkyl.

64. R 2 Halo, C 1~6 Alkyl, and C 1~6 62. The compound of any one of claims 2 to 5, 7 to 25, and 40 to 61, selected from the group consisting of haloalkyl.

65. R 2 The compound of claim 64, wherein is halo.

66. R 2 C 1~6 65. The compound of claim 64, which is alkyl.

67. R 2 C 1~6 65. The compound of claim 64 which is a haloalkyl.

68. R 3 C 1~6 Alkoxy, Hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 alkylene-OH), and -NR e R f -NR c R d O--C which may be substituted 3~7 Cycloalkyl, -(C 0~6 alkylene)-(C 1~6 Alkyl, benzyl, and -C(O)O-C 1~6 -O-3 to 8 membered heterocyclyl, each of which may be substituted with one or more (e.g., one, two, three, or four) substituents independently selected from the group consisting of alkyl, and -NR A R B wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a 68. The compound of any one of claims 1, 3-25 and 40-67, optionally substituted with:

69. R 3 C 1~6 Alkoxy, Hydroxy, C 0~6 Alkylene-(C 1~6 Alkyl, (C 1~6 alkylene-OH), -C(O)O-C 1~6 Alkyl, and -NR e R f -NR c R d -O-C 3~7 Cycloalkyl, -(C 0~6 alkylene)-(C 1~6 Alkyl, benzyl, and -C(O)O-C 1~6 O-3 to 9 membered heterocyclyl, each of which may be substituted with one or more (e.g., 1, 2, 3, or 4) substituents independently selected from the group consisting of alkyl, and NR AA R BB wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a 70. The compound of any one of claims 2 to 25 and 40 to 67, optionally substituted with:

70. R 3 C 1~6 Alkoxy and -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)O-C 1~6 alkyl, -NR c R d O--C which may be substituted 3~7 cycloalkyl, 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a 68. The compound of any one of claims 1, 3-25 and 40-67, optionally substituted with:

71. R 3 C 1~6 Alkoxy and -(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)O-C 1~6 alkyl, -NR c R d -O-C 3~7 cycloalkyl, 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a 68. The compound of any one of claims 1, 3-25 and 40-67, optionally substituted with:

72. R 3 -NR AA R BB or one or more (e.g., one, two, three, or four) R 3a C which may be substituted with 1~20 70. The compound of any one of claims 2 to 25 and 40 to 67, which is alkoxy.

73. R 3 one or more (e.g., one, two, three, or four) R 3a C which may be substituted with 1~20 70. The compound of any one of claims 2 to 25 and 40 to 67, which is alkoxy.

74. R A and R B are each independently H or C 1~6 70. The compound of claim 1 or 68, which is alkyl.

75. R 3 -NR AA R BB 70. The compound of any one of claims 2 to 25 and 40 to 67,

76. R AA and R BB H, C 1~6 Alkyl, C 1~20 Alkylene -NR c R d , and -(C 0~20 alkylene)-(3- to 10-membered heterocyclyl), wherein said 3- to 10-membered heterocyclyl is selected from the group consisting of C 1~6 Alkyl, hydroxy, and C 1~6 80. The compound of any one of claims 2, 69, and 75, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

77. R AA and R BB H, C 1~6 Alkyl, C 1~20 Alkylene -NR c R d , and -(C 1~20 alkylene)-(3- to 5-membered heterocyclyl), wherein the 3- to 5-membered heterocyclyl is C 1~6 80. The compound of any one of claims 2, 69, and 75, optionally substituted with alkyl.

78. Each R c and R d are independently H or C 1~6 80. The compound of any one of claims 2, 68-71, 76, or 77, which is alkyl.

79. R 3 one or more (e.g., one, two, three, or four) R 3a C which may be substituted with 1~6 70. The compound of any one of claims 1 to 25 and 40 to 67, which is alkoxy.

80. R 3 But-(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)O-C 1~6 68. The compound of any one of claims 1 to 25 and 40 to 67, wherein the heterocyclyl is 3 to 8 membered, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkyl.

81. R 3 But-(C 0~6 alkylene)-O-(C 1~6 Alkyl, benzyl and -C(O)O-C 1~6 68. The compound of any one of claims 2 to 25 and 40 to 67, wherein the heterocyclyl is 3 to 9 membered, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkyl.

82. R 4 H, C 1~6 82. The compound of any one of claims 1 to 5, 7 to 25, and 40 to 81, wherein the compound is selected from the group consisting of alkyl, and halo.

83. R 4 H, C 1~6 C optionally substituted with alkyl, phenyl or 5- to 6-membered heteroaryl 2~6 82. The compound of any one of claims 2 to 5, 7 to 25, and 40 to 81, which is selected from the group consisting of alkynyl, and halo.

84. R 4 is H, hydroxy, -NR e R f , C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 82. The compound of any one of claims 2 to 5, 7 to 25, and 40 to 81, selected from the group consisting of haloalkyl.

85. R 4 is H, hydroxy, -NH 2 , -NH(C 1~6 alkyl), -N(C 1~6 Alkyl) 2 , C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 82. The compound of any one of claims 2 to 5, 7 to 25, and 40 to 81, selected from the group consisting of haloalkyl.

86. R 4 The compound of any one of claims 1 to 5, 7 to 25, and 40 to 81, wherein

87. R 3 and R 4 together with the atoms to which they are attached form an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to a phenyl, said 5- to 10-membered ring containing at least one heteroatom, and said 5- to 10-membered ring is 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5- to 6-membered heteroaryl, -(C 0~6 alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -(C 0~6 alkylene)-NR c R d , -(C 0~6 (alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 (alkylene)-C 1~6 68. The compound of any one of claims 1, 3-25, and 40-67, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

88. R 5 is H or C 1~6 88. The compound of any one of claims 1 to 25 and 40 to 87, wherein said compound is alkyl.

89. R 5 The compound of claim 88, wherein is H.

90. R 5 C 1~6 89. The compound of claim 88, which is alkyl.

91. R 6 is H or C 1~6 91. The compound of any one of claims 1 to 25 or 40 to 90, wherein said compound is alkyl.

92. R 6 The compound of claim 91, wherein

93. R 6 C 1~6 92. The compound of claim 91, which is alkyl.

94. Each R 3a -NR A R B , C 1~6 Alkoxy, hydroxy, 3- to 8-membered heterocyclyl, and -(C 0~6 alkylene)-(NR c R d C which may be substituted with 3~6 cycloalkyl), wherein the 3-8 membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 100. The compound of any one of claims 1 to 25, 40 to 73, 79, 82 to 86, and 88 to 93, optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy.

95. Each R 3a D, -NR A R B , C 1~6 Alkoxy, hydroxy, 3- to 10-membered heterocyclyl, and -(C 0~6 alkylene)-(NR c R d C which may be substituted with 3~6 cycloalkyl), wherein the 3- to 10-membered heterocyclyl is optionally substituted with halo, hydroxy, one or more (1, 2, 3, or 4) D. 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 100. The compound of any one of claims 2 to 25, 40 to 73, 79, 82 to 86, and 88 to 93, optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy.

96. Each R 3a -NR A R B 100. The compound of claim 1, wherein

97. Each R 3a is a 3- to 8-membered heterocyclyl, said 3- to 8-membered heterocyclyl being halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 100. The compound of any one of claims 1 to 25, 40 to 73, 79, 82 to 86, and 88 to 93, optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy.

98. Each R 3a is a 3- to 10-membered heterocyclyl, said 3- to 10-membered heterocyclyl being selected from halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, -C(O)O-C 1~6 Alkyl, and C 1~6 Alkylene-C 1~6 100. The compound of any one of claims 2 to 25, 40 to 73, 79, 82 to 86, and 88 to 93, optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy.

99. Each R A and R B Independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylene -NR c R d , 3- to 6-membered heterocyclyl optionally substituted by oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy; -(C 0~6 alkylene)-phenyl, and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 Alkylene and C 3~6 97. The compound of any one of claims 1, 2, and 94-96, wherein each cycloalkyl is optionally substituted with hydroxy.

100. Each R A and R B Independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 Alkylene -NR c R d 100. The compound of any one of claims 1, 2, and 99, selected from the group consisting of:

101. Each R A and R B is independently, for each occurrence, H or C 1~6 100. The compound of any one of claims 1, 2, and 99, wherein said compound is alkyl.

102. Each R c and R d Independently, for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 101. The compound of any one of claims 2, 94, 95, 99, and 100, wherein the compound is selected from the group consisting of alkyl.

103. Each R c and R d is independently, for each occurrence, H or C 1~6 101. The compound of claims 2, 94, 95, 99, and 100, which is alkyl.

104. Each R c and R d The compound of claim 103, wherein is H.

105. Each R e and R f is H.

106. R g and R h 5. The compound of claim 1 , wherein each of is H.

107. R i is H.

108. R x C 1~6 108. The compound of any one of claims 1, 2, 7-25, and 40-107, wherein the compound is alkyl.

109. R x The compound of any one of claims 1, 2, 7-25, and 40-107, wherein is halo.

110. R x The compound of any one of claims 2, 7 to 25, and 40 to 107, wherein is D.

111. Compound of formula (I-1″) 【Chemistry 23】 or a pharma- ceutically acceptable salt thereof (In the formula, Each R 1 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 independently selected from the group consisting of haloalkoxy, halo, and -CN; n is 0, 1, or 2; R 2 , R 3 , R 4 , and R 6 Each of 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 independently selected from the group consisting of haloalkoxy, halo, and -CN; and R 5 is C 1~6 Alkylene -C(O)NH 2 and NH 2 wherein each hydrogen is optionally substituted.

112. The compound of claim 111, wherein n is 0.

113. R 2 , R 3 , R 4 , and R 6 113. The compound of claim 111 or 112, wherein is hydrogen.

114. R 5 C 1~6 Alkylene-C(O)NH-NH-C(O)-C 2~6 Alkenylene -C(O)O-C 1~6 114. The compound of any one of claims 111 to 113, which is alkyl.

115. R 5 C 2 Alkylene-C(O)NH-NH-C(O)-C 2 Alkenylene -C(O)OCH 3 115. The compound according to any one of claims 111 to 114, wherein

116. Compound of formula (II') 【Chemistry 24】 or a pharma- ceutically acceptable salt thereof (In the formula, Ring A is one or more (e.g., one, two, three, or four) R 1 is phenyl optionally substituted with Each X is CH 2 , CH, NH, and O; R x When R is substituted on a carbon atom, each R x is independent, C 1~6 alkyl or halo, or R x When R is substituted on a nitrogen atom, each R x is independent, C 1~6 is alkyl; m is 0, 1, or 2; 【Chemistry 25】 is a single bond or a double bond; n is 1 or 2; Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, 3- to 7-membered heterocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 Alkyl, C 1~6 Alkoxy, —O—(C 0~6 alkylene)-phenyl, -S-C 1~6 Alkyl, -S-C 1~6 Haloalkyl, -NR e R f and hydroxy, wherein the phenyl and 5- to 6-membered heteroaryl are optionally substituted with halo, 3- to 7-membered heterocyclyl. 1~6 Alkyl, C 1~6 Alkylene -NR A R B , C 1~6 Haloalkyl, and C 1~6 may be substituted with one or more (e.g., 1, 2, 3, or 4) substituents each selected from the group consisting of alkoxy; R 2 Ha, Haro, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~6 Alkoxy, Hydroxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, —NR c R d -O-C 3~7 Cycloalkyl, —C(O)O—C 1~6 -O-3 to 8 membered heterocyclyl optionally substituted with alkyl, -NR c R d C which may be substituted with 1~6 Alkyl, —O-5 to 6 membered heteroaryl, C 0~6 Alkylene-CN,C 0~6 Alkylene-C(O)NR e R f and -NR A R B wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a may be substituted with; R 4 is H, C 1~6 Alkyl, halo, hydroxy, and -NR e R f or R 3 and R 4 together with the atoms to which they are attached form together an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to a phenyl, said 5- to 10-membered ring containing at least one heteroatom, and said 5- to 10-membered ring is 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5- to 6-membered heteroaryl, -(C 0~6 alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -(C 0~6 alkylene)-NR c R d , -(C 0~6 (alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 (alkylene)-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; Each R 3a is C 1~6 Alkyl, -NR A R B , C 1~6 Alkoxy, hydroxy, -C(O)NR c R d , 3- to 8-membered heterocyclyl, phenyl, and -(C 0~6 alkylene)-(NR c R d C which may be substituted with 3~6 cycloalkyl), wherein the 3-8 membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkyelene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, S(O) 2 C 1~6 Alkyl, —C(O)—C 1~6 Alkyl, C 1~6 Alkylene -NR c R d , 3- to 6-membered heterocyclyl optionally substituted by oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy; -(C 0~6 alkylene)-phenyl, and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Each cycloalkyl may be optionally substituted with hydroxy; Each R c and R d independently for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and R d may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; Each R e and R f is independently, for each occurrence, H or C 1~6 (alkyl).

117. Compound of formula (II″) 【Chemistry 26】 or a pharma- ceutically acceptable salt thereof (In the formula, Ring A is one or more (e.g., one, two, three, or four) R 1 is phenyl optionally substituted with Each X is CH 2 , CH, NH, and O; R x When R is substituted on a carbon atom, each R x is independent, C 1~6 alkyl or halo, or R x When R is substituted on a nitrogen atom, each R x is independent, C 1~6 is alkyl; m is 0, 1, or 2; 【Chemistry 27】 is a single bond or a double bond; n is 1 or 2; Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, 3- to 7-membered heterocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 Alkyl, C 1~6 Alkoxy, —O—(C 0~6 alkylene)-phenyl, -S-C 1~6 Alkyl, -S-C 1~6 Haloalkyl, -NR e R f and hydroxy, wherein the phenyl and 5- to 6-membered heteroaryl are optionally substituted with halo, 3- to 7-membered heterocyclyl. 1~6 Alkyl, C 1~6 Alkylene -NR A R B , C 1~6 Haloalkyl, and C 1~6 may be substituted with one or more (e.g., 1, 2, 3, or 4) substituents each selected from the group consisting of alkoxy; R 2 Ha, Haro, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, and C 3~6 cycloalkyl; R 3 is C 1~6 Alkoxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, —NR c R d -O-C 3~7 Cycloalkyl, —C(O)O—C 1~6 -O-3 to 8 membered heterocyclyl optionally substituted with alkyl, -NR c R d C which may be substituted with 2~6 Alkyl, —O-5 to 6 membered heteroaryl, C 0~6 Alkylene-C(O)NR e R f and -NR A R B wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a is substituted with R 3 -N(H)C(O)CH 3 But -NH 2 But not; R 4 is H, C 1~6 Alkyl, halo, hydroxy, and -NR e R f or R 3 and R 4 together with the atoms to which they are attached form together an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to a phenyl, said 5- to 10-membered ring containing at least one heteroatom, and said 5- to 10-membered ring is 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5- to 6-membered heteroaryl, -(C 0~6 alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -(C 0~6 alkylene)-NR c R d , -(C 0~6 (alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 (alkylene)-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; Each R 3a is C 1~6 Alkyl, -NR A R B , C 1~6 Alkoxy, hydroxy, -C(O)NR c R d , 3- to 8-membered heterocyclyl, phenyl, and -(C 0~6 alkylene)-(NR c R d C which may be substituted with 3~6 cycloalkyl), wherein the 3-8 membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-(C 1-6 alkyelene-)C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R A and R B independently for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, S(O) 2 C 1~6 Alkyl, —C(O)—C 1~6 Alkyl, C 1~6 Alkylene -NR c R d , oxo or -C(O)O-C 1~6 3- to 6-membered heterocyclyl optionally substituted with alkyl, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy; -(C 0~6 alkylene)-phenyl, and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 Alkylene and C 3~6 Each cycloalkyl may be optionally substituted with hydroxy; Each R c and R d independently for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 alkyl; or R c and R d may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered heterocyclyl; Each R e and R f is independently, for each occurrence, H or C 1~6 (alkyl).

118. Compound of formula (IIa'): 【Chemistry 28】 118. The compound of claim 116 or 117, which is: or a pharma- ceutically acceptable salt thereof, wherein the variables are as defined in claim 116 or 117.

119. Compound of formula (IIb'): 【Chemical Formula 29】 or a pharma- ceutically acceptable salt thereof (In the formula, s is 0, 1, 2, or 3; R 1 ~R 6 is as defined in claim 119.

119. The compound according to any one of claims 116 to 118, wherein

120. Compound of formula (IIc'): 【Chemistry 30】 120. The compound of any one of claims 116 to 119, which is: or a pharma- ceutically acceptable salt thereof, wherein the variables are as defined in claim 119.

121. X is CH 2 119. The compound according to any one of claims 116 to 118, wherein

122. 119. The compound of claims 116 to 118, wherein X is NH.

123. 119. The compound of claims 116 to 118, wherein X is O.

124. 124. The compound of any one of claims 116, 117, and 121 to 123, wherein m is 0.

125. 124. The compound of any one of claims 116, 117, and 121 to 123, wherein m is 1.

126. 124. The compound of any one of claims 116, 117, and 121 to 123, wherein m is 2.

127. 【Fig. 31】 127. The compound of any one of claims 116, 117, and 121-126, wherein is a single bond.

128. 【Fig. 32】 127. The compound of any one of claims 116, 117, and 121-126, wherein is a double bond.

129. 129. The compound according to any one of claims 116 to 118 and 121 to 128, wherein n is 1.

130. 129. The compound according to any one of claims 116 to 118 and 121 to 128, wherein n is 2.

131. Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 Alkyl, C 1~6 Alkoxy, -S-C 1~6 Alkyl, -NR e R f 131. The compound of any one of claims 116 to 130, independently selected from the group consisting of:

132. Each R 1 is phenyl, 5-6 membered heteroaryl, C 3~7 Carbocyclyl, C 1~6 Haloalkyl, Halo, C 1~6 alkyl, wherein said phenyl and 5-6 membered heteroaryl are independently selected from the group consisting of halo, C 1~6 Alkyl, C 1~6 Alkylene -NR A R B , C 1~6 Haloalkyl, and C 1~6 131. The compound of any one of claims 116 to 130, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy.

133. R 2 Halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 3~6 133. The compound of any one of claims 116-119 or 121-132, selected from the group consisting of cycloalkyl.

134. R 2 134. The compound of any one of claims 116, 117, and 133, wherein is halo.

135. R 2 C 1~6 134. The compound of any one of claims 116, 117, and 133, which is alkyl.

136. R 3 C 1~6 Alkoxy, Hydroxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, —NR c R d -O-C 3~7 Cycloalkyl, —C(O)O—C 1~6 -O-3 to 8 membered heterocyclyl optionally substituted with alkyl, and -NR A R B wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a 136. The compound of any one of claims 116 and 118-135, optionally substituted with:

137. R 3 C 1~6 Alkoxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, —NR c R d -O-C 3~7 Cycloalkyl, —C(O)O—C 1~6 -O-3 to 8 membered heterocyclyl optionally substituted with alkyl, -NR c R d C which may be substituted with 2~6 Alkyl, —O-5 to 6 membered heteroaryl, C 0~6 Alkylene-C(O)NR e R f and -NR A R B wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a is substituted with R 3 -N(H)C(O)CH 3 But -NH 2 136. The compound of any one of claims 117 to 135, which is not

138. R 3 C 1~6 Alkoxy, C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, —NR c R d -O-C 3~7 Cycloalkyl, —C(O)O—C 1~6 -O-(3- to 8-membered heterocyclyl) optionally substituted with alkyl, and -NR A R B wherein C is selected from the group consisting of 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a 136. The compound of any one of claims 116 and 118-135, optionally substituted with:

139. R 3 C 1~6 Alkoxy and C 1~6 3- to 8-membered heterocyclyl optionally substituted with alkyl, —NR c R d -O-C 3~7 cycloalkyl, 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a 136. The compound of any one of claims 116 to 135, optionally substituted with:

140. R 3 one or more (e.g., one, two, three, or four) R 3a C which may be substituted with 1~6 140. The compound of any one of claims 116, 117, and 139, which is alkoxy.

141. R 3 C 1~6 140. The compound of any one of claims 116, 117, and 139, which is a 3-8 membered heterocyclyl optionally substituted with alkyl.

142. R 4 H, C 1~6 142. The compound of any one of claims 116-119 or 121-141, wherein the compound is selected from the group consisting of alkyl, and halo.

143. R 4 The compound of any one of claims 116, 117, and 142, wherein

144. R 3 and R 4 together with the atoms to which they are attached form an aromatic or non-aromatic 5- to 10-membered monocyclic or bicyclic ring fused to a phenyl, said 5- to 10-membered ring containing at least one heteroatom, and said 5- to 10-membered ring is 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5- to 6-membered heteroaryl, -(C 0~6 alkylene)-C(O)NR e R f , -C(O)-C 1~6 Heteroalkyl, -(C 0~6 alkylene)-NR c R d , -(C 0~6 (alkylene)-C 1~6 Alkoxy, -(C 0~6 alkylene)-OH, oxo, -C(O)OH, and -(C 0~6 (alkylene)-C 1~6 136. The compound of any one of claims 116 to 119 and 121 to 135, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

145. R 5 is H or C 1~6 145. The compound according to any one of claims 116 to 119 and 121 to 144, which is alkyl.

146. R 5 The compound of claim 145, wherein is H.

147. R 5 C 1~6 The compound of claim 145, which is alkyl.

148. R 6 is H or C 1~6 148. The compound of any one of claims 116-119 or 121-147, which is alkyl.

149. R 6 The compound of claim 148, wherein is H.

150. R 6 C 1~6 The compound of claim 148, which is alkyl.

151. Each R 3a -NR A R B , C 1~6 Alkoxy, hydroxy, 3- to 8-membered heterocyclyl, and -(C 0~6 alkylene)-(NR c R d C which may be substituted with 3~6 cycloalkyl), wherein the 3-8 membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 150. The compound of any one of claims 116-140, 142, 143, and 145-150, optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy.

152. Each R 3a -NR A R B 152. The compound of any one of claims 116, 117, and 151, wherein

153. Each R 3a is a 3- to 8-membered heterocyclyl, said 3- to 8-membered heterocyclyl being halo, hydroxy, C 1~6 Alkyl, C 1~6 Haloalkyl, -C(O)OC 1~6 Alkyl, C 1~6 Alkylene-C 3~7 Cycloalkyl, benzyl, C 1~6 Alkylene-OH, and C 1~6 Alkylene-C 1~6 152. The compound of any one of claims 116, 117, and 151, optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy.

154. Each R A and R B Independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylene -NR c R d , 3- to 6-membered heterocyclyl optionally substituted by oxo, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy; -(C 0~6 alkylene)-phenyl, and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 Alkylene and C 3~6 154. The compound of any one of claims 116 to 153, wherein each cycloalkyl is optionally substituted with hydroxy.

155. Each R A and R B Independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylene -NR c R d , oxo or -C(O)O-C 1~6 3- to 6-membered heterocyclyl optionally substituted with alkyl, C 1~6 Alkyl or C 1~6 5-6 membered heteroaryl optionally substituted with alkoxy; -(C 0~6 alkylene)-phenyl, and -(C 0~6 (alkylene)-C 3~6 cycloalkyl, 1~6 Alkyl, C 1~6 Alkylene and C 3~6 154. The compound of any one of claims 117 to 153, wherein each cycloalkyl is optionally substituted with hydroxy.

156. Each R A and R B Independently, for each occurrence, H, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 Alkylene -NR c R d 156. The compound of claim 154 or 155, selected from the group consisting of:

157. Each R A and R B is independently, for each occurrence, H or C 1~6 156. The compound of claim 154 or 155, which is alkyl.

158. Each R c and R d Independently, for each occurrence, H, C 1~6 Alkyl, benzyl, and -C(O)OC 1~6 158. The compound of any one of claims 116 to 157, wherein the compound is selected from the group consisting of alkyl.

159. Each R c and R d is independently, for each occurrence, H or C 1~6 The compound of claim 158, which is alkyl.

160. Each R c and R d The compound of claim 158, wherein is H.

161. Each R e and R f is H.

162. Compound of formula (III″) 【Chemical 33】 or a pharma- ceutically acceptable salt thereof (In the formula, Ring A is selected from naphthyl and 8-12 membered bicyclic heteroaryl, said naphthyl and 8-12 membered bicyclic heteroaryl being selected from one or more (e.g., one, two, three, or four) R 1 may be substituted with; Y 1 is N or CR 6 and Y 2 is N or CR 4 and Y 3 is N or CR 5 and Y 4 is N or CR 3 and Y 5 is N or CR 2 and Each X is CH 2 , C.H., N.R. h and O, h are independently H or C 1~6 is alkyl; 【Chemical Formula 34】 is a single bond or a double bond; each R x is independent, C 1~6 is alkyl or halo; n is 1 or 2; m is 0, 1, or 2; Each R 1 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 independently selected from the group consisting of haloalkoxy, halo, and -CN; R 2 Ha, Haro, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 alkoxy; R 3 is C 1~6 Alkyl, C 1~6 alkoxy, and hydroxy; 1~6 Alkoxy is one or more (e.g., one, two, three, or four) -NR A R B Or C 1~6 optionally substituted with 3-8 membered heterocyclyl optionally substituted with alkyl; R 4 is H, C 1~6 selected from the group consisting of alkyl, halo, and hydroxy; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; Each R A and R B independently for each occurrence, H, C 1~6 Alkyl, and C 1~6 haloalkyl).

163. 163. The compound of claim 162, wherein Ring A is naphthyl.

164. Ring A is 【Chemistry 35】 The compound of claim 163,

165. Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 165. The compound of any one of claims 162 to 164, wherein at least one of is N.

166. Y 1 is N.

167. Y 2 , Y 3 , Y 4 , and Y 5 The compound of claim 166, wherein is not N.

168. Y 2 is N.

169. Y 1 , Y 3 , Y 4 , and Y 5 The compound of claim 168, wherein is not N.

170. Y 3 is N.

171. Y 1 , Y 2 , Y 4 , and Y 5 The compound of claim 170, wherein is not N.

172. Y 2 and Y 3 is N.

173. Y 1 , Y 4 , and Y 5 The compound of claim 172, wherein is not N.

174. X is CH 2 174. The compound of any one of claims 162 to 173, wherein

175. 175. The compound of any one of claims 162 to 174, wherein n is 1.

176. 176. The compound of any one of claims 162 to 175, wherein m is 0.

177. R 2 C 1~6 177. A compound according to any one of claims 162 to 176, which is alkyl, for example methyl.

178. R 3 one or more (e.g., one, two, three, or four) -NR A R B C which may be substituted with 1~6 Alkoxy, for example, —O—(CH 2 ) 2 -N(CH 3 ) 2 178. The compound of any one of claims 162 to 177, wherein

179. R 3 C 1~6 C optionally substituted with 3- to 8-membered heterocyclyl optionally substituted with alkyl 1~6 178. The compound of any one of claims 162 to 177, which is alkoxy.

180. R 4 is H.

181. R 5 is H. The compound according to any one of claims 162-169 and 172-180,

182. Compound of formula (IV″) 【Chemical 36】 or a stereoisomer or a pharma- ceutically acceptable salt thereof (In the formula, Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, and C 1~6 independently selected from the group consisting of alkyl; n is 0, 1, or 2; (A) R 2 is C 1~6 is alkyl or halo; R 3 is C 1~6 Alkoxy, hydroxy, -C(O)-C 1~6 Alkyl; -O-(one or more (e.g., one, two, three, or four) C 1~6 3-8 membered oxygen-containing heterocyclyl optionally substituted with alkyl, -NR A R B and nitro, 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a and R 3 Hydroxy, nitro, NH 2 , N.H.H. 3 , or N(CH 3 ) 2 If R 7 Also R 8 Also not methyl; R 4 is H, C 1~6 alkyl, halo, and hydroxy; or (B) R 2 is H, C 1~6 Alkyl, C 1~6 Haloalkyl, and C 1~6 alkoxy; R 3 and R 4 together with the atoms to which they are bonded, i) an aromatic or non-aromatic 5-membered monocyclic ring fused to a phenyl, R 3 a five-membered ring having at least one nitrogen or two oxygen atoms connected to a phenyl at the ii) an aromatic or non-aromatic 6-membered monocyclic ring fused to a phenyl, R 3 A six-membered ring having one and only one nitrogen attached to a phenyl at the Forming The five- or six-membered ring may be oxo, hydroxy, or -NR c R d C which may be substituted with 1~6 Alkyl, -(C 0~6 (alkylene)-C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl; R 5 H, halo, and C 1~6 selected from the group consisting of alkyl; R 6 H, halo, and C 1~6 selected from the group consisting of alkyl; R 7 is hydrogen, C 1~6 C optionally substituted with alkoxy 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Haloalkyl, cyano, and C 1~6 selected from the group consisting of 3-8 membered heterocyclyl optionally substituted with alkyl; R 8 is hydrogen or C 1~6 is alkyl; Each R 3a is C 1~6 Alkyl, -NR e R f and 3- to 8-membered heterocyclyl, wherein the 3- to 8-membered heterocyclyl is selected from the group consisting of halo, hydroxy, C 1~6 Alkyl, and C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of haloalkyl; Each R A and R B independently for each occurrence, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, S(O) 2 C 1~2 Alkyl, —C(O)-unsubstituted C 1~6 alkyl, 3- to 6-membered unsaturated heterocyclyl optionally substituted with one oxo, C 1~6 Alkyl or C 1~6 alkoxy-substituted 5- to 6-membered heteroaryl, and pyrazolyl; 1~6 Alkyl may contain one or more (e.g., one, two, three, or four) hydroxyl and / or one NH 2 and R A and R B One of the groups is -C(O)-unsubstituted C 1~6 When R is alkyl, A and R B The other is not H, but R A and R B Ha-(CH 2 ) 2 N.H. 2 But-CH 2 C (CH 3 ) 2 N.H. 2 But not; Each R c and R d independently for each occurrence, H, C 1~6 Alkyl, and -C(O)OC 1~6 alkyl, and Each R e and R f independently for each occurrence, H, C 1~6 Alkyl, and -C(O)OC 1~6 alkyl) and the compound is 【Chemical 37】 or a stereoisomer or a pharma- ceutically acceptable salt thereof, which is not a compound represented by the formula:

183. The compound of claim 182, wherein n is 0.

184. R 2 C 1~6 184. The compound of claim 182 or 183, which is alkyl.

185. R 2 is methyl.

186. R 2 is halo.

187. R 2 184. The compound of claim 182 or 183, wherein is hydrogen.

188. R 3 C 1~6 Alkoxy, hydroxy, -C(O)-C 1~6 Alkyl; -O-(one or more (e.g., one, two, three, or four) C 1~6 3-8 membered oxygen-containing heterocyclyl optionally substituted with alkyl, -NR A R B and nitro, 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a and R 3 Hydroxy, nitro, NH 2 , N.H.H. 3 , or N(CH 3 ) 2 If R 7 is not methyl; R 4 H, C 1~6 188. The compound of any one of claims 182 to 187, which is alkyl, halo, and hydroxy.

189. R 3 C 1~6 Alkoxy, hydroxy, -O- (one or more (e.g., one, two, three, or four) C 1~6 3-8 membered oxygen-containing heterocyclyl optionally substituted with alkyl, -NR A R B and nitro, 1~6 Alkoxy is one or more (e.g., one, two, three, or four) R 3a and R 3 Hydroxy, nitro, NH 2 , N.H.H. 3 , or N(CH 3 ) 2 If R 7 is not methyl; R 4 H, C 1~6 188. The compound of any one of claims 182 to 187, which is alkyl, halo, and hydroxy.

190. R 3 one or more (e.g., one, two, three, or four) R 3a C which may be substituted with 1~6 188. The compound of any one of claims 182 to 187, which is alkoxy.

191. R 3 is hydroxy.

192. R 3 -C(O)-C 1~6 188. The compound of any one of claims 182 to 187, which is alkyl.

193. R 3 is -O-(one or more (e.g., one, two, three, or four) C 1~6 188. The compound according to any one of claims 182 to 187, which is a 3-8 membered oxygen-containing heterocyclyl optionally substituted with alkyl.

194. R 3 -NR A R B 188. The compound of any one of claims 182 to 187,

195. R 3 is nitro.

196. R 4 is H.

197. R 5 is H.

198. R 6 The compound according to any one of claims 182 to 197, wherein

199. R 7 199. The compound of any one of claims 182 to 198, wherein is hydrogen.

200. R 7 C 1~6 C optionally substituted with alkoxy 1~6 199. The compound of any one of claims 182 to 198, which is alkyl.

201. R 7 C 2~6 199. The compound of any one of claims 182 to 198, which is alkynyl.

202. R 7 C 1~6 199. The compound of any one of claims 182 to 198, which is a haloalkyl.

203. R 7 is cyano.

204. R 7 C 1~6 199. The compound of any one of claims 182 to 198, which is a 3-8 membered heterocyclyl optionally substituted with alkyl.

205. R 8 205. The compound of any one of claims 182 to 204, wherein is hydrogen.

206. R 8 C 1~6 205. The compound of any one of claims 182 to 204, which is alkyl.

207. R 3a -NR e R f 207. The compound according to any one of claims 182 to 190 and 196 to 206,

208. R 3a Halo, hydroxy, C 1~6 Alkyl, and C 1~6 207. The compound of any one of claims 182 to 190 and 196 to 206, which is a 3-8 membered heterocyclyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of haloalkyl.

209. Each R A and R B Independently, for each occurrence, H, C 1~6 Alkyl, S(O) 2 C 1~2 Alkyl, —C(O)-unsubstituted C 1~6 alkyl, 3- to 6-membered unsaturated heterocyclyl optionally substituted with one oxo, C 1~6 Alkyl or C 1~6 alkoxy-substituted 5- to 6-membered heteroaryl, and pyrazolyl; 1~6 The alkyl group may contain one or more (e.g., one, two, three, or four) hydroxy groups and / or one NH 2 207. The compound of any one of claims 182-189 and 196-206, optionally substituted with:

210. Each R A and R B Independently, for each occurrence, H, C 1~6 Alkyl, S(O) 2 C 1~2 Alkyl, —C(O)-unsubstituted C 1~6 Alkyl, C 1~6 Alkyl or C 1~6 alkoxy-substituted 5- to 6-membered heteroaryl, and pyrazolyl; 1~6 The alkyl group may contain one or more (e.g., one, two, three, or four) hydroxy groups and / or one NH 2 207. The compound of any one of claims 182-189 and 196-206, optionally substituted with:

211. R A is H and R B The compound according to any one of claims 182 to 189 and 196 to 206, wherein

212. R A is H, and R B has one or more (e.g., one, two, three, or four) hydroxyl and / or one NH 2 C which may be substituted with 1~6 207. The compound of any one of claims 182-189 and 196-206, which is alkyl.

213. R A is H, and R B is S(O) 2 C 1~2 207. The compound of any one of claims 182-189 and 196-206, which is alkyl.

214. R A is H, and R B C 1~6 Alkyl or C 1~6 The compound of any one of claims 182 to 189 and 196 to 206, which is a 5-6 membered heteroaryl substituted with alkoxy.

215. Each R A is H and R B is pyrazolyl.

216. Each R A C 1~6 alkyl, R B is -C(O)-unsubstituted C 1~6 alkyl, 1~6 The alkyl group may contain one or more (e.g., one, two, three, or four) hydroxy groups and / or one NH 2 207. The compound of any one of claims 182-189 and 196-206, optionally substituted with:

217. R 3 and R 4 together with the atoms to which they are attached form a 5-membered aromatic or non-aromatic monocyclic ring fused to a phenyl, R 3 forming a five-membered ring having at least one nitrogen or two oxygens connected to the phenyl at the -position, said six-membered ring being an oxo, hydroxy or -NR c R d C which may be substituted with 1~6 Alkyl, -(C 0~6 alkylene)--(C 0~6 (alkylene)-C 1~6 217. The compound of any one of claims 182 to 187 and 197 to 216, optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

218. R 3 and R 4 together with the atoms to which they are attached form a 5-membered aromatic or non-aromatic monocyclic ring fused to a phenyl, R 3 forming a 5-membered cyclic ring having at least one nitrogen connected to a phenyl at the -position, said 6-membered ring being oxo, hydroxy or -NR c R d C which may be substituted with 1~6 Alkyl, -(C 0~6 (alkylene)-C 1~6 217. The compound of any one of claims 182 to 187 and 197 to 216, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

219. R 3 and R 4 together with the atoms to which they are attached form an aromatic or non-aromatic 6-membered monocyclic ring fused to a phenyl, R 3 and only one nitrogen atom connected to the phenyl at the -position, forming a six-membered cyclic ring with the remaining atoms in the ring being carbon, said six-membered ring being oxo, hydroxy or -NR c R d C which may be substituted with 1~6 Alkyl, -(C 0~6 (alkylene)-C 1~6 217. The compound of any one of claims 182 to 187 and 197 to 216, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of 3- to 7-membered heterocyclyl optionally substituted with alkyl.

220. Compound of formula (VI″): 【Chemical Formula 38】 or a stereoisomer or a pharma- ceutically acceptable salt thereof (In the formula, 【Chemical 39】 teeth 【Chemistry 40】 or optionally substituted phenyl; X is NR 9 or a bond; Y is NR 9 , C.H. 2 or a bond; R 9 is H and C 1~6 alkyl; 【Chemistry 41】 is a nitrogen-containing 4- to 6-membered heterocyclylene or 4- to 6-membered heterocycle fused to a phenyl; X 1 , X 2 , X 3 , X 4 , X 5 , and X 6 is CH or N, and each of said CH is R 1 may be substituted with; 【Chemistry 42】 but 【Chemistry 43】 If 【Chemistry 44】 is not a 6-membered monocyclic heterocyclylene; Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, C 1~6 Alkyl, C 1~6 Alkoxy, -NR e R f , 3- to 8-membered heterocyclyl, and 5- to 6-membered heteroaryl; n is 0, 1, or 2; R 2 , R 3 , R 4 , R 5 , and R 6 Each of 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, -NR e R f , C 1~6 Alkoxy, and C 1~6 independently selected from the group consisting of alkyl; R 7 is C 1~6 C optionally substituted with alkoxy 1~6 Alkyl, C 2~6 Alkynyl, C 1~6 Haloalkyl, cyano, and C 1~6 selected from the group consisting of 3-8 membered heterocyclyl optionally substituted with alkyl; R 8 is hydrogen; or R 7 and R 8 may be taken together with the carbons to which they are attached to form a 3- to 4-membered cycloalkyl or heterocyclyl ring; Each R e and R f independently for each occurrence, H, C 1~6 Alkyl, and -C(O)OC 1~6 (selected from the group consisting of alkyl).

221. 【Chemical Formula 45】 but 【Chemistry 46】 The compound of claim 220,

222. 【Fig. 47】 C 1~6 The compound of claim 220, which is phenyl optionally substituted with alkyl.

223. X is NR 9 222. The compound of claim 220 or 221,

224. 222. The compound of claim 220 or 221, wherein X is a bond.

225. Y is NR 9 225. The compound of any one of claims 220 to 224, wherein

226. Y is CH 2 225. The compound of any one of claims 220 to 224, wherein

227. 225. The compound of any one of claims 220 to 224, wherein Y is a bond.

228. R 9 is H.

229. R 9 C 1~6 228. The compound of any one of claims 220 to 227, which is alkyl.

230. 【Fig. 48】 is a nitrogen-containing 4-6 membered heterocyclylene, for example a 4-5 membered heterocyclylene, a 4 membered heterocyclylene, a 5 membered heterocyclylene, a 6 membered heterocyclylene, for example a 6 membered monocyclic heterocyclylene, a 6 membered bicyclic heterocyclylene.

231. 【Fig. 49】 is a nitrogen-containing 4-6 membered heterocycle fused to a phenyl, e.g., a 4 membered heterocycle fused to a phenyl, a 5 membered heterocycle fused to a phenyl, a 6 membered heterocycle fused to a phenyl.

232. R 1 C 1~6 232. The compound of any one of claims 220, 221, and 223-231, which is alkoxy.

233. R 1 is 5-6 membered heteroaryl.

234. 232. The compound of any one of claims 220, 221, and 223 to 231, wherein n is 0.

235. 234. The compound of any one of claims 220, 221, and 223 to 233, wherein n is 1.

236. R 2 , R 3 , R 4 , R 5 , and R 6 236. The compound of any one of claims 220 to 235, wherein each of is independently selected from the group consisting of hydrogen and halo.

237. R 7 C 1~6 C optionally substituted with alkoxy 1~6 alkyl, R 8 237. The compound of any one of claims 220 to 236, wherein is hydrogen.

238. R 7 is methyl and R 8 237. The compound of any one of claims 220 to 236, wherein is hydrogen.

239. R 7 and R 8 are taken together with the carbons to which they are attached to form a 3-4 membered cycloalkyl ring.

240. R 7 and R 8 together with the carbons to which they are attached form a 3-4 membered heterocyclyl ring.

241. Compound of formula (VII″): 【Chemistry 50】 or a stereoisomer or a pharma- ceutically acceptable salt thereof (In the formula, Ring A is 【Chemistry 51】 is selected from Z is CH 2 or NH, 2 or any hydrogen atom of NH is R 1 may be substituted with; Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, C 1~6 Alkyl, C 1~6 Alkoxy, -S(O) t C 1~6 Alkyl; -NR e R f , 3- to 8-membered heterocyclyl, and 5- to 6-membered heteroaryl; t is 0, 1, or 2; n is 0, 1, or 2; R 2 , R 3 , R 4 , R 5 , and R 6 Each of 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, -NR e R f , C 1~6 Alkoxy, and C 1~6 alkyl; or R 3 and R 4 together with the atoms to which they are attached, R 3 and R 4 may form an aromatic 5-6 membered monocyclic ring fused to the phenyl to which is attached; The 5- to 6-membered ring is hydroxy or -NR c R d one or more (e.g., one, two, three, or four) C 1~6 may be substituted with alkyl; R 7 is hydrogen or C 1~6 is alkyl; R 8 is hydrogen, C 1~6 Alkyl, or C 1~6 haloalkyl; R 9 is hydrogen or C 1~6 is alkyl; R 10 is (5- to 6-membered heteroarylene)-(C 0~6 (alkylene)-R 11 and R 11 is 3- to 7-membered heterocyclyl or -NR g R h and R 12 and R 13 is hydrogen; or R 7 and R 9 together with the atoms to which they are attached, R 9 may form a 5- to 6-membered heterocyclic ring fused to the phenyl to which R 9 and R 10 together with the atoms to which they are attached, R 9 and R 10 may form a 6-membered heterocyclic or cyclohexane ring fused to the phenyl to which is attached; R 12 and R 13 together with the atoms to which they are attached, R 12 and R 13 may form a phenyl ring fused to the ring to which it is attached; Each R c and R d are independently H or C 1~6 is alkyl; and Each R e and R f is H, C 1~6 Alkyl, C 3~6 cycloalkyl, 3- to 7-membered heterocyclyl, and 5- to 6-membered heteroaryl; 3~6 Cycloalkyl, 3- to 7-membered heterocyclyl and 5- to 6-membered heteroaryl are C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents each independently selected from the group consisting of alkoxy; Each R g and R h is H, C 1~6 Alkyl, C 3~6 cycloalkyl, 3- to 7-membered heterocyclyl, and 5- to 6-membered heteroaryl; 3~6 Cycloalkyl, 3- to 7-membered heterocyclyl and 5- to 6-membered heteroaryl are C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 alkoxy; R g is hydrogen, R h is not hydrogen; R 10 (5- to 6-membered heteroarylene)-(C 0~6 alkylene)-(3- to 7-membered heterocyclyl), R 3 -NR c R d If R 8 is hydrogen; and R g Or R h C 3~6 cycloalkyl or 3- to 7-membered heterocyclyl, and R 3 -NR e R f If R e Or R f is not a 3- to 7-membered heterocyclyl).

242. Ring A is 【Chemistry 52】 The compound of claim 241,

243. Ring A is 【Chemistry 53】 The compound of claim 241,

244. Z is CH 2 and the CH 2 R 1 244. The compound of claim 241 or 243, optionally substituted with:

245. Z is NH, and said NH is R 1 244. The compound of claim 241 or 243, optionally substituted with:

246. 246. The compound according to any one of claims 241 and 243 to 245, wherein t is 0.

247. 243. The compound of any one of claims 241 or 242, wherein n is 0.

248. R 2 , R 3 , R 4 , R 5 , and R 6 Each of e R f 248. The compound of any one of claims 241 to 247, independently selected from:

249. R 3 and R 4 Together with the atoms to which they are attached, R 3 and R 4 is attached to a phenyl group, said 5-6 membered ring being fused to a hydroxy or -NR c R d one or more (e.g., one, two, three, or four) C 1~6 248. The compound of any one of claims 241 to 247, optionally substituted with alkyl.

250. R 7 250. The compound of any one of claims 241 to 249, wherein is hydrogen.

251. R 7 C 1~6 250. The compound of any one of claims 241 to 249, which is alkyl.

252. R 8 252. The compound of any one of claims 241 to 251, wherein is hydrogen.

253. R 8 C 1~6 252. The compound of any one of claims 241 to 251, which is alkyl.

254. R 9 The compound of any one of claims 241, 242, and 247-253, wherein is hydrogen.

255. R 9 C 1~6 254. The compound of any one of claims 241, 242, and 247-253, which is alkyl.

256. R 11 is 3-7 membered heterocyclyl.

257. R 11 -NR g R h 254. The compound of any one of claims 241, 242, and 247 to 253, wherein

258. R 7 and R 9 Together with the atoms to which they are attached, R 9 The compound according to any one of claims 241, 242, 247 to 249, 252, and 253, wherein the phenyl to which the ring is attached may form a 5- to 6-membered heterocyclic ring fused thereto.

259. R 9 and R 10 Together with the atoms to which they are attached, R 9 and R 10 257. The compound of any one of claims 241, 242, 247-253, 256, and 257, wherein:

260. R 12 and R 13 However, these, together with the atoms to which they are bonded, form R 12 and R 13 Optionally, the compound according to any one of claims 241 and 243 to 257 forms a phenyl ring fused to the ring to which it is attached.

261. Each R e and R f However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 C optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy; 3~6 261. The compound of any one of claims 241 to 260, independently selected from cycloalkyl.

262. Each R e and R f However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 261. The compound of any one of claims 241 to 260, wherein each of the heterocyclyl groups is independently selected from 3-7 membered heterocyclyl, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of alkoxy.

263. Each R e and R f However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 261. The compound of any one of claims 241 to 260, independently selected from 5-6 membered heteroaryl, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of alkoxy.

264. Each R e and R f H and C 1~6 261. The compound of any one of claims 241 to 260, independently selected from alkyl.

265. Each R g and R h H and C 1~6 264. The compound of any one of claims 241, 242, 247-259, and 261-264, independently selected from alkyl.

266. Each R g and R h However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 C optionally substituted with one or more (e.g., one, two, three, or four) substituents each independently selected from the group consisting of alkoxy; 3~6 264. The compound of any one of claims 241, 242, 247-259, and 261-264, independently selected from cycloalkyl.

267. Each R g and R h However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 264. The compound of any one of claims 241, 242, 247-259, and 261-264, wherein each of the heterocyclyls is independently selected from 3-7 membered heterocyclyl, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of alkoxy.

268. Each R g and R h However, H and C 1~6 Alkyl, halogen, -OH, -C(O)OC 1~6 Alkyl, and C 1~6 264. The compound of any one of claims 241, 242, 247-259, and 261-264, wherein each of the 5-6 membered heteroaryls is independently selected from the group consisting of 5-6 membered heteroaryl, optionally substituted with one or more (e.g., 1, 2, 3, or 4) substituents, each independently selected from the group consisting of alkoxy.

269. Compound of formula (VIII″): 【Chemical Formula 54】 or a stereoisomer or a pharma- ceutically acceptable salt thereof (In the formula, B is 【Chemistry 55】 is selected from Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, and C 1~6 independently selected from the group consisting of alkyl; n is 0, 1, or 2; R 2 , R 3 , R 4 , R 5 , and R 6 Each of 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, -NR e R f , NO 2 , C 1~6 Alkoxy, and C 1~6 alkyl; or R 4 and R 5 together with the atoms to which they are attached, R 4 and R 5 may form a 5-membered heteroaryl fused to the phenyl to which is attached; R 9 is hydrogen or C 1~6 is alkyl; Each R 10 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, -NR e R f , NO 2 , C 1~6 Alkoxy, C 1~6 Alkyl, and C(O)NH(C 1~6 alkylene)Ph, wherein Ph is optionally substituted with halogen; m is 0, 1, or 2; R 6 and R 9 together with the atoms to which they are attached, R 6 may form a piperidine ring fused to the phenyl to which is attached; R 7 and R 8 each independently represents hydrogen, C 1~6 Alkyl or C 1~6 haloalkyl or R 7 and R 8 may be taken together with the atom to which they are attached to form a 3-4 membered cycloalkyl or heterocyclyl ring; R 9 is methyl, R 7 and R 8 is not methyl; R 9 is hydrogen, R 2 and R 6 at least one of is not hydrogen; R e and R f Each of 1~6 Alkyl, and -C(O)CH 2 Ph).

270. B 【Chemistry 56】 The compound of claim 269,

271. B 【Chemistry 57】 The compound of claim 269,

272. 272. The compound of any one of claims 269 to 271, wherein n is 0.

273. R 2 , R 3 , R 4 , R 5 , and R 6 Each of e R f , NO 2 , and C 1~6 273. The compound of any one of claims 269, 270, and 272, independently selected from the group consisting of alkyl.

274. R 4 and R 5 Together with the atoms to which they are attached, R 4 and R 5 Optionally, the compound of any one of claims 269, 270, 272, and 273 further comprises a 5-membered heteroaryl fused to the phenyl to which is attached.

275. R 9 The compound of any one of claims 269, 270, and 272-274, wherein is hydrogen.

276. R 9 C 1~6 275. The compound of any one of claims 269, 270, and 272-274, which is alkyl.

277. R 10 C(O)NH(C 1~6 277. The compound according to any one of claims 269 and 271 to 276, wherein Ph is optionally substituted with halogen.

278. 277. The compound of any one of claims 269 and 271 to 276, wherein m is 0.

279. 277. The compound of any one of claims 269 and 271 to 276, wherein m is 1.

280. R 6 and R 9 Together with the atoms to which they are attached, R 6 277. The compound of any one of claims 269, 270, and 272-276, wherein:

281. R 7 281. The compound of any one of claims 269 to 280, wherein each of is hydrogen.

282. R 7 Each of the C 1~6 281. The compound of any one of claims 269 to 280, which is alkyl.

283. R 7 and R 8 together with the atom to which they are attached form a 3-4 membered cycloalkyl or heterocyclyl ring.

284. R 8 281. The compound of any one of claims 269 to 280, wherein each of is hydrogen.

285. R 8 Each of the C 1~6 281. The compound of any one of claims 269 to 280, which is alkyl.

286. Compound of formula (IX″): 【Chemistry 58】 or a stereoisomer or a pharma- ceutically acceptable salt thereof (In the formula, Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, and C 1~6 independently selected from the group consisting of alkyl; n is 0, 1, or 2; R 2 is C 1~6 is alkyl; R 3 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, -NR e R f , NO 2 , C 1~6 Alkoxy, and C 1~6 selected from the group consisting of alkyl; R 6 is hydrogen or C 1~6 is alkyl; and R e and R f Each of 1~6 alkyl).

287. The compound of claim 286, wherein n is 0.

288. R 2 is methyl.

289. R 3 -NR e R f 289. The compound of any one of claims 286 to 288, wherein

290. R 6 290. The compound of any one of claims 286 to 289, wherein is hydrogen.

291. R 6 C 1~6 290. The compound of any one of claims 286 to 289, which is alkyl.

292. R e and R f 292. The compound of any one of claims 286 to 291, wherein is hydrogen.

293. Compound of formula (X″): 【Chemistry 59】 or a stereoisomer or a pharma- ceutically acceptable salt thereof (In the formula, Each R 1 is C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, and C 1~6 independently selected from the group consisting of alkyl; n is 0, 1, or 2; R 2 is C 1~6 is alkyl; R 3 is C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, halo, -CN, -NR e R f , NO 2 , 3- to 8-membered heterocyclyl or -NR e R f C which may be substituted with 1~6 alkoxy; and R 4 is hydrogen or C 1~6 is alkyl; R 5 is hydrogen, C 1~6 Alkyl, C 1~6 haloalkyl; R 6 is hydrogen or C 1~6 is alkyl; or R 5 and R 6 may be taken together with the carbons to which they are attached to form a 3- to 4-membered cycloalkyl or heterocyclic ring; and R e and R f Each of 1~6 alkyl).

294. The compound of claim 293, wherein n is 0.

295. R 2 295. The compound of claim 293 or 294, wherein is methyl.

296. R 3 -NR e R f 296. The compound of any one of claims 293 to 295,

297. R 3 -NR e R f C which may be substituted with 1~6 296. The compound of any one of claims 293 to 295, which is alkoxy.

298. R 3 C may be substituted with 3- to 8-membered heterocyclyl 1~6 296. The compound of any one of claims 293 to 295, which is alkoxy.

299. R 4 300. The compound of any one of claims 293 to 298, wherein is hydrogen.

300. R 4 C 1~6 300. The compound of any one of claims 293 to 298, which is alkyl.

301. R 5 The compound of any one of claims 293 to 300, wherein is hydrogen.

302. R 5 C 1~6 301. The compound of any one of claims 293 to 300, which is alkyl.

303. R 6 The compound of any one of claims 293 to 302, wherein is hydrogen.

304. R 6 C 1~6 303. The compound of any one of claims 293 to 302, which is alkyl.

305. R 5 and R 6 are taken together with the carbons to which they are attached to form a 3-4 membered cycloalkyl ring.

306. R 5 and R 6 may be taken together with the carbon to which they are attached to form a 3-4 membered heterocyclic ring.

307. Compound of formula (Ie″): 【Chemistry 60】 or a pharma- ceutically acceptable salt thereof (In the formula, 【Chemistry 61】 is cyclopropylene or oxetan-3-ylene (i.e. 【Chemistry 62】 ) represents; R 1aa Ha, Haro, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, -NH(C 1~6 alkyl), -N(C 1~6 Alkyl) 2 , 5- or 6-membered monocyclic heteroaryl, 4- or 5-membered heterocyclyl; R 1bb H, halo, C 1~6 Alkyl, C 1~6 Alkoxy, and C 1~6 haloalkyl; R 2 Ha, Haro, C 1~6 Alkyl, and C 1~6 haloalkyl; R 4 is H, hydroxy, -NH 2 , -NH(C 1~6 alkyl), -N(C 1~6 Alkyl) 2 , and C 1~6 selected from the group consisting of alkyl; R 3 is C 1~6 Alkoxy or -NR A R B and C is selected from 1~6 The alkoxy may be substituted with one or more (e.g., one, two, three, or four) 3- to 8-membered heterocyclyls, said 3- to 8-membered heterocyclyls being C 1~6 may be substituted with alkyl; and R A and R B is H, C 1~6 Alkyl, and -C 1~6 Alkylene -NR c R d R is independently selected from the group consisting of c and R d is H and C 1~6 alkyl) 3. The compound according to claim 1 or 2,

308. 【Fig. 63】 is cyclopropylene (i.e., 【Chemistry 64】 ). The compound of claim 307,

309. 【Chemical Formula 65】 is oxetan-3-ylene (i.e. 【Chemistry 66】 ). The compound according to claim 307,

310. R 1aa C 1~6 310. The compound of any one of claims 307 to 309, which is alkoxy.

311. R 1aa C 2~6 310. The compound of any one of claims 307 to 309, which is alkenyl.

312. R 1bb The compound according to any one of claims 307 to 311, wherein

313. R 1bb C 1~6 312. The compound of any one of claims 307 to 311, which is alkyl.

314. R 2 C 1~6 314. The compound of any one of claims 307 to 313, which is alkyl.

315. R 3 C 1~6 315. The compound of any one of claims 307 to 314, which is alkoxy.

316. Said C 1~6 316. The compound of claim 315, wherein said alkoxy is substituted with a 3-8 membered heterocyclyl.

317. Said C 1~6 The compound of claim 315, wherein the alkoxy is substituted with a 3-8 membered heterocyclyl substituted with methyl.

318. R 3 is NR A R B 315. The compound of any one of claims 307 to 314, wherein

319. R A Ga-C 1~6 Alkylene -NR c R d and R B is H or C 1~6 The compound of claim 318, which is alkyl.

320. R c and R d C 1~6 The compound of claim 319, which is alkyl.

321. R c and R d The compound of claim 319, wherein is H.

322. R c C 1~6 alkyl, R d The compound of claim 319, wherein is H.

323. R A and R B C 1~6 The compound of claim 318, which is alkyl.

324. R A and R B The compound of claim 318, wherein is H.

325. R A C 1~6 alkyl, R B The compound of claim 318, wherein is H.

326. 326. A pharmaceutical composition comprising a compound according to any one of claims 1 to 325, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable excipients.

327. A method of treating a viral infection in a subject in need of such treatment, comprising administering to the subject an effective amount of a compound described in any one of claims 1 to 325 or a pharmaceutical composition described in claim 326.

328. A method for preventing a viral infection in a subject in need of such prevention, comprising administering to the subject an effective amount of a compound described in any one of claims 1 to 325 or a pharmaceutical composition described in claim 326.

329. The method of claim 327 or 328, wherein the viral infection is a coronavirus infection.

330. The method of claim 327 or 328, wherein the viral infection is caused by a coronavirus.

331. The method of claim 330, wherein the coronavirus is SARS-CoV-2.

332. 332. The method of any one of claims 327 to 331, wherein the viral infection is chronic.

333. 332. The method of any one of claims 327 to 331, wherein the viral infection is acute.

334. A method for inhibiting PLPro in a subject in need of inhibition of PLPro, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 325 or a pharmaceutical composition according to claim 326.

335. A method for preventing viral replication in a subject in need thereof, comprising administering to the subject an effective amount of a compound described in any one of claims 1 to 325 or a pharmaceutical composition described in claim 326.

336. The method of claim 335, wherein the virus is a coronavirus.

337. The method of claim 336, wherein the coronavirus is SARS-Cov-2.